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Chapter 1
INTRODUCTION
Use of Thiopurines for the treatment of inflammatory bowel diseases
The conventional thiopurines (azathioprine (AZA), Imuran® and meraptopurine 
(MP), puri-nethol®) are already used for the treatment of inflammatory bowel 
diseases (IBD) since 1962.(1, 2) IBD refers to chronic inflammatory diseases 
affecting the gastrointestinal tract, with ulcerative colitis (UC) and Crohn’s disease 
(CD) being the most prevalent. In UC, only the colon is affected while in CD the 
entire gastro-intestinal tract may be involved.(3) In brief, treatment of UC and CD 
relies on keeping control on an exaggerated immune response.(4)
AZA and MP (from now on referred to as thiopurines) are effective in maintaining 
remission of both UC and CD. Given the slow mechanism of action there is 
currently no position for the use of thiopurines in induction of remission of both 
diseases.(3, 5, 6) In addition to the use of thiopurines as monotherapy, combination 
of thiopurines with anti-tumour necrosis factor (anti-TNF) agents has added value 
as it is superior compared to monotherapy with anti-TNF agents.(7-10) Taking into 
account that the number of registered drugs for the treatment of IBD is limited, 
thiopurines remain an important cornerstone for the treatment of IBD.(11) This is 
supported by data showing that up to 60% of patients with CD are treated with 
thiopurines in the first five years after diagnosis. (12)
Unfortunately, perceived lack of effectiveness and side effects lead to a high 
number of patients discontinuing treatment prematurely.(13) For this reason, much 
effort has been put in therapeutic drug monitoring (TDM) with assessment of 
thiopurine metabolites in order to optimize efficacy and reduce the risk of side 
effects.(14) Despite these efforts, idiosyncratic and dose-dependent side effects 
result in 40% of patients discontinuing treatment within one year after initiation.
(13, 15) Most of these patients discontinue treatment in the first months. In 
view of the scarce alternatives, much can be gained in the quest for a strategy 
that successfully maintains patients on thiopurine treatment. This thesis explores 
factors that contribute to side effects and safety of thiopurines in the treatment of 
IBD. The knowledge obtained with these studies should benefit in the optimization 
of starting thiopurines. Ultimately, the goal is to achieve a higher rate of patients 
successfully initiated on long-term thiopurine treatment.
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General Introduction
Thiopurine metabolism
History
Initially, thiopurines were developed for the treatment of cancer. The mechanism 
of action of thiopurines was already proposed at the moment the exact structure 
of the DNA still needed to be revealed. Based on the theory that dividing cells 
depend on the supply of nucleic acids, administration of fraudulent nucleic acids 
would disrupt this process, especially in rapidly dividing cells.(16) In 1951, MP and 
6-thioguanine turned out to have the highest efficacy for the treatment of cancer 
from a selection of 100 different substrates. Because MP was more easier to 
produce and had a superior safety profile compared to 6-thioguanine, Hitchings 
and Elion continued in the development of MP.(17) Trials of MP in the treatment of 
acute leukaemia showed an increase in life expectancy from three months to 12 
months. For this reason, MP was approved by the Food and Drug Administration 
for the treatment of leukaemia only two years after its discovery.(16)
AZA, a pro-drug of MP, was developed a few years later in an attempt to bypass 
the high first-pass effect of MP.(18) AZA and MP are both inactive and need to be 
metabolized by a complex system of several steps to yield the pharmacological 
active substrates.
Metabolism
Thiopurines enter the cells by a variety of nucleoside transporters.(19, 20) As 
mentioned before, MP is subjected to a high first-pass metabolism due to 
oxidation in intestinal cells by the enzyme Xanthine Oxidase (XO). This reaction 
delivers 8-OH-6-MP and subsequently 6-thiouric acid, which is excreted in urine. 
To bypass this first pass metabolism, an 1-methyl-4-nitrol-5-imidazol group 
(nitroimidazol group) was attached to the MP molecule. This modified MP drug 
was named AZA. AZA is no substrate for XO and in this way oxidation by intestinal 
cells is prevented, which results in a higher bioavailability.(18) Studies in patients 
with leukaemia demonstrated similar efficacy of AZA and MP.(21) However, in the 
prevention of transplant rejection after kidney transplantation AZA had a superior 
safety profile compared to MP. This resulted in a preferential prescription of AZA 
in kidney transplants.(22)
1
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Chapter 1
After ingestion, some 88% of AZA is converted to MP and 1-methyl-4-nitrol-5-
imidazol. The remaining 12% of AZA is converted to methyl-4-nitro-5-thioimidazole.
(23) The conversion of AZA to MP was considered to be non-enzymatic, however 
recent studies revealed an important role for Gluthatione S-transferases (GSTs) in 
cleaving the nitroimidazole group (Figure 1).(24, 25) In this process glutathione 
serves as substrate for the nitroimidazole group. Of the many GST classes, GST 
Mu 1, GST Alpha 1 and GST Alpha 2 have the highest substrate-specificity for 
this reaction.(25)
As follows from Figure 2, mercaptopurine is metabolized in three pathways. Apart 
from oxidation by XO, two other competitive pathways, namely methylation by 
thiopurine methyl S-transferase (TPMT) and conversion by hypoxanthine-guanine 
phosphoribosyltransferase (HPGRT) are involved in the metabolism of MP.
Methylation of MP by TPMT leads to formation of 6-methylmercaptopurine (6-
MMPR). The third route converts MP to 6-thioinosine 5’-monophosphate (6-
TIMP) by HPGRT and subsequently by the rate limiting inosine monophosphate 
dehydrogenase (IMPDH) to 6-thioxanthosine monophosphate (6-TXMP).(26) The 
latter compound is further metabolized by guanosine monophosphate synthetase 
(GMPS) to produce 6-thioguanine monophospate (6-TGMP), 6-thiguanine 
diphosphate (TGDP) and 6-thioguanine triphosphate (TGTP), together mentioned 
as 6-thioguanine nucleotides (6-TGNs). 6-TIMP is also a substrate for methylation 
Figure 1. Conversion of azathioprine to mercaptopurine. In the presence of glutathione 
S-transferase alpha and mu, azathioprine is conjugated to mercaptopurine and glutathi-
one-nitroimidazole. Mercaptopurine is subsequently further metabolized.
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General Introduction
by TPMT to produce 6-methylmercaptopurine ribonucleotides (6-MMPR) and 
phosphorylation to 6-thioinosine 5’-diphosphate (6-TIDP). In general, 6-TGNs are 
considered as pharmacological active metabolites, while 6-MMPR metabolites 
are generally associated with hepatotoxicity. The metabolism of thiopurines is 
influenced by tissue specific enzyme activity. Table 1 illustrates the presence of 
enzymes involved in thiopurine metabolism for specific cell types.
Mechanisms of action
Thiopurines are already used for more than fifty years, but still there are many 
gaps in knowledge concerning its immunosuppressive actions.(4, 32) Several 
mechanisms of actions have been proposed.(33-35)
The best known way of action originates from the proposed mechanism as 
fraudulent base pair and depends on the incorporation of 6-TGNs as decoy 
nucleotides into the DNA and RNA. 6-TGNs have a high similarity with endogenous 
guanine. The decoy base pair is tolerated by DNA-polymerases, but leads to 
Figure 2. Metabolism of azathioprine (AZA), mercaptopurine (6-MP) and 6-thioguanine 
(6-TG).
1
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inhibition of the S and G2 phases in cell replication, and subsequently to DNA 
strand breakage and apoptosis.(36-38) In addition, an unintended therapeutic 
effect is the inhibition of de novo purine synthesis by 6-MMPR nucleotides. Due to 
a decrease in the endogenous purine supply 6-TGNs metabolites are the preferred 
purines incorporated into the DNA.(16, 39). This amplifies the mechanism of action 
and results in an increased cytotoxic effect.
The aforementioned mechanisms are probably of limited relevance in the 
immunosuppressive effects exerted by thiopurines in the treatment of IBD, 
because of the relatively low dose prescribed in immune-mediated diseases 
compared to the treatment of cancer.(4) More sophisticated effects, such as 
down-regulation of pro-inflammatory cytokine expression probably contribute to 
the immunosuppressive effects of thiopurines in IBD treatment. Another recent 
discovered mechanism relates to TGTP induced inactivation of Rac1 by Guanosine 
triphosphate (GTP) (Figure 2). The inhibition of Rac1 activation after CD28 co-
stimulation impairs downstream signalling of NF-KB, STAT3 and bcl-XL, which 
eventually results in apoptosis.(40)
Drug monitoring
From the mid-nineties onwards, techniques have developed to assess levels of 
the most relevant thiopurine metabolites 6-TGN and 6-MMPR.(41) 6-TGN and 
6-MMPR metabolite levels correlate well with efficacy and side effects. 6-TGN 
levels above 230 pmol/8x108 Red Blood Cells (RBC) are associated with clinical 
remission (42-44), while levels above 490 pmol/8x108 RBC increase the risk 
Table 1. Tissue specific activity of enzymes involved in thiopurine metabolism
Intestinal cells 
(25, 27, 28)
Hepatocytes 
(26)
Leukocytes 
(29-31)
Erythrocytes 
(30, 31)
TPMT + + + +
XO + + - -
IMPDH + + ± ±
HGPRT + + + +
GST Alpha / Mu + + - -
+: enzyme expression, ±: some enzyme expression, -: no enzyme expression. TPMT; 
thiopurine methyl S-transferase, XO; xanthine oxidase, IMPDH; inosine monophosphate 
dehydrogenase, HPGRT; hypoxanthine-guanine phosphoribosyltransferase, GST; 
glutathione S-transfersase
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General Introduction
for myelotoxicity.(43) Although, 6-MMPRs possess some therapeutic effect 
by inhibition of de novo purine synthesis, elevated levels are associated with 
hepatotoxicity and myelotoxicity.(15, 45-47) Assessment of thiopurine metabolites 
is particularly useful in the management of patients not responding to thiopurines 
or those presenting with side effects.(48)
It is evident that thiopurine metabolism is complex and involves many enzymes. 
Genetic and environmental factors may affect enzyme activity and subsequently 
may influence 6-TGN and 6-MMPR levels.(49) The best known and most relevant 
are genetic variants in TPMT, leading to a reduced enzyme activity of TPMT 
resulting in a shift of thiopurine metabolism towards a preferred metabolism of 
6-TGN metabolites.(50-52) Around 10% of Caucasians carry an heterozygote 
variant in TPMT and ± 0.1 - 0.3 % of the population carries a homozygous variant 
in TPMT leading to negligible TPMT enzyme activity.(53, 54) In particular, patients 
with an homozygous variant are at high risk for life-threatening pancytopenia 
due to extreme 6-TGN levels causing severe myelosuppression.(55) Also genetic 
variants in other enzymes involved in thiopurine metabolism such as XO, ITP-
ase, HGPRT and GST may affect thiopurine metabolism.(56, 57) Hence, not only 
genetic variants, but also food and concomitant drugs, such as 5-aminosalicylic 
acids (5-ASA) or biologics may influence the pharmacokinetics of thiopurines.
(58-61)
Glutathione transferases
General information
GSTs are a family of enzymes with an essential role in conjugation and detoxification 
of toxic or carcinogenic compounds, such as reactive oxygen species.(62) There 
are eight different classes of GSTs (Alpha, Kappa, Mu, Omega, Pi, Sigma, Theta 
and Zeta) in humans, which all have their own specific properties and organ 
expression.(63) Of these, GST Alpha (GSTA), GST Mu (GSTM), GST Pi (GSTP) 
and GST Theta (GSTT) are the most relevant. In general, (toxic) compounds are 
conjugated with glutathione as co-substrate to yield (less toxic) products which 
can be excreted more efficient by the human body.(64) The different classes of 
GSTs have some overlap in compound specificity, however substantial difference 
between the subclasses in substrate-selectivity exist.(65)
1
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Genetic variants in GSTs may have qualitative (loss or gain of enzyme function) 
or quantitative effects (impact on enzyme expression). Various single nucleotide 
polymorphisms (SNPs) have been described in GSTA and GSTP1.(66) These SNPs 
may result in an altered, either increased or decreased, affinity for substrates or 
affect enzyme expression.(67, 68) In GSTM and GSTT, alleles may possess a gene 
deletion. Homozygous presence of this deletion results in an complete absence 
of protein production. Approximately 50% of the Caucasian and Asian population 
has a homozygous gene deletion in GSTM class 1 (GSTM1), while for GSTT1 these 
numbers vary between in 20-60%.(63, 69) The gene deletion in GSTM1 is likely 
to originate from an unequal crossing over with the closely positioned and highly 
similar GST Mu class 2.(70)
The altered function, reduced transcription or lack of protein formation, of GSTs 
may reduce the ability to eliminate toxic compounds from the body, which might 
increase carcinogenesis.(62) Associations with a variety of malignancies have 
been found.(71-74) The reduced ability to neutralize reactive oxygen species may 
also lead to a state of oxidative stress, which subsequently might increase the 
susceptibility to several immune mediated diseases.(75, 76) Case-control studies 
have shown associations between the presence of gene deletions in GSTM1 and 
GSTT1 and risk for asthma and type 2 diabetes mellitus.(77, 78) For IBD, conflicting 
results with respect to genetic variants in GSTs and susceptibility for IBD have 
been published.(79-81) In this thesis, we addressed this question by performing 
a large case-control study and incorporate these findings in a meta-analysis.
Role of Glutathione transferases in thiopurine metabolism
The conversion of AZA to MP is for 90% facilitated by GSTs and for 10% in a non 
enzymatic fashion. GSTM1, GSTA Alpha 1 (GSTA1) and Alpha 2 (GSTA2) have 
a crucial role in this process.(25) Both GSTM1, GSTA1 and GSTA2 are highly 
expressed in the liver and to a lesser degree in intestinal cells.(25, 63) After 
absorption of AZA by intestinal cells, conversion of AZA to MP by GSTs is primarily 
localized in the liver, after which MP is further metabolized.
Genetic variants in GSTA and GSTM1 affecting expression or function might 
influence the proportion of AZA converted to MP.(82) As mentioned before, a 
large part of the population has a homozygous gene deletion on GSTM1 leading 
to no protein formed at all. The most applied technique to identify patients with a 
517689-L-sub01-bw-Broekman
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homozygous GSTM1 gene deletion is by real-time polymerase chain reaction. In 
patients with a homozygous gene deletion in the GSTM1 gene no PCR product is 
produced and in this way, these patients can be distinguished from persons that 
are heterozygous or homozygous carriers of the GSTM1 gene.(83) In a relative 
small study in patients treated with AZA, metabolite levels were significant 
different in those who carried a homozygous GSTM1 deletion.(84) Effects of 
genetic variants in GSTA1 and GSTA2 are less pronounced, since there is not an 
on/off mechanism as with GSTM1. In patients with a down regulation of GSTA1 
expression due to genetic variant, there is a compensatory increase in GSTA2 
expression.(68) Furthermore, most genetic variants in GSTA2 have no significant 
effect on in vitro thiopurine metabolism.(24, 85) Therefore, the consequences of 
genetic variants in GSTA1 and GSTA2 on thiopurine metabolism are probably less 
pronounced, however no in vivo studies have yet been published.(64)
In this thesis, we tried to further elucidate the role of genetic variants in GSTA1, 
GSTA2 and GSTM1 in thiopurine metabolism. To answer this question, we used 
data of a large prospective multi-centre trial conducted in the Netherlands in 
which thiopurine naive patients with IBD were randomized for thiopurine dosing 
based on their TPMT genotype versus the standard thiopurine dose. Patients were 
assigned to either AZA or MP.(86) With the knowledge that GSTs are only involved 
in the conversion of AZA to MP, effects of genetic variants in GSTM, GSTA1 and 
GSTA2 on metabolite levels should come forward in patients taking AZA but not 
in those treated with MP.
Use of thiopurines in daily practice
Rationale of thiopurine dosing in IBD
Currently, guidelines express no preference for either AZA or MP as first choice 
thiopurine.(5, 87, 88) Despite a lack of comparative studies, equivalence is 
considered and for this reason guidelines use combined naming, such as “AZA/
MP”. For both agents starting dose is based on bodyweight, with AZA being 
dosed at 2.0-2.5 mg/kg and MP at 1.0 -1.5 mg/kg.(89-91) The difference in dosing 
between AZA and MP follows from a differences in molecular weight of both 
compounds. As mentioned previously, approximately 88% of AZA is converted 
to MP. This in combination with the different molecular weight (AZA 277.27 g/
mol and MP 152.19 g/mol) leads to a conversion factor of 2.08 to calculate an 
equivalent dose of MP from AZA.(92, 93)
1
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Although AZA and MP are considered equal, there are some relevant issues. 
Some immunosuppressive effects have been ascribed to the 12% of AZA 
which is converted to methyl-4-nitro-5-thioimidazole.(94, 95) On the other 
side, the nitro-imidazolegroup, which is present in AZA but not in MP, has been 
associated with gastro-intestinal side effects.(96) Recent studies suggest that 
MP may be considered in patients with a history of AZA-induced pancreatitis.
(97, 98) Differences in national approval have led to large global differences in the 
preference for either AZA or MP in patients with IBD, yet no clinical comparative 
studies nor retrospective analysis have been performed to prove equivalence. 
Therefore, the level of evidence for equivalence of AZA and MP in the treatment 
of IBD remains limited to expert opinions. In this thesis, we compared safety and 
effectiveness of AZA and MP in patients with IBD. For this study we used data 
from a large, prospective study executed in the Netherlands.(86) In this study 
physicians were free in their choice to start either with AZA or MP. This resulted 
in 497 patients assigned to AZA and 273 patients with IBD taking MP.
In case treatment with the one of the conventional thiopurines (AZA or MP) fails 
two alternative strategies may be applied. First, low dose azathioprine allopurinol: 
This strategy has proven to be especially effective in patients with a preferential 
metabolism toward 6-MMPR metabolites, the so called ‘shunters’. Allopurinol 
is a strong XO-inhibitor and for not yet completely understood mechanisms also 
inhibits TPMT.(99) Co-administration of allopurinol results in a shift in metabolism 
from preferential 6-MMPR formation towards especially 6-TGNs being formed.
(100, 101) Reduction of the AZA dose prevents the patient from a life-threatening 
myelosuppression due to high 6-TGN levels.(102) Other positive effects subscribed 
to the low dose azathioprine allopurinol strategy are the anti-oxidant characteristics 
of allopurinol. In this thesis, we further explored the effects of allopurinol co-
administration in an in vitro setting. The second strategy is to start thioguanine 
(6-TG) (Lanvis®, ACES-TG®, Thiosix®). The clinical use of 6-TG in patients with 
IBD is limited due to associations with hepatic nodular regenerative hyperplasia in 
the past.(103) Metabolism of 6-TG is less complex and the number of steps before 
6-TGNs are being formed is lower (Figure 2). Moreover, no 6-MMPR metabolites 
are being produced and 6-TG is less subjective to metabolism by TPMT and 
XO.(104)
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Side effects of thiopurine treatment
Despite its proven effectiveness many patients prematurely discontinue thiopurine 
treatment, due to a variety of reason such as a lack of response or the occurrence 
of side effects.(13) Thiopurine related side effects can be categorized as either 
idiosyncratic or dose-dependent (Table 2).(48, 105) Idiosyncratic side effects 
include rash, flu-like symptoms, vomiting, myalgia, arthralgia, thiopurine-induced 
acute pancreatitis and hair loss.(105) Dose-dependent side effects can be 
subscribed to elevated 6-MMPR or 6-TGN levels. Thiopurine-induced increase in 
liver enzymes (from now on mentioned as hepatotoxicity) and thiopurine-induced 
myelosuppression are the best known and most prevalent dose-dependent side 
effects.(106-108)
Side effects often lead to dose reductions or treatment discontinuation.(15) The 
consequence of dose reductions may be that a patient receives a suboptimal 
treatment. There are no official guidelines for the management of thiopurine-
induced side effects. In the case of side effects it is relevant to assess 6-MMPR 
and 6-TGN metabolites and subsequent tailor dosage if necessary.(48) Only in 
the case of thiopurine-induced acute pancreatitis it is generally accepted that the 
thiopurine needs to be discontinued permanently.(110) There is no consensus 
whether a trial with MP is safe in the case of an AZA induced acute pancreatitis 
or another side effect.(97)
Thiopurine-induced hepatotoxicity is a major clinical problem leading to treatment 
discontinuation in approximately 4% of patients with IBD. The proportion of 
patients with elevations in liver enzymes is much higher.(106, 107) The variety in 
reported incidence rates can be explained by different definitions of hepatotoxicity.
(106) Management of thiopurine-induced hepatotoxicity remains challenging in the 
Table 2. Incidence rates of frequent reported thiopurine-induced side effects
Side effect (reference) Incidence
Hepatotoxicity*(106) 2-13%
Leukopenia*(108) 2-10%
Gastro-intestinal symptoms (nausea / vomiting) (109) 8%
Arthralgia (13, 109) 1-8%
Flu like symptoms (13, 109) 1-2%
Acute pancreatitis (110) 3-4%
* The variance in incidence is largely explained by differences in used definitions
1
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absence of guidelines and the knowledge that liver enzymes frequently restore 
without treatment interference.(106) Unnecessary dose reductions may hamper 
treatment efficacy, while long-term increase of liver enzymes might result in 
hepatic nodular regenerative hyperplasia.(111)
One of the most feared complications of thiopurine treatment is myelosuppression. 
Leukopenia is feared due to the risk for infectious complications in immune-
comprised patients.(108) The incidence of thiopurine-induced myelosuppression is 
estimated to be around 5%, depending on the applied defintions.(108) Most cases 
of leukopenia are only mild, but severe and even fatal cases have been described 
in literature.(50, 52) For this reason, most patients with leukopenia are subjected 
to dose reductions in order to restore leukocyte levels.(15) Leukopenia mostly 
develops in the first months after treatment initiation or dose-increasements. 
The best known risk factor for leukopenia is the presence of genetic variants in 
TPMT. These variants explain up to 25% of leukopenia cases in patients taking 
thiopurines.(112) Genetic variants in TPMT may lead to a reduced TPMT enzyme 
activity resulting in a thiopurine metabolism with a preferred production of 6-TGNs. 
This may result in extreme high 6-TGN levels (in the range of thousands pmol x 108 
RBCs) in patients with a homozygote variant in TPMT on standard thiopurine dose. 
(113) These patients may develop a severe pancytopenia, which subsequently 
increases the risk for (fatal) infectious complications.(50, 114) Life-threatening 
myelosuppression may be prevented by assessment of the TPMT status prior to 
initiation of thiopurine treatment. Management of patients with a genetic variant 
in TPMT comprises a reduction in thiopurine dose to 50% of the initial dose in 
patients with a heterozygous variant and 0-10% of the original recommended dose 
in patients with a homozygous variant.(115) The TPMT status can be investigated 
by genotyping patients DNA for variants in TPMT (genotype) or assessment of 
TPMT enzyme activity (phenotype).(86, 116) Both methods have their advantages 
and disadvantages.(115) Studies have shown that pre-emptive assessment of 
TPMT status is a cost-effective strategy, however clinical implementation remains 
limited.(117-119)
In patients without a genetic variant in TPMT leukopenia rates are still around 
5%.(15) This begs the question whether there are TPMT-independent pathways 
that explain leukopenia. Some other genetic variants have been described, 
however these are very rare in Caucasians.(120) Recently, a large study showed 
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that leukopenia was more frequent in patients treated with MP compared to AZA.
(109) Other factors related to thiopurine-induced myelosuppression mentioned in 
literature are concomitant use of 5-ASA and viral infections.(121, 122) This suggest 
that leukopenia might be temporarily and potentialy self-limiting. It is questionable 
whether patients who developed a mild or moderate leukopenia in the absence 
of a variant in TPMT are at increased risk for infections. This raises the question 
whether patients with a leukopenia in the absence of a TPMT variant should be 
subjected to thiopurine dose reduction.
Altogether, there is only limited knowledge with regard to the optimal management 
of thiopurine-induced leukopenia in the absence of genetic variants in TPMT. In this 
thesis, we analyzed other risk factors for thiopurine-induced leukopenia besides 
genetic variants in TPMT. In addition, we explored whether the risk for infections 
is increased in patients with a thiopurine-induced leukopenia. These analyses were 
performed with data derived from the TOPIC trial.(86) In this trial, thiopurine-naive 
patients with IBD were followed for five months after thiopurine initiation with 
routinely leukocyte measurements.
Patients’ believes about drugs
In the optimization of treatment with thiopurines much effort is put in the 
development of diagnostic tools such as TPMT genotyping and assessment of 
metabolite levels. However, in the current era of exhaustive technical possibilities, 
we underestimate the importance of taking a good medical history. A patient 
continuously balances the benefits of a specific treatment against potential harms. 
These perceptions are important for the coping mechanism during unexpected 
side effects or in case the body fails to respond on the drug. Knowledge of 
patients perceptions regarding their treatment is highly relevant. Patients with a 
low necessity or patients with high concerns towards a treatment tend to have 
lower adherence rates.(123)
In this thesis, we explored whether feelings and concerns of patients regarding 
thiopurine treatment are relevant in the identification of groups at risk for 
premature treatment discontinuation. For this study, we used the Believes about 
Medicine Questionnaire (BMQ). This questionnaire was developed to quantify 
personal needs and concerns regarding a particular treatment.(124) The BMQ was 
developed to assess both disease-specific beliefs as well as beliefs to medication 
1
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in general and is validated in patients with various chronic diseases such as 
asthma, rheumatoid arthritis, diabetic, IBD, chronic kidney diseases, chronic heart 
disease, and psychiatric diseases. Based on the score on statements regarding 
the necessity of treatment and potential drawbacks or concerns patients can be 
categorized in four groups of ‘treatment beliefs’.(124)
AIMS OF THIS THESIS
This thesis focuses on the use of the conventional thiopurines; AZA and MP in IBD. 
Ineffectiveness and high rates of side effects lead to high discontinuation rates. 
The development of biologics in the nineties of the previous century introduced 
a new era in the treatment of IBD.(125, 126) Moreover, new drugs with different 
targets of action have recently been developed or are under development, but the 
range of options for patients with IBD remains limited.(11) Therefore, thiopurines 
remain a cornerstone in the treatment of IBD, though it is of great importance to 
optimize its use.
The aim of this thesis is to improve knowledge about thiopurine metabolism 
and the clinical use of thiopurines in order to successfully initiate a higher rate 
of patients on long-term thiopurine use. We specifically aimed to answer the 
following research issues:
 - Which of the thiopurines (AZA or MP) should be preferred as first choice 
thiopurine in the treatment of IBD
 - Identification of risk factors for thiopurine-induced leukopenia
 - Identification of patients at risk for early treatment discontinuation
 - Increase knowledge about thiopurine metabolism, with specific interest for 
the role of GSTs in thiopurine metabolism and in vitro thiopurine toxicity
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ABSTRACT
Background: There are substantial global differences in the preference for 
mercaptopurine (MP) or its prodrug azathioprine (AZA) as first choice thiopurine 
to treat inflammatory bowel diseases (IBD). Studies comparing both agents are 
scarce. Our aim was to compare AZA and MP in thiopurine-naive IBD patients 
for the frequency of side effects and efficacy.
Methods: Post-hoc analysis of the ‘Thiopurine response Optimization by 
Pharmacogenetic testing in Inflammatory bowel disease Clinics’ (TOPIC) trial, 
in which thiopurine naive IBD patients with an indication for a thiopurine were 
randomized for a genotype based dose versus standard of care. For this study 
Cox-proportional hazard ratios (HR) were calculated to compare AZA and MP for 
discontinuation rates within five months, incidence of hepatotoxicity, leukopenia 
and gastrointestinal side effects. Treatment efficacy was compared by logistic 
regression.
Results: Patient characteristics were similar for patients treated with AZA (n=494, 
64.4%) and MP (n=273, 35.6%), yet patients with MP were relatively higher dosed 
compared to patients on AZA. Discontinuation rates within five months were not 
different, 39.3% (AZA) and 38.1% (MP), HR 0.92 (95%CI, 0.72–1.17; p=0.50), 
however patients on MP were more often subjected to dose reductions (30% 
versus 14%, p<0.01). Higher rates of hepatotoxicity, HR 1.93 (95%CI, 1.35-2.76; 
p<0.01) and leukopenia, HR 2.55 (95%CI, 1.51-4.30; p<0.01) were observed with 
MP, which annulled in a secondary analysis with adjustment for the higher dose 
and metabolite levels.
Conclusion: Patients treated with MP were relatively higher dosed, which resulted 
in more dose-dependent side effects and a higher rate of dose reductions.
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INTRODUCTION
Thiopurines have a central role in the treatment of inflammatory bowel diseases 
(IBD) and are also used in the treatment of numerous immune-mediated diseases 
and malignancies as well as for the prevention of posttransplantation organ 
rejection.(1-3) Azathioprine (AZA) and mercaptopurine (MP) are classified as the 
conventional thiopurines. Both agents have proven efficacy in the treatment of 
Crohn’s disease (CD) and ulcerative colitis (UC).(4-7) Unfortunately, the use of 
thiopurines is frequently accompanied by side effects such as hepatotoxicity, 
gastrointestinal complaints, flu-like symptoms or leukopenia, often leading to 
premature treatment discontinuation.(8, 9)
After absorption AZA is metabolized to MP and further metabolism leads to the 
formation of several metabolites of which 6-thioguanine nucleotides (6-TGN) and 
6-methylmercaptopurine ribonucleotides (6-MMPR) are considered to be the most 
important.(10) Current guidelines for IBD express no preference for AZA or MP 
because an equal efficacy is assumed and head-to-head comparisons are lacking.
(5, 11, 12) Accompanied with marketing related issues, this has led to major 
global differences in the preference for AZA or MP as first-choice thiopurine to 
treat IBD.(13) Although many studies have reported on thiopurine-induced side 
effects, none of these focused on a direct comparison of AZA and MP, or these 
investigations were limited by the fact that one drug was overrepresented in the 
study population.(14-17)
Nevertheless, some reports showed differences between AZA and MP in terms 
of side-effects.(18) The methylnitroimidazole group, which is released in the 
conversion of AZA to MP, has been associated with gastrointestinal side effects, 
but also with enhanced immunosuppressive effects.(19, 20) Furthermore, genetic 
variants in glutathione transferase, an enzyme involved in the conversion of AZA 
to MP, might affect thiopurine metabolite levels in patients on AZA but not in 
those on MP.(21, 22) Recent data suggest that MP might be considered as an 
alternative in patients intolerant to AZA.(23, 24) Notably, if AZA and MP would 
have been developed in the current era, randomized blinded trials would have been 
mandatory to compare their safety and efficacy profiles prior to routine use. Such 
data are currently lacking and given the cost of such studies and relatively low 
financial implications, it is highly unlikely that such trials will ever be performed. 
2
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In the present post-hoc analysis of the “Thiopurine response Optimization by 
Pharmacogenetic testing in Inflammatory bowel disease Clinics” (TOPIC) trial, 
we evaluated the hypothesis that AZA and MP are equally effective and safe in 
the treatment of thiopurine-naive IBD patients.
PATIENTS AND METHODS
Patients
The study design, patient data and results of the TOPIC trial have been published 
previously.(25) Briefly, thiopurine-naive IBD patients with an indication for 
thiopurine treatment were randomized 1:1 for thiopurine dosing based on their 
thiopurine S-methyltransferase (TPMT ) genotype versus the standard AZA (2.0-2.5 
mg kg-1) or MP dose (1.0-1.5 mg kg-1). Patients assigned to the TPMT genotyping 
arm received a 50% dose reduction when they carried a heterozygote variant 
in TPMT*2, TPMT*3A or TPMT*3C, whereas carriers of a homozygote variant 
received 10% of the original dose or were advised to start an alternative treatment. 
Patients assigned to the standard of care arm were genotyped for variants in 
TPMT afterwards. TPMT activity was assessed in all patients after the execution 
of the clinical trial.
Indication for thiopurine treatment was determined by the treating physician. 
Indication was not reported on the case report form. Physicians were free in 
the choice whether to start AZA or MP, and advised to start full regular dose 
immediately. The main exclusion criteria of the TOPIC trial were previous use 
of thiopurines, co-treatment with allopurinol, a baseline white blood cell (WBC) 
count < 3.0 x109 /L, baseline liver test abnormalities (alanine transaminase [ALT], 
aspartate transaminase [AST] or alkaline phosphatase [AP)] ≥ two times the 
normal upper limit (ULN), a known TPMT enzyme activity or TPMT genotype. 
Biochemical and hematological safety parameters were assessed at baseline and 
weeks 1, 2, 4, 6, 8 and 20. The patients were followed for 20 weeks. The TOPIC 
trial was approved by the institutional ethic committees, and all patients provided 
written informed consent (clinicaltrials.gov, NCT00521950).
6-MMPR and 6-TGN Metabolite levels
Week eight 6-MMPR and 6-TGN metabolite levels were assessed in red blood 
cells (RBCs) by high-performance liquid chromatography, according to the Lennard 
517689-L-sub01-bw-Broekman
Processed on: 7-3-2018 PDF page: 39
39
Comparison of azathioprine and mercaptopurine in IBD
method and reported as median pmol/8 × 108 RBCs with the interquartile range 
(IQR).(25) Week eight levels were assessed in the first 301 patients included in 
the TOPIC trial. Next to week eight levels, 6-MMPR and 6-TGN levels were also 
assessed at week one in 267 patients according to the same method.(26, 27)
Study design
In this study, we compared AZA and MP for their safety and efficacy. All patients 
who complied with the study protocol and started with AZA or MP were included 
in an intention to treat analysis. The AZA dosage in mg/kg bodyweight was divided 
by 2.08 for comparison with the MP dose. The molecular weight of MP (Mw 
= 152.18 g/mol) is 55% of the molecular weight of AZA (Mw =277.27 g/mol), 
resulting in a conversion factor of 2.08 (1/0.55 · 1/0.88), when converting MP to 
an equivalent pharmaceutical dose of AZA, assuming 100% bioavailability.(18, 28) 
In 30 patients the dose was escalated within one or two weeks. In these cases 
we used the final dose for analysis.
The primary outcome was the proportion of the patients who were still using the 
initial thiopurine after five months. Dose reductions and temporarily interruption 
were accepted; however, when the thiopurine was discontinued for more than 
20% of the study time (one month or longer) the primary endpoint was not 
reached. If the indication for discontinuation after temporarily interruption was 
identical to the final reason to stop, the first date of discontinuation was used for 
analysis. When a different indication led to definite treatment discontinuation after 
temporarily discontinuation, the last date was used for analysis.
Secondary outcomes were signs of hepatotoxicity (defined as increase more than 
two times ULN of ALT or conjugated bilirubin, or a combined increase in AST and 
AP provided that one of them is above two times ULN).(29) When baseline levels 
were between one and two times ULN, a two times increase of the baseline value 
was required. Furthermore, the frequency of gastrointestinal side effects (defined 
as occurrence of nausea, vomiting or decreased appetite during the study as 
reported by the patient), leukopenia (defined as a WBC count ≤ 3.0 x 109 /L) and 
the incidence of thiopurine-induced pancreatitis (TIAP) were compared for AZA 
and MP. TIAP was defined as the presence of amylase or lipase three times the 
ULN according to the reference value of the local laboratory in combination with 
radiological or clinical signs suggestive for pancreatitis in the absence of another 
2
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likely cause.(30) Treatment response was evaluated with the Harvey-Bradshaw 
Index in CD and partial Mayo score in UC. Treatment response was defined as a 
reduction of three points or more at week 20 compared to week 0.
Statistical analysis
All the statistical analyses were performed using SPSS version 20.0.0.1 (SPSS 
Inc., Chicago, IL, USA). The patient characteristics between patients on AZA 
and MP were compared by chi-square test for dichotomous variables, and the 
students’ t-tests or Mann Whitney U tests were used for continuous variables. 
We performed Cox proportional hazards survival analysis to calculate the 
Hazard ratio for AZA and MP with 95% confidence intervals (CI) for the time to 
treatment discontinuation, gastrointestinal side effects, signs of hepatotoxicity and 
leukopenia. Kaplan-Meier curves with separate lines for AZA and MP were plotted 
to illustrate differences in treatment discontinuation, gastrointestinal side effects, 
signs of hepatotoxicity and leukopenia. Log rank tests were used to compare the 
Kaplan-Meier curves.
Secondary multivariate Cox-proportional Hazard models were computed to 
calculate the Hazard ratio for AZA and MP adjusted for confounders. Differences 
in the patient characteristics between AZA and MP users with a P-value < 0.1 
were included in a Cox-proportional hazard model to calculate the adjusted Hazard 
ratio with 95% confidence intervals (CI) for AZA compared to MP for the primary 
outcome treatment discontinuation as well as the secondary outcomes signs of 
hepatotoxicity, leukopenia and gastrointestinal side effects. As follows from the 
comparison of baseline characteristics between AZA and MP, metabolite levels 
were included as covariate in this analysis. Week one metabolite data were chosen 
instead of week eight levels, because most adverse events, amongst others 
hepatotoxicity and leukopenia, occurred in the first weeks of treatment initiation. 
As a consequence, week eight metabolite levels were either biased in these 
patients due to already applied dose reductions or were not available because 
of treatment discontinuation before week eight because of the adverse event. 
Moreover, patients with severe hepatotoxicity or leukopenia are more likely to be 
subjected to dose reductions or treatment discontinuation, which also might lead 
to biased results. With the use of week one metabolite levels this was obviated, 
since patients did not develop the adverse event yet. Week one metabolite 
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levels were available for 267 patients and Cox-proportional Hazard analysis were 
performed in these patients.
The treatment response in AZA and MP was compared by chi-squared test. For 
further analysis, the response rates in CD and UC were merged to have sufficient 
numbers. Logistic regression was used to calculate the odds ratio of treatment 
response adjusted for confounders. A p-value of <0.05 was considered statistically 
significant.
RESULTS
Patients
In the TOPIC trial 796 patients were randomized, of whom 29 did not start with 
a thiopurine or were excluded due to protocol violations.(25) The remaining 767 
patients treated with either AZA (n=494, 64.4%) or MP (n=273, 35.6%) were 
included in this analysis. The baseline characteristics of both groups are depicted 
in Table 1 and showed no differences between AZA and MP users except for 
the median dose in mg/kg, which was higher in patients taking MP (1.21 mg/kg, 
IQR 1.10-1.30) compared to the converted rate of AZA (1.05 mg/kg, IQR 0.99-
1.11), p<0.001. Furthermore, both week one and week eight 6-MMPR and 6-TGN 
metabolite levels were significantly higher in patients treated with MP (Table 1). 
Otherwise, no differences in characteristics were observed between the patients 
assigned to AZA and MP.
Treatment discontinuation
Overall, 298 patients (38.9%) discontinued the initial thiopurine within five months 
after starting treatment. In patients taking AZA, n=194 (39.3%) discontinued 
treatment and in patients taking MP, n=104 (38.1%), p=0.75. The Kaplan-Meier 
curves showed no difference in treatment discontinuation rates between AZA 
and MP, p=0.57 (Figure 1). The hazard ratio for AZA versus MP with 95% CI for 
discontinuation in the first five months was 0.92 (0.72–1.17; p=0.50).
Of the patients still taking the initial prescribed thiopurine at week 20 (n=469), 
those treated with MP were more often subjected to dose reductions compared 
to the patients treated with AZA (30.1% vs. 13.7%, p<0.001). Additionally, at week 
20 the median dose of the patients still taking the initial prescribed thiopurine 
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was significantly more decreased in patients taking MP (n=168), 1.14 mg/kg (IQR 
0.82-1.25), compared to patients treated with AZA (n=300), 1.04 mg/kg (IQR 
0.96-1.11), p<0.001.
Signs of hepatotoxicity
Signs of hepatotoxicity (defined as more than two times ULN increase of ALT or 
conjugated bilirubin, or a combined increase in AST and AP provided that one of 
them is above two times ULN) were reported in 59 patients treated with AZA 
(11.9%) and in 62 patients taking MP (22.7%), hazard ratio 1.93 (95% CI, 1.35-
2.76; p<0.001). In 88% per cent of the patients (106 of 121) with hepatotoxiticity, 
this developed in the first eight weeks of treatment. Time to hepatotoxicity was 
not significantly different between AZA and MP (p=0.64) (Figure 2). The median 
[IQR] rise of ALT was not different between AZA-users, 90 U/l [65-148], and MP 
users, 96 U/l [68-133], p=0.83 (Figure 3).
Because patients with MP were relatively higher dosed and therefore probably 
showed higher metabolite levels, we also calculated the hazard ratio adjusted 
for these variables. This secondary analysis in 267 patients, with adjustment for 
dosage in mg/kg and week one 6-MMPR and 6-TGN metabolite levels showed a 
hazard ratio of 1.79 (95% CI, 0.82-3.92; p=0.15).
Figure 1. Time to treatment discontinuation for patients assigned to AZA and MP. No 
difference in treatment discontinuation was observed between AZA and MP, p=0.57. 
AZA, azathioprine; MP, mercaptopurine.
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Figure 3. Maximum increase in ALT in Units/litre compared to baseline in patients on AZA 
(n=59) and patients on MP (n=62) who developed signs of hepatotoxicity. No difference 
was observed between AZA and MP (p=0.83). ALT, alanine transaminase; AZA, azathio-
prine; MP, mercaptopurine.
Figure 2. Time to development of signs of hepatotoxicity (defined as more than two times 
the normal upper limit increase of ALT or conjugated bilirubin, or a combined increase in 
AST and AP provided that one of them is above two times the normal upper limit) in pa-
tients taking AZA or MP. No difference was observed in the time to the development of 
signs of hepatotoxicity between AZA and MP (p=0.64). ALT, alanine transaminase; AST, 
aspartate transaminase; AP, alkaline phosphatase; AZA, azathioprine; MP, mercaptopurine.
2
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Leukopenia
Leukopenia (defined as a WBC count ≤ 3.0 x 109 /L) was observed in 58 patients 
(7.6%). Eight of these patients (four patients on AZA and four on MP) had a variant 
in TPMT and were randomized to the standard of care group and subsequently 
received the standard thiopurine dose. Leukopenia was observed in 24 patients 
(4.9%) treated with AZA and in 34 patients (12.5%) treated with MP, hazard ratio 
2.55 (95% CI, 1.51-4.30; p<0.001). Secondary analysis with adjustment for dosage 
in mg/kg and week one 6-MMPR and 6-TGN metabolite levels showed a hazard 
ratio of 0.92 (95% CI, 0.28-3.05; p=0.89). The time to development of leukopenia 
was not significantly different between AZA and MP (p=0.62) (Figure 4).
Gastrointestinal side effects
Gastrointestinal side effects were reported by 345 patients (45.0%), of whom 
216 patients (43.7%) were treated with AZA and 129 patients (47.3%) with MP, 
hazard ratio 1.09 (95% CI, 0.87-1.3; p=0.46). Median time to the occurrence of 
gastrointestinal side effects was 14 (7-34) days. No difference was observed in the 
Kaplan-Meier curve between AZA and MP, p=0.52 (Figure 5). In the secondary 
analysis the hazard ratio for AZA or MP on gastrointestinal side effects was hazard 
ratio 1.38 (95% CI, 0.90-2.10; p=0.17).
Thiopurine-induced acute pancreatitis
In total 14 patients (1.8%), of whom 11 on AZA (2.2%) and three on MP (1.1%) 
developed a TIAP for which the initial thiopurine was stopped. Characteristics of 
patients with a TIAP are depicted in Supplementary Table 1. Mean time to TIAP 
was 20 ± 5 days and no cases of severe (necrotizing) pancreatitis were reported. 
One patient with a TIAP on AZA was later switched to MP, however this was 
stopped after one day because of fever (no laboratory measurements were done).
Treatment efficacy
Information about treatment response was available for 351 patients (45.7%), 
AZA (n=242) and MP (n=109). Baseline disease activity scores (mean ± SD) were 
not different for patients of whom treatment response was known or unknown 
(Harvey-Bradshaw index, 3.43 ± 2.88 vs. 3.62 ±3.36, p=0.63) and (partial Mayo 
score, 3.74 ± 1.73 vs. 3.90 ± 1.70, p=0.50), respectively. In CD, 38 patients on 
AZA (26%) and 21 patients on MP (26%) achieved a reduction in Harvey-Bradshaw 
Index of three points of more, p=0.90. In UC, a reduction in partial Mayo score 
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of three points of more was seen in 22 patients on AZA (24%) and 9 patients on 
MP (32%), p=0.42. For further analysis, the response rates in CD and UC were 
merged to have sufficient numbers. No difference in treatment response was 
observed between AZA (26%) and MP (27%), odds ratio 1.12 (95%, CI 0.67-1.87; 
p=0.66). In this group week one metabolite levels and thiopurine dose were 
available for 126 patients. Secondary analysis in this group with adjustment for 
week one metabolite levels and thiopurine dose did not influence the odds ratio 
1.11 (95% CI, 0.44-2.88; p= 0.88).
Figure 4. Time to development of leukopenia (defined as a white blood cell count ≤ 3.0 
x109/L) in patients taking AZA or MP. No difference was observed between patients on 
AZA and MP (p=0.62). AZA, azathioprine; MP, mercaptopurine.
Figure 5. Time to development of gastrointestinal side effects in patients taking AZA or 
MP. No difference was observed between AZA and MP (p=0.52). AZA, azathioprine; MP, 
mercaptopurine.
2
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DISCUSSION
Our data showed that in thiopurine-naive IBD patients the treatment discontinuation 
rates within the first five months were similar between AZA and MP users. The 
higher rates of signs of hepatotoxicity and leukopenia in patients taking MP are 
most likely explained by the relatively higher average dose and subsequent higher 
6-MMPR and 6-TGN metabolite levels compared to patients with AZA, rather than 
by interdrug differences. Furthermore, no differences were found in treatment 
efficacy and gastrointestinal side effects.
The baseline characteristics were similar for the patients on AZA and MP. This 
excluded a preference for one of both agents in particular patient groups. Our data 
on dosage and metabolite levels showed that patients with MP were relatively 
higher dosed in mg/kg bodyweight compared to AZA-users. This might well 
explain the higher rates of dose dependent side effects like leukopenia and signs 
of hepatotoxicity with MP.(31) Adjustment for the baseline differences in thiopurine 
dose and week one metabolite levels annulled these higher rates of side effects. 
Week one 6-MMPR and 6-TGN levels have been shown to be promising factors 
to predict leukopenia and hepatotoxicity.(26, 27) Most side effects were seen in 
the first weeks of treatment initiation and often led to dose reduction or treatment 
discontinuation. As a consequence steady-state week eight metabolite levels were 
not available or biased due to dose reductions in these patients. For this reason we 
used week one metabolite levels for our secondary analysis. Both drug dose and 
thiopurine metabolite levels were significant higher in MP users. Because most 
studies showed no clear correlation between drug dose and thiopurine metabolite 
levels we included both variables in the multivariate analysis.(32, 33)
Current studies exploring the safety profile of thiopurines are mostly limited by 
the inclusion of patients only taking AZA or MP.(15, 16, 34) This problem is mainly 
due to global variation in the preference for either AZA or MP, and is partly caused 
by the fact that not everywhere both drugs are registered for the treatment of 
IBD.(13) Although not specifically designed for this purpose, some studies did 
compare AZA and MP in their analysis. In a recent study, a five-fold higher rate of 
leukopenia was found in patients taking MP compared to AZA.(14) Despite the 
large study population of almost 4,000 patients, the lack of detailed information 
on the dosage and metabolite levels precluded detailed dose-related analysis as in 
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our study. The incidence of hepatotoxicity in the current study was 15.8%, which 
is within the range of the highly variable incidence reported in previous studies.(9, 
35) This wide range (4-17%) is probably the result of differences in study protocols 
and definitions of drug-induced liver toxicity.(35) The frequent routine laboratory 
controls in the TOPIC trial in combination with our criteria for hepatotoxicity and 
the fact that in the TOPIC trial patients started with the full regular dose probably 
contributed to the high rate found in our study. Present criteria for drug-induced 
liver toxicity include an increase of ALT or AST five times the ULN.(36) Only 11 
patients in our study would meet these criteria, yet most of the patients with liver 
test abnormalities between two and five times the ULN received a dose reduction 
or the treatment was (temporarily) discontinued. Given the clinical relevance, 
we applied the more liberal criteria formulated by Benichou.(29) There are many 
factors involved in the development of thiopurine induced hepatotoxicity including 
thiopurine dose, bodyweight, gender and age. (27)
In the TOPIC trial patients were randomized for dose adjustment based on their 
TPMT genotype versus standard dosing. This resulted in a group of patients 
with a heterozygous variant in TPMT treated with the standard dose as well as a 
group who received 50% of the standard dose. Supplementary Table 2 provides 
detailed information about side effects rates for these different groups. Absolute 
numbers are low, which precludes additional analyses to compare AZA with MP 
within these subgroups. However, taking the small groups into account no large 
differences were seen between AZA and MP with respect to hepatotoxicity, 
leukopenia and gastrointestinal side effects.
As mentioned above, our results show that when official clinical guidelines 
are applied MP is prescribed in a relatively higher dose than AZA. This finding 
has been described previously in a large retrospective analysis, where patients 
with AZA received 1.94 mg/kg (0.93 mg/kg after conversion by 2.08) and MP 
was dosed at around 1.20 mg/kg.(8) A reason might be that the only available 
pharmaceutical dosage form of MP is 50 mg, whereas for AZA there are 25 mg 
and 50 mg tablets available in Europe. Introduction of 25 mg tablets of MP (and 
AZA, if not yet available) would allow more accurate dosing and will circumvent 
the need of scoring tablets to acquire the optimal tailored dose. Additionally, given 
that the absolute dosage is lower in MP, increasing the dose with 25 or 50 mg 
leads to a larger effect in terms of percentages in a patient on MP compared to a 
2
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patient taking AZA. Another explanation might be that in clinical practice a more 
convenient conversion rate of 2.0 is used instead of 2.08 to calculate the AZA 
dose from the equivalent MP dose.(28) Current guidelines recommend AZA in a 
dose between 2.0-2.5 mg kg-1 and MP between 1.0-1.5 mg kg-1, however when 
the 2.08 rate is applied to the recommended AZA dose, MP should actually be 
dosed between 0.96 and 1.20 mg/kg.(6, 37, 38) The equal discontinuation rates, 
despite more dose-dependent side effects with MP, can be explained by the 
higher rate of dose reductions applied in patients treated with MP. This advocates 
for a slightly lower starting dose of MP.
In the TOPIC trial a high rate (38.9%) of treatment discontinuation was observed 
within the first five months, primarily due to side effects. This rate is in line with 
previous studies which reported discontinuation rates of approximately 30% within 
the first months.(8, 39) The high discontinuation rate underlines the potential 
impact of thiopurine-induced adverse events. As expected, gastrointestinal 
side effects were the most frequent reported adverse event and occurred in 
approximately 50% of the patients. Our data corroborate with a recent study in 
almost 4,000 IBD patients on thiopurine therapy, which also found similar rates of 
gastrointestinal side effects in patients treated with AZA and MP.(14) Some studies 
have shown the gain of switching from AZA to MP in the presence of adverse 
events. (24) Although some patients were rechallenged after discontinuing the 
initial thiopurine no detailed information was available to report on success rates 
of this switch.
TIAP is considered to be a non dose-dependent adverse reaction linked with single 
nucleotide polymorphisms in the class II human leukocyte antigen region but 
also with blood group B.(40, 41) This makes a difference between AZA and MP 
in frequency unlikely. Our results showed a higher rate of TIAP in AZA compared 
to MP; however, given the low number of cases, we had insufficient power to 
perform statistic analysis.
This study provides novel insights on the comparability of AZA and MP as a result 
of some exclusive characteristics. First, this study focused on the comparison 
of AZA and MP, which was possible due to the large number of thiopurine-
naive patients assigned to AZA and MP. Additionally, the similarity of the baseline 
characteristics does not suggest selection bias.
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Limitations of this study are that the current analyses were not prespecified in 
the original study protocol. Furthermore, week one metabolite levels used for 
the secondary analysis were only available for 267 patients.(26) Importantly, 
there were no differences in baseline characteristics between the patients with 
known week one metabolite data compared to the patients without week one 
metabolite data (Supplementary Table 3). The use of week one metabolite 
levels is still limited to clinical trials. Secondary analyses with the use of week 
eight metabolite levels instead of week one levels showed consistent results, 
however with less cases included (Supplementary Table 4). Furthermore, in 
the TOPIC trial the Harvey-Bradshaw index and partial Mayo score were used to 
assess treatment efficacy. Ideally, colonoscopies should have been implemented 
for the assessment of mucosal healing, however since the TOPIC trial primarily 
focused on safety outcomes rather than effectiveness, these were not included.
(25) Furthermore, thiopurines were started both for active disease as well as 
maintenance of remission, which limits the assessment of the treatment effect. 
Also, the use of co-medication, such as corticosteroids or biologic drugs, is an 
important confounder in the evaluation of treatment effects. Considering these 
limitations, the treatment response of 26% and 27% in AZA and MP users, 
respectively, is in line with the data from the SONIC trial.(42, 43) In the TOPIC 
trial, physicians were advised to start the full dose immediately, in which the 
recommended dose depended on the TPMT genotype and whether the patient 
was randomized to the intervention arm or not. Beginning with the full thiopurine 
dose might result in relative higher rates of side effects compared to a step up 
approach (starting with half the dose and increase to full dose after one or two 
weeks if the drug is tolerated). With a step up approach the difference in dose 
dependent side effects between AZA and MP might decrease, because first 
signs of side effects already may result in a postponement of further increase to 
the intended dose.
In conclusion, in this study, we showed that when current clinical guidelines for 
IBD are followed, the patients treated with MP are relatively higher dosed, suffer 
from higher rates of dose-dependent side effects, and subsequently need more 
frequent dose reductions compared to patients treated with AZA. This might be 
prevented when the initial MP dose is adjusted to 0.96-1.20 mg kg-1 bodyweight 
and 25 mg tablets MP are introduced for a more accurate tailored dose; however, 
feature studies are necessary to further evaluate this. Despite these differences 
overall treatment discontinuation rates were equal for AZA and MP.
2
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Supplementary Table 3. Comparison of baseline characteristics of the patients with 
known week one metabolite data compared with those without week one metabolite 
data available.
Week one 
levels available 
(n=267)
No week one 
levels available 
(n=500)
p-value
Gender, male, n (%) 116 (43) 230 (46) 0.49
Age (years), median (IQR) 39.9 (26.0-52.4) 41.2 (26.8-53.4) 0.75
Weight, mean kg (SD) 73.9 (16.2) 74.6 (16.1) 0.61
Drug, AZA, n (%) 182 (68) 312 (62) 0.11
Randomized for genotyping, n (%) 134 (50) 264 (53) 0.49
Heterozygous TPMT genotype, n (%) 24 (9.0) 48 (9.6) 0.78
TPMT activity in mg/mmol Hb.h, 
mean (SD)
89.9 (21.9) 90.6 (22.7) 0.69
Disease, CD, n (%) 147 (55) 316 (63) 0.09
Dosage in mg/kg, median (IQR) a 1.07 (1.00-1.17) 1.10 (1.01-1.19) 0.18
a AZA doses was divided by 2.08 and pooled with MP dosage to compare dosage in 
mg/kg. AZA, azathioprine; CD, Crohn’s disease; MP, mercaptopurine ; TPMT, thiopurine 
S-methyltransferase
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Supplementary Table 4. Results of secondary multivariate Cox-proportional Hazard 
analysis to calculate the Hazard ratio for AZA and MP for the risk of adverse events 
adjusted for thiopurine dose and week eight metabolite levels.
Adverse event
Hazard Ratio  
(95% CI interval)
p-value
Cases and controls 
included in the analysis
Hepatotoxicity 1.65 (0.56-4.84) 0.36 19 cases, 136 controls
Leukopenia 2.28 (0.54-9.61) 0.26 11 cases, 143 controls
Gastrointestinal side effects 1.28 (0.72-2.29) 0.40 62 cases, 93 controls
Treatment response 0.77 (0.22-2.75) 0.70 84 patients included
Analyses were identical to the secondary analyses presented in the main text, with the 
difference that week eight 6-MMPR and 6-TGN levels were used instead of week one 
metabolite levels. The rationale behind this is that most cases of hepatotoxicity and 
leukopenia occurred before week eight and as a consequence most patients stopped 
treatment or were subjected to dose reductions. Therefore, week eight metabolite levels 
were either not available or levels were not representative in the majority of the cases. 
For this reason secondary analyses with week one levels were more representative and 
in addition more patients could be included. The results presented in this supplementary 
file corroborate those from the main text, indicating that the significant higher rates of 
hepatotoxicity and leukopenia in the univariate analysis in patients on MP do not stand in 
a secondary analysis with adjustment for the relative higher dose and higher metabolite 
levels in patients on MP compared to AZA.
 6-MMPR, 6-methylmercaptopurine ribonucleotides; 6-TGN, 6-thioguanine nucleotides; 
AZA, azathioprine; CI, Confidence Interval; MP, mercaptopurine
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ABSTRACT
Background: The conversion of azathioprine (AZA) to mercaptopurine (MP) is 
mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 
(GSTA2).
Methods: We designed a case-control study with data from the TOPIC trial to 
explore the effects of genetic variation on steady state 6-methylmercaptopurine 
ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels.
Results: We included 199 patients with inflammatory bowel disease (126 on 
AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 
6-MMPR levels than AZA users carrying one or two copies of GSTM1 [2239 
(1006-4587) versus 4371 (1897-7369) pmol/8x108 RBCs; p<0.01]. In patients on 
MP (control group) 6-MMPR levels were comparable [6195 (1551-10712) versus 
6544 (1717-11600) pmol/8x108 RBCs; p=0.84]. The 6-TGN levels were not affected 
by the GSTM1 genotype. The presence of genetic variants in GSTA1 and GSTA2 
was not related to the 6-MMPR and 6-TGN levels.
Conclusion: Homozygous GSTM1 deletion leads to a twofold reduction of 
6-MMPR levels in patients treated with AZA, but not in patients treated with 
6-MP.
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INTRODUCTION
Thiopurines exert cytotoxic and immunosuppressive effects and therefore are 
used in transplantation medicine and the treatment of cancer and a wide range of 
immune-mediated diseases, including Crohn’s disease and ulcerative colitis.(1-3)
Azathioprine (AZA) is a nitro-imidazole analogue of mercaptopurine (MP). AZA and 
MP are metabolized in several enzymatic steps to yield 6-thioguanine nucleotides 
(6-TGN), which are considered the main pharmacologically active compounds 
leading to therapeutic efficacy (Figure 1). The 6-methylmercaptopurine 
ribonucleotides (6-MMPR) are abundant side products formed during this process, 
and elevated levels have been linked to hepatotoxicity.(4) The formation of AZA 
from MP is considered to be primarily non-enzymatic; however, recent evidence 
surfaced that this process is mediated by the action of glutathione transferases.
(5) In the presence of gluthatione transferases, the electrophilic carbon of AZA 
is conjugated by glutathione, which results in the formation of MP and the 
glutathione-nitroimidazole conjugate.(6)
Glutathione transferases belong to a family of enzymes that have crucial 
functions in the conjugation, detoxification and transport within the cell of 
potentially toxic or carcinogenic compounds.(7, 8) In the wide range of glutathione 
Figure 1. Overview of AZA and MP metabolism. The involved enzymes are indicated in 
gray boxes. AZA, azathioprine; MP, mercaptopurine; GSTA, glutathione transferase alpha; 
GSTM, glutathione transferase mu; 6-MMP, 6‐methylmercaptopurine; 6-MMPR, 6‐meth-
ylmercaptopurine ribonucleotides; TPMT, thiopurine S‐methyltransferase; XO, xanthine 
oxidase; 6-TUA, 6‐thiouric acid; HGPRT, hypoxanthine‐guanine phosphoribosyl transferase; 
6-TIMP, 6‐thioinosine monophosphate; 6-TITP, 6‐thioinosine triphosphate; IMPDH, inosine 
monophosphate dehydrogenase; 6-TXMP, 6‐thioxanthosine monophosphate; GMPS, gua-
nosine monophosphate synthetase; 6-TGN, 6‐thioguaninenucleotides
3
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transferase subclasses, only glutathione transferase alpha 1 (GSTA1), glutathione 
transferase alpha 2 (GSTA2) and glutathione transferase mu 1 (GSTM1) have 
a significant contribution in the conversion of AZA to MP.(5) Genetic variants 
in the corresponding genes may affect enzyme activity and thus influence the 
conversion rate.(7) Higher GSTA1, GSTA2 or GSTM1 activity theoretically leads to 
increased conversion of MP from AZA. In addition to higher thiopurine metabolites 
levels, this increase may also lead to the production of more reactive oxygen 
species due to glutathione depletion.(9)
GSTM1 is located on chromosome 1. Notably, ±50% of the Caucasian and Asian 
populations carry a homozygous gene deletion in the GSTM1 gene (the so called 
GSTM1-null genotype). This deletion results in the complete absence of GSTM1 
enzyme activity.(10-12) Clinical studies that exclusively included patients on AZA 
revealed that patients with the GSTM1-null genotype formed lower thiopurine 
metabolite concentrations and had a lower rate of side effects compared to 
patients carrying one or two copies of the GSTM1 gene.(13, 14) However, no 
clinical studies have included patients on MP as a control group.(15)
GSTA1 and GSTA2 are both positioned on chromosome 6p12 and have high 
structural similarities.(16, 17) For GSTA1, several genetic variants have been 
described in the promoter region. These variants are all in linkage disequilibrium 
and lead to reduced GSTA1 expression. The liaison between GSTA1 and GSTA2 is 
illustrated by a compensatory increase in GSTA2 expression.(17) Genetic variants 
in GSTA1 and GSTA2 may also affect the protein structure, leading to a change in 
substrate specificity.(18-20) Although many combinations are possible, variants in 
GSTA1 and GSTA2 mainly occur in two haplotypes.(21) To date, no in vivo studies 
have been conducted to establish the effects of genetic variants in GSTA1 and 
GSTA2 on thiopurine metabolite formation.(6)
The aims of this study are two-fold: first, to provide further evidence of GSTM1 
involvement in AZA metabolism by investigating the effects of the GSTM1-null 
genotype on AZA metabolism using patients treated with MP as the control group, 
and second, to explore the effects of genetic variants in GSTA1 and GSTA2 on 
AZA metabolism.
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PATIENTS AND METHODS
Patients
We designed a case-control study with data from the Thiopurine response 
Optimization by Pharmacogenetic testing in Inflammatory bowel disease 
Clinics (TOPIC) trial, which evaluated the efficacy and cost-effectiveness of 
pretreatment thiopurine S-methyltransferase (TPMT) genotyping on thiopurine-
induced myelosuppresion.(22) In the TOPIC trial, thiopurine-naive patients with 
inflammatory bowel disease who had an indication for thiopurine treatment (as 
determined by the treating physician) were randomized 1:1 for thiopurine dosing 
based on their TPMT genotype versus the standard thiopurine AZA (2.0 - 2.5 
mg/kg) or MP dose (1.0 - 1.5 mg/kg). Patients randomized to the prior to treat 
genotyping arm who carried a heterozygote variant in *2, *3A or *3C of the TPMT 
gene received 50% of the original dose, whereas carriers of a homozygote variant 
received 0-10% of the original dose. The main exclusion criteria were previous 
thiopurine treatment, a known TPMT genotype or activity, liver test abnormalities 
(alanine transaminase, aspartate transaminase, alkaline phosphatase, and/or 
gamma glutamate transpeptidase ≥2 times the normal upper limit), or a leukocyte 
count <3.0x109/L. Physicians were free in their choice of AZA or MP and were 
advised to start the full dose immediately. The patients were followed for 20 
weeks. In total, 852 patients were assessed for eligibility; of the 796 randomized 
patients, 768 started with a thiopurine. For a detailed description of the study 
design, patient selection and patient data, please refer to Coenen et al.(22)
Blood samples were collected from all patients for TPMT genotyping, although 
the genotyping was performed after execution of the clinical trial in the patients 
randomized for standard thiopurine dosing. The 6-TGN and 6-MMPR metabolite 
levels were assessed at week 8 in the first 301 patients included in the trial. 
The TOPIC trial was approved by the institutional ethics committee, and all 
patients provided written informed consent prior to participation (clinicaltrials.
gov, NCT00521950).
For the current study, all patients who started with AZA or MP in whom the 
6-TGN and 6-MMPR levels were assessed at week 8 were eligible. Two exclusion 
criteria were applied. First, patients with a thiopurine dose adjustment within the 
first eight weeks were excluded because these adjustments affect metabolite 
3
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concentrations. Second, patients with a variant in TPMT were excluded due to 
the large interference of variants with thiopurine metabolism and because half 
of this group (patients randomized to the intervention arm) received a 50% dose 
reduction.
Polymerase chain reactions
Genomic DNA was extracted automatically using the Chemagic DNA isolation 
kit special (PerkinElmer, Waltham, MA, USA) according to the manufacturer’s 
instructions and stored at 4 °C prior to use. The presence of the GSTM1-null 
genotype was analyzed as previously described.(12) Briefly, the primers 5’-CTC 
CTG ATT ATG ACA GAA GCC-3’ and 5’-CTG GAT TGT AGC AGA TCA TGC-3’ were 
used with a Mg2+ concentration of 2.0 mM and an annealing temperature of 58 °C. 
To detect the GSTM1-null genotype a real-time polymerase chain reaction (PCR) 
and a melt curve analysis were performed with Bio-Rad Precision Melt Analysis 
Software version 1.0 (Bio-Rad, Hercules, CA, USA). The absence of a 650 base 
pair (bp) product suggests a homozygous gene deletion. The PCR was performed 
twice on two separate occasions. This method distinguishes homozygous and 
heterozygous carriers of the gene from the GSTM1-null genotype.(23)
Genetic variants in GSTA1 and GSTA2 were identified through restriction fragment 
length polymorphism analysis as previously described.(17, 19, 20) The primers and 
PCR conditions are depicted in Supplementary Table 1. Briefly, four functional 
genetic variants in the GSTA1 promoter region have been described, all of which are 
in linkage disequilibrium. The -697G, -633G, -135T, -118A combination (previously 
denoted with the base pairs -631, -567, -69, -52) is designated GSTA1*A and the 
-697T, -633T, -135C, -118G combination is designated as GSTA1*B.(24) The PCR 
results in a 480-bp gene-specific product. The presence of a GSTA1*B variant 
leads to a cut at the -135C position by the digestion enzyme EarI, resulting in 
96-bp and 384-bp products.(17) The products were visualized by electrophoresis 
on a 2% agarose gel to identify patients who are heterozygous or homozygous 
carriers of the GSTA1*B variant.(17) The three most relevant genetic variants for 
GSTA2 were identified in a similar fashion. The GSTA2 variants were designated 
as GSTA2*B, GSTA2*C and GSTA2*E according to previous reports.(21) A strong 
association exists between GSTA1 and GSTA2, and the variants primarily occur in 
two haplotypes. The homozygous GSTA1*A and homozygous GSTA2*C (haplotype 
1) and heterozygous GSTA1*B and GSTA2*C (haplotype 2) combinations are most 
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prevalent in Caucasians. The haplotypes were generated for GSTA1 and GSTA2 
using Partition-Ligation-Expectation-Maximization (PL-EM) software.(25) The 
haplotypes were used as markers for the total GSTA1/GSTA2 activity and were 
correlated with the thiopurine metabolite levels. The most prevalent haplotypes 
were used for the analysis.
6-MMPR and 6-TGN metabolite measurements
The 6-TGN and 6-MMPR levels were determined in red blood cells (RBCs) by 
high-performance liquid chromatography according to the Lennard method.(26) 
The thiopurine metabolite concentrations are presented as the median pmol/8x108 
RBCs with the interquartile range (IQR).
Statistical analysis
We assumed the presence of an effect due to genetic variants in GSTA1, GSTA2 
and GSTM1 in patients treated with AZA but not in patients treated with MP. 
Therefore, we analyzed the effects of the genotypes separately in the AZA and 
MP users. First we compared the baseline characteristics of the AZA users with 
the MP users to ensure that potential differences in the metabolite levels between 
polymorphisms found only in the AZA or MP users contributed to the tested 
polymorphism. We used the chi-square test, Student’s t test or Mann-Whitney 
U test as appropriate.
Next, we compared the baseline characteristics and week 8 6-MMPR and 6-TGN 
levels between patients on AZA with and without a GSTM1-null genotype. 
Additionally, the 6-MMPR/6-TGN ratio, which provides an indication for toxicity 
and therapeutic efficacy, was compared between the GSTM1 genotypes.(27) For 
these analyses, we used the chi-square test, Student’s t test or Mann-Whitney U 
test as appropriate. Separate analyses were performed for the patients on MP. In 
the same way, differences in patient characteristics and metabolite levels were 
compared for the two most frequent GSTA1/GSTA2 haplotypes in the AZA and 
MP users.
Genetic variants leading to a significant change in the metabolite levels and 
known factors from the literature that might influence the metabolite levels were 
included in an analysis of covariance. General linear models were performed with 
the metabolite levels set as the dependent variable. The 6-MMPR levels were 
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first log-transformed due to a skewed distribution. Gender and concomitant use 
of 5-aminosalicylic acid were included as fixed factors, and age and thiopurine 
dosage (mg/kg) were included as covariates.(28-30) The AZA dose was converted 
by 2.08 to compare the dose in mg/kg with MP.
For genotypes leading to a significant change in the metabolite levels, we 
evaluated the clinical relevance based on the treatment response and incidence 
of hepatotoxicity. The treatment response was compared using the Harvey-
Bradshaw Index for Crohn’s disease and the partial Mayo score for ulcerative 
colitis. A positive treatment response was defined as a reduction of three points or 
more at week 20 compared to week 0. Hepatotoxicity was defined as an increase 
in the serum concentration of alanine transaminase, aspartate transaminase or 
alkaline phosphatase ≥ 2 times the upper normal limit. Both parameters were 
compared using Pearson’s chi-square test. All statistical analyses were performed 
using SPSS version 20.0.0.1 (SPSS Inc., Chicago, IL, USA). Tests were two-sided 
and a p-value <0.05 was considered statistically significant.
RESULTS
Patients
Metabolite levels from week 8 were available for 301 patients. Thirty-eight 
patients were excluded due to a variant in the TPMT gene, and an additional 64 
patients were excluded due to dose adjustments before week 8, resulting in the 
inclusion of 199 patients (126 on AZA and 73 on MP) in this analysis. The baseline 
characteristics are provided for the patients treated with AZA and MP (Table 1). No 
differences were found between the two groups with the exception of a relatively 
higher thiopurine dose in mg/kg in the patients treated with MP. Table 2 shows 
the genotype frequencies of the GSTM1, GSTA1 and GSTA2 genetic variants. The 
genotype frequencies were in line with the population references.
GSTM1-null genotype influences AZA metabolism
No differences in the baseline characteristics were observed between patients 
with and without a GSTM1-null genotype in both the AZA and MP users (Table 3). 
The GSTM1-null genotype was reported in 56% of the patients on AZA and 47% 
of the patients on MP (p=0.22). Patients treated with AZA carrying a GSTM1-null 
genotype had lower 6-MMPR levels than the hetero- or homozygous carriers 
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Table 1. Baseline characteristics of the patients on AZA and MP included in this study
AZA users 
(n=126)
MP users 
(n=73)
p-value
Gender, male, n (%) 58 (46) 32 (44) 0.76
Age (years), median (IQR) 31 (24-48) 40 (26-50) 0.14
Weight, mean kg (SD) 72 (14) 71(19) 0.72
Thiopurine dose in mg/kg, median (IQR) 2.20 (2.09-2.33) 1.21 (1.11-1.30) N/A
Thiopurine dose in mg/kg, median (IQR) 
after conversion of AZA dose by 2.08
1.06 (1.00-1.12) 1.21 (1.11-1.30) <0.01
Disease type, CD, n (%) 76 (60) 41 (56) 0.68
TPMT activity in mg/mmol Hb.h, mean 
(SD)
96 (21) 95 (18) 0.58
Baseline disease activity
 CD (HBI), mean (SD) 3.1 a (2.3) 3.5b (3.6) 0.54
 UC (partial Mayo), mean (SD) 3.6c (1.9) 4.2d (2.0) 0.27
a available for 63 patients. b available for 31 patients. c available for 47 patients. d available 
for 26 patients. MP, mercaptopurine; AZA, azathioprine; CD, Crohn’s disease; HBI, Harvey-
Bradshaw Index; N/A, not applicable; TPMT, thiopurine S-methyltransferase; UC, ulcerative 
colitis
Table 2. Genotype frequencies of genetic variants in GSTA1, GSTA2 and GSTM1
Genotype
Frequencies
Total 
(n=199)
AZA 
(n=126)
MP (n=73)
Population 
reference^
GSTM1 1/1 and 1/null 0.48 0.44 0.53 0.47
GSTM1 null/null 0.52 0.56 0.47 0.53
GSTA1*A / GSTA1*A 0.37 0.43 0.27 0.34
GSTA1*A / GSTA1*B 0.47 0.42 0.56 0.50
GSTA1*B / GSTA1*B 0.16 0.15 0.16 0.17
GSTA2*B (c.629A>C) AA 0.89 0.89 0.89 0.87
AC 0.09 0.09 0.08 0.13
CC 0.02 0.02 0.03 0.00
GSTA2*C (c.335G>C) GG 0.17 0.17 0.18 0.16
GC 0.47 0.42 0.55 0.54
CC 0.36 0.41 0.27 0.30
GSTA2*E (c.328C>T) CC 0.92 0.91 0.93 0.89
CT 0.08 0.09 0.07 0.11
TT 0.00 0.00 0.00 0.00
GSTM1 1/1 and GSTM1 1/null indicate homozygous and heterozygous carrier of the 
GSTM1 gene. GSTM1 null/null indicates a homozygous gene deletion on the GSTM1 
gene. Detailed information about nomenclature of variants in GSTA1 and GSTA2 is provided 
in supplementary file 1. ^ based on Garte et al.(11) for GSTM1 and the HapMap-CEU for 
GSTA1 and GSTA2. MP, mercaptopurine; AZA, azathioprine; GSTM, glutathione transferase 
mu; GSTA, glutathione transferase alpha.
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of the GSTM1 gene (2239 [1006-4587] versus 4371 [1897-369] pmol/8x108 
RBCs, p=0.006) (Figure 2). In the patients treated with MP, no differences in 
the 6-MMPR levels were found per GSTM1 genotype (6543 [1717-11600] versus 
6195 [1551-10712] pmol/8x 108 RBCs) (Figure 2). The week 8 6-TGN levels were 
similar in the AZA and MP users (Table 3). In the patients on AZA, the reduced 
6-MMPR levels in combination with the unaffected 6-TGN levels in the patients 
with a GSTM1-null genotype resulted in a significantly lower 6-MMPR/6-TGN ratio 
(Table 3). Despite the higher 6-MMPR levels, no increased rate of hepatotoxicty 
(8.6% versus 8.9%, p=0.94) was observed in the patients on AZA with a GSTM1-
null genotype compared to the patients carrying one or two copies of the GSTM1 
gene. Additionally, the clinical response did not differ between the groups (24% 
versus 26%, p=0.89).
Variants in GSTA1 and GSTA2s do not affect the thiopurine 
metabolite levels
The GSTA1 and GSTA2 genotypes varied widely in frequency, with GSTA1*B and 
GSTA2*C showing the highest prevalence (Table 2). The generation of haplotypes 
Figure 2. Boxplot showing the 6-MMPR levels for homo- and heterozygous carriers of 
the GSTM1 gene (GSTM1) versus the homozygous GSTM1 gene deletion (GSTM1-null) 
genotype for patients treated with AZA and MP. Median values with interquartile range 
are provided. AZA, azathioprine; MP, mercaptopurine, 6-MMPR, 6-methylmercaptopurine 
ribonucleotides; GSTM1, glutathione transferase mu1
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showed two predominant haplotypes: the homozygous GSTA1*A and homozygous 
GSTA2*C (haplotype 1) and heterozygous GSTA1*B and GSTA2*C (haplotype 2) 
combinations. Together, these two combinations were found in approximately 
60% of the patients. The patient characteristics were similar for both groups 
(Table 4). The 6-MMPR and 6-TGN levels and the 6-MMPR/6-TGN ratio did not 
differ between the two haplotypes in the patients on AZA and patients MP (Table 
4).
Analysis of covariance with factors influencing thiopurine 
metabolism
The univariate analysis only showed a significant effect of the GSTM1-null 
genotype on the 6-MMPR levels in the patients on AZA. Therefore, a multivariate 
analysis was conducted in the patients on AZA to evaluate the effect of the 
GSTM1-null genotype on the log-transformed 6-MMPR levels after controlling 
for the following factors known to influence the 6-MMPR levels: age, gender, 
thiopurine dose and 5-aminosalicylic acid use. Multivariate analysis showed that 
the GSTM1-null genotype (p=0.04) and gender (p<0.01) have a significant effect 
on 6-MMPR levels in patients using AZA (Table 5).
Table 5. Analysis of covariance in patients on AZA to estimate the effect of the GSTM1-null 
genotype on the log-transformed 6-methylmercaptopurine ribonucleotide (6-MMPR) levels 
controlling for factors with a known influence on 6-MMPR levels (age, gender, thiopurine 
dose and 5-aminosalicylic acid use).
Variable Effect 95% CI p-value
Female gender 0.54 0.29 – 0.79 <0.01
GSTM1-null genotype -0.21 -0.45 – 0.03 0.04
Age (years) 0.006 -0.002 – 0.014 0.13
Concomitant 5-ASA use -0.21 -0.46 – 0.04 0.08
Thiopurine dose in mg/kg* 1.26 -0.13 – 2.64 0.08
* Azathioprine dose was converted by 2.08 to compare with the mercaptopurine dose. 
CI, confidence interval; GSTM1, glutathione transferase mu1
3
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DISCUSSION
In this study, we provide strong clinical evidence for the involvement of GSTM1 
in the conversion of AZA to MP. Patients on AZA with a GSTM1-null genotype 
have twofold lower 6-MMPR levels. As a control, the 6-MMPR levels remained 
unaffected by the GSTM1 status in patients treated with MP. Taking potential 
confounders into account, the GSTM1-null variant remained significantly related 
to the 6-MMPR levels in patients on AZA. Genetic variants in GSTA1 and GSTA2 
had no impact on the steady state week 8 thiopurine metabolite levels in both 
the AZA and MP users.
Despite robust biochemical evidence showing the involvement of GSTM1, GSTA1 
and GSTA2 in the conversion of AZA to MP(5), few studies have explored the 
clinical effects of these variants.(13, 14, 31) Our results corroborate the studies 
that demonstrated the relevance of the frequently seen GSTM1-null genotype in 
AZA metabolism, although some points require further clarification. In a study with 
72 patients with inflammatory bowel disease on AZA the 6-MMPR and 6-TGN 
levels were compared for patients with and without a GSTM1-null genotype.(14) In 
contrast to our findings, the authors found no differences in the 6-MMPR levels, 
possibly because dose adjustments were allowed, which resulted in a significantly 
lower AZA dose in mg/kg in the patients with one or two copies of the GSTM1 
gene. Furthermore, elevated 6-MMPR levels are associated with hepatotoxicity, 
whereas the 6-TGN levels are correlated with efficacy.(4, 32) Two previous studies 
in inflammatory bowel disease patients on AZA showed a lower rate of side 
effects in patients with a GSTM1-null genotype.(13, 31) Despite the differences in 
the 6-MMPR levels in patients on AZA with and without the GSTM1-null genotype 
in our study, we found no differences in the hepatotoxicity rates. One explanation 
for this result might be that the median 6-MMPR levels were far below 5700 pmol 
x 108/RBCs in both groups, which is the threshold above which hepatotoxicity 
is more likely to occur.(4) We found no difference in the treatment response 
between patients with and without the GSTM1-null genotype, which seemed 
logical given that the 6-TGN levels were equal. The reduction in the 6-MMPR 
levels in combination with unaffected 6-TGN levels, results in a more beneficial 
6-MMPR/6-TGN ratio. Theoretically, this might result in fewer side effects with 
an equal efficacy in half of the population (i.e., those with a GSTM1-null genotype) 
when treated with AZA.
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This study is unique compared to preceding studies because we also included 
patients treated with MP.(5, 33) The current conception is that glutathione 
transferases are involved in the conversion of AZA to MP but not in further 
downstream thiopurine metabolism, which makes patients on MP an ideal control 
group. Additionally, the prospective data collection and the exclusion of patients 
with a variant in TPMT or dose adjustments further increased the consistency 
of our work. Both the similar baseline characteristics between patients with and 
without the GSTM1-null genotype and the analysis of covariance support the 
notion that the observed differences can only be contributed to GSTM1.
A novel aspect of the present study is that we explored the effect of genetic 
variants in GSTA1 and GSTA2 on thiopurine metabolism.(6) Most of the variants 
occurred in two haplotypes, which was in agreement with the literature in 
Caucasians.(21) In our study, the metabolite levels did not differ between the two 
most prevalent haplotypes. A likely explanation is that the haplotypes probably 
neutralized the effects caused by individual genetic variants. This phenomenon is 
illustrated by Coles et al., who showed that GSTA1 expression in the human liver 
was reduced in patients with one GSTA1*B variant and was further decreased 
in patients homozygous for GSTA1*B. However, the reduced GSTA1 expression 
level was compensated by an increase in GSTA2 expression: thus the total GSTA1/
GSTA2 expression was similar.(17) Moreover, large variability in GSTA1 expression 
exists between humans with a similar GSTA1 genotype. Together, this might 
explain why the metabolite levels cannot be predicted with the most prevalent 
GSTA1/GSTA2 haplotypes.(17)
We show that the 6-MMPR levels are increased in AZA users that carry one or 
two copies of GSTM1 compared to patients with a GSTM1-null genotype. Carriers 
of the GSTM1 gene metabolize AZA more effectively, resulting in more MP 
being available for further metabolism.(33) Interestingly, although the 6-MMPR 
levels were two-fold lower in patients on AZA with a GSTM1-null genotype, no 
difference was observed in the 6-TGN levels. The most likely explanation for this 
finding is that inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting 
enzyme in purine synthesis.(34-36) Since IMPDH is positioned more distally in 
the thiopurine pathway, hypothetically the 6-TGN levels are influenced to a lesser 
degree by a higher supply of MP.(37)
3
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Genetic variants in the enzymes involved in thiopurine metabolism may have 
important clinical consequences.(38) The most relevant is the presence of 
homozygous variants in the TPMT gene, which lead to diminished or negligible 
TPMT activity and subsequently to an excessive 6-TGN level.(39, 40) The 
homozygous presence of a variant in TPMT occurs in 0.3% of the population, 
whereas the GSTM1-null genotype is reported in approximately 50% of the 
population.(3, 11) Therefore, this variant significantly contributes to the individual 
variation in AZA metabolism. Moreover, other factors, such as gender, age, 
thiopurine dose and use of concomitant drugs, may influence thiopurine 
metabolism and subsequently have an effect on the thiopurine metabolite levels. 
In this study, only gender had a significant effect on the 6-MMPR levels: in 
contrast, the thiopurine dose and concomitant 5-ASA use had no significant effect 
but tended to result in higher and lower 6-MMPR levels, respectively.
A limitation of the present work is that the use of a melt-curve analysis might 
lead to patients being mistakenly assigned to the GSTM1-null genotype when 
the PCR technique fails. To minimize the influence of technical failure, all PCRs 
were performed in duplicate on different occasions. Another limitation is that the 
categorization of patients into subgroups may curtail the power of the analysis. This 
possibility is illustrated by some degree of variation in the genotype frequencies 
between the AZA and MP users compared to the reference population, although 
the overall genotype frequencies correspond to the population references.
In conclusion, we demonstrated that the common GSTM1-null genotype resulted 
in lower 6-MMPR levels in patients treated with AZA, whereas the 6-TGN levels 
remained unaffected, leading to a potentially more beneficial 6-MMPR/6-TGN 
ratio. In contrast, genetic variants in GSTA1 and GSTA2 do not influence the 
thiopurine metabolite levels. The reduction in the 6-MMPR levels in patients with 
a GSTM1-null genotype on AZA without a corresponding in efficacy may lead to 
a lower rate of side effects in these patients.
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ABSTRACT
Background: Glutathione S-transferases (GSTs) are important in the detoxification 
of many compounds, including reactive oxygen species. Polymorphisms in GSTs 
resulting in a decreased enzyme activity might enhance the risk for inflammatory 
bowel disease by eliciting a state of oxidative stress. Previous case-control studies 
showed divergent results and were frequently limited in sample size; therefore we 
conducted a meta-analysis including results from our case-control study.
Methods: For the case-control study we genotyped 552 patients with Crohn’s 
disease, 223 patients with ulcerative colitis and 972 healthy controls by polymerase 
chain reaction for functional deletions in GST Mu and GST Theta. Both were 
not analysed in recent genome wide association studies. For the meta-analysis, 
PubMed, EMBASE and Web of Science were searched.
Results: In this meta-analysis we show an enhanced susceptibility for ulcerative 
colitis in individuals with the GSTT1null genotype (OR 2.27, 95% CI 1.31-3.92). 
In our case-control study, a reduced risk for Crohn’s disease was seen with the 
GSTT1null genotype (OR 0.58, 95% CI 0.43-0.77), however pooled analysis 
showed an OR of 1.67, 95% CI; 0.81-3.45.
Conclusion: In this meta-analysis, we showed an increased risk for ulcerative 
colitis in individuals with the GSTT1null genotype.
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INTRODUCTION
Genetic factors become more and more recognized as contributing factors in 
the development of inflammatory bowel disease (IBD). Recent genome wide 
association studies generated a large set of candidate genes for Crohn’s disease 
(CD), ulcerative colitis (UC) and for IBD in general (1).
Glutathione S-transferases (GSTs) are a family of enzymes that have an essential 
role within cells, including the conjugation and detoxification of toxic or carcinogenic 
compounds, such as reactive oxygen species (ROS) (2). Polymorphisms in GSTs 
can lead to a decreased enzyme function and an inadequate detoxification of ROS 
might modulate the susceptibility for IBD (3). Biopsies of colonic mucosa of IBD 
patients showed an increased ROS production compared to healthy controls (4). A 
reduced enzyme function of GSTs and therewith impaired scavenging of ROS can 
contribute to a state of oxidative stress, which can trigger the onset of IBD (5, 6).
Human GSTs can be divided in four main classes, GST Alpha (GSTA), GST Mu 
(GSTM1), GST Pi (GSTP1) and GST Theta (GSTT1). For GSTP1 several polymorphisms 
have been described, with GSTP1 105 (rs1695) and GSTP1 114 (rs1138272) 
considered as the most important, because these GSTP1 polymorphisms result 
in a reduce enzyme function (7). Both GSTP1 105 and GSTP1 114 were not found 
associated with UC or CD in a genome wide association study (1). For GSTM1, 
three alleles have been described of which one, GSTM1*0, is characterized by 
a gene deletion, leading to a non-functional protein. Homozygous presence of 
the GSTM1*0 allele (GSTM1null ) results in no enzyme activity and is found in 
approximately 50% of Caucasians and Asians (2, 8). The same applies to GSTT1, 
where a gene deletion (GSTT1*0 allele), is responsible for a failed protein synthesis. 
The homozygous GSTT1*0 genotype, GSTT1null, which occurs in approximately 
10-20% of Caucasians and 16-64% of Asians, leads to absence of GSTT1 enzyme 
activity (2, 8). The gene deletions of GSTM1*0 or GSTT1*0 were not analysed in 
genome wide association studies (1), so evidence is limited to case-control studies. 
In these studies an association between GSTM1*0, GSTT1*0 or a combination of 
these polymorphisms and susceptibility for CD or UC was found. However, it has to 
be stressed that some studies had relatively low patient numbers and overall results 
remain inconsistent (9-12). Therefore we conducted a large case-control study and 
included our results in a meta-analysis of studies addressing the susceptibility for 
CD and UC with respect to GSTM1 and GSTT1 null polymorphisms.
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PATIENTS AND METHODS
Study design and ethics
For the case-control study, IBD patients were recruited at the outpatient clinic 
of the Radboud University Medical Center, Nijmegen, the Netherlands. Healthy 
controls were recruited from the Nijmegen area, by advertisement in local papers, 
as described earlier (13). Diagnosis of IBD was based on accepted clinical, 
endoscopic, radiological and histological findings (14). The investigations were 
approved by the Medical Ethical Review Committee of the Radboud University 
Nijmegen Medical Center under the protocol number CWOM-nr 9804-0100.
DNA isolation & genotyping
Peripheral blood samples of IBD patients and healthy controls were collected 
and genomic DNA was isolated with the ROCHE High Pure PCR template 
Preparation Kit (Roche Applied Science, Mannheim, Germany). DNA was stored 
at 4°C until further use. Polymorphisms in GSTM1 and GSTT1 were analysed using 
polymerase chain reaction as described previously (15). The primers 5’-CTG GAT 
TGT AGC AGA TCA TGC-3’/5’-CTC CTG ATT ATG ACA GAA GCC-3’ and 5’-TCA 
CCG GAT CAT GGC CAG CA-3’/ 5’-TTC CTT ACT GGT CCT CAC ATC TC-3’ were 
used for GSTM1 and GSTT1 respectively. To detect GSTM1 and GSTT1 genotypes, 
melt curve analysis was applied using Bio-Rad Precision Melt Analysis Software 
version 1.0 (Bio-Rad, Hercules) and in this way homo- and heterozygous most 
common genotypes could be distinguished from homozygous GSTM1*0 (null) or 
GSTT1*0 (null) genotypes.
Data search
The meta-analysis was conducted according to PRISMA guidelines. Articles for 
the meta-analyses were retrieved by searching PubMed, EMBASE and Web of 
Science on 13 October 2013 with the following search terms: GST, glutathione 
S-transferase, detoxification enzymes, inflammatory bowel disease, ulcerative 
colitis and Crohn’s disease. Case-control studies examining the association of GST 
polymorphisms in patients with IBD in relation to healthy controls were included, 
provided that absolute numbers of genotypes of patients and controls were given. 
Studies were excluded when no full text was available or written in a language 
other than English, German or Dutch. In case of overlapping data, the study 
with the largest number of cases was included. The reference lists of included 
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articles were screened for potential eligible studies. Two researchers (MB and 
RM) independently extracted raw data of the genotype distributions of GSTM1, 
GSTT1 and the combination of GSTM1 with GSTT1 from the included studies and 
in case of inconsistency, results were discussed until consensus was reached.
Statistical analysis
For the case control study, baseline continuous variables were compared by 
independent t-test. Categorical data between patients and healthy controls were 
analysed with the chi-squared test. Genotypes with predicted high enzyme activity 
were used as reference to calculate odds ratios (OR) and 95% confidence intervals 
(95% CI) with logistic regression. The combination GSTM1null and GSTT1null was 
compared with all other genotypes. Analyses were conducted with SPSS for 
windows version 20.0 (SPSS Inc., Chigaco, Il, USA).
For the meta-analyses a random effect model was used to calculate pooled odds 
ratios from studies, including results of our case control study. ORs with 95% CI 
were calculated with the Mantel-Haenszel method in Review Manager (RevMan) 
V5.2. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2012). The P values of significance of the odds ratios are depicted in the bottom 
line of the corresponding forest plots. Finally, heterogeneity was assessed with 
the I2 test, and publication bias was estimated with a funnel plot.
RESULTS
Case control study
For the case control study, we included 552 patients with CD (mean age 44.4 
years, SD±13.8), 233 patients with UC (mean age 45.8 year, SD ± 13.7) and 972 
healthy controls (mean age 47.2 year, SD±16.6). Table 1 shows the GST genotype 
distribution in patients with CD and UC in comparison with healthy controls. With 
the homozygous + heterozygous most common genotypes set as reference, the 
GSTM1null genotype was not associated with a significant increased susceptibility 
for CD or UC. The GSTT1null genotype was more often present in healthy controls 
compared to patients with CD (OR 0.58; 95% CI 0.43-0.77). Although in UC 
patients the GSTT1null genotype was more frequently seen, difference was 
not significant (OR 1.14, 95% CI; 0.81-1.61). The combination of GSTM1null and 
GSTT1null genotypes was significantly more seen in healthy controls compared 
4
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to patients with CD (OR 0.44, 95% CI; 0.29-0.66). The association with the 
GSTT1null genotype and CD and the combination of GSTT1null and GSTM1null 
had a P value of <0.001. This was still significant after correction for multiple 
testing (Bonferroni correction).
Study characteristics of the meta-analyses
In total 251 articles were identified. After removing duplicates and screening for 
title and abstract, 11 articles remained (9-12, 16-22). Three studies (20-22) were 
excluded because of Chinese language. One study was excluded (18), because of 
overlapping data with the results of our case control study. In the study of Karban 
et al.(10) the results of Jewish, Arab moslems and Druze were merged. No studies 
had to be excluded because of no full text availability. Furthermore, all studies use 
genotyping methods which can detect the null genotype with equivalent accuracy 
except one study which uses a genotype validated assay based on the GSTMu 
activity to identify patients with the null genotype.
Results of the meta-analyses
No increased susceptibility was found for CD with the GSTM1null (Figure 1) or 
GSTT1null genotype (Figure 2) (OR 1.08, 95% CI; 0.84-1.39 and 1.67, 95% CI; 
0.81-3.45, respectively). Also the combination of both did not influence disease 
susceptibility OR 1.30, 95% CI; 0.41-4.14) (Figure 3). Pooled analysis revealed 
an increased risk for UC with the GSTT1null genotype (OR 2.27, 95% CI 1.31-
3.92) (Figure 5) Still significant after correction for multiple testing (p= 0.003). 
For GSTM1null (OR 1.35, 95% CI 0,89-2.03) and the combination of GSTT1null 
and GSTM1null (OR 1.99, 95% CI; 0.65-6.12) no significant influence on disease 
susceptibility was seen (see Figures 4 and 6).
Publication bias
The funnel plot from the pooled analysis of GSTT1 in UC, the only meta-analysis 
showing a significant effect, is depicted in Figure 7. This meta-analysis included 
7 studies and with the exception of one outlier the shape of the plot appears 
symmetrical.
4
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Figure 1. Forest plot of the association of the GSTM1null genotype with CD. Effect of 
GSTM1null on the risk of CD (ORs and the 95% CI) for each study is shown. The overall 
OR is 1.08 (95% CI; 0.84–1.39). GSTM1null: homozygous presence of the GSTM1*0 allele, 
CD: Crohn’s disease, OR: Odds Ratio ,95% CI: 95% confidence interval
Figure 2. Forest plot of the association of the GSTT1null genotype with CD. Effect of the 
GSTT1null genotype on the risk of CD (ORs and the 95% CI) for each study is shown. The 
overall OR is 1.67 (95% CI; 0.81-3.45). GSTT1null: homozygous presence of the GSTT1*0 
allele, CD: Crohn’s disease, OR: Odds Ratio, 95% CI: 95% confidence interval
Figure 3. Association of the combination of GSTM1null and GSTT1null genotypes with 
CD. Risk of CD (ORs and the 95% CI) with both the GSTM1null and GSTT1null genotype 
versus all other variants is shown for each study. The overall OR is 1.30 (95% CI; 0.41–
4.14). GSTM1null: homozygous presence of the GSTM1*0 allele, GSTT1null: homozygous 
presence of the GSTT1*0 allele CD: Crohn’s disease, OR: Odds Ratio, 95% CI: 95% 
confidence interval
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Figure 4. Forest plot of the association of the GSTM1null genotype with UC. Effect of the 
GSTM1null genotype on the risk of UC (ORs and the 95% CI) for each study is shown. 
The overall OR is 1.35 (95% CI; 0.89-2.03). GSTM1null: homozygous presence of the 
GSTM1*0 allele, UC: Ulcerative colitis, OR: Odds Ratio, 95% CI: 95% confidence interval
Figure 5. Forest plot of the association of the GSTT1null genotype with UC. Effect of the 
GSTT1null genotype on the risk of UC (ORs and the 95% CI) for each study is shown. The 
overall OR is 2.27 (95% CI; 1.31-3.92). GSTT1null: homozygous presence of the GSTT1*0 
allele, UC: Ulcerative colitis, OR: Odds Ratio, 95% CI: 95% confidence interval
Figure 6. Association of the combination of GSTT1null and GSTM1null genotypes with UC. 
Risk of UC (ORs and 95% CI) with both the GSTM1null and GSTT1null genotype versus all 
other variants is shown for each study. The overall OR is 1.99 (95% CI; 0.65–6.12). GSTM-
1null: homozygous presence of the GSTM1*0 allele, GSTT1null: homozygous presence 
of the GSTT1*0 allele, UC: Ulcerative colitis, OR: Odds Ratio, 95% CI: 95% confidence 
interval
4
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DISCUSSION
The results of the current meta-analyses show a significantly increased risk for UC, 
but not for CD, when bearing the GSTT1null genotype. The GSTM1null genotype 
was not associated with CD or UC. It is important to mention that the GSTM1null 
and GSTT1null polymorphisms were not analysed in genome wide association 
studies (1), because these polymorphisms consist of large deletions rather than 
single nucleotide substitutions. With pooling data from case-control studies, 
supplemented with our data, overall IBD patient numbers exceed 3200, which 
makes this meta-analyses the largest study so far.
The mechanism, that absence of GSTT1 enzyme activity in GSTT1null individuals 
contributes to the risk for UC might be explained by the important role of this 
enzyme in the detoxification of ROS (23), which may provide a trigger in the 
aetiology of IBD (24, 25). Also in other inflammatory driven diseases, such as 
asthma or type 2 diabetes mellitus an increased susceptibility was found with the 
GSTT1null genotype (26, 27). In this meta-analyses we showed that the GSTT1null 
genotype is associated with UC but not with CD. This finding is not unique as 53 
of the 163 loci associated with IBD were disease specific (1).
Although the studies conducted in Asia showed a larger association between 
the GSTT1null genotype and UC than European studies, all studies revealed an 
increased risk with only variation in the magnitude. When the studies of Mittal et 
Figure 7. Funnel plot for the meta-analysis of the GSTT1null genotype in UC to detect 
potential publication bias.
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al. (OR 51.09, 95% CI; 22.05-118.34) and Ye et al. (OR 2.06, 95% CI; 1.53-2.77) 
were excluded from the pooled analysis, leaving only Caucasians studies, the 
GSTT1null genotype was still significantly more seen in UC patients (OR 1.36, 
95% CI; 1.11-1.65). The increased, though not significant susceptibility, for CD 
with the GSTT1null genotype is to a large extent caused by the study of Mittal 
et al. with an OR of 47.8 (95% CI 10.5-218.4) (19). The likely cause of this large 
OR is the low number of patients (n=20) with CD included , which is reflected 
by the broad confidence interval. When this study is excluded from the meta-
analysis the OR is 1.08 (95% CI; 0.59-2.00). Furthermore, in the forest plot of 
GSTT1 in CD, a large difference was seen between the study of Ernst et al. and 
our results, despite only a small geographical difference (11). This might be caused 
by a relatively low number of healthy controls with the GSTT1null genotype in 
the Danish study compared to our study (13.2% vs. 20.8%, respectively), where 
19.7% is the average for this area (8).
Also with the GSTM1null genotype both the two studies conducted in Asia (Mittal 
et al. and Ye et al.) revealed the highest association with IBD. However, overall no 
significant influence was found. It might be that the loss of function of the GSTM1 
enzyme is compensated by other GST Mu classes, such as GSTM2 (28), this also 
explains why the combination of both GSTM1null and GSTT1null did not have a 
synergistic effect on disease susceptibility. Another explanation could be that the 
expression of GSTM1 in the bowel is limited and therefore does not contribute in 
the pathogenesis of IBD (2).
The difference between the studies conducted in Asia and Europe support the 
recent insights in differences in genetic variants associated with IBD between 
the Caucasian and Asian race (29, 30). Ng et al. (29), showed that genetic 
variants of NOD2 frequently seen in Caucasian IBD patients, were rare in the 
Asian IBD population and vice versa. Therefore, it can be hypothesized that for 
Asians both GSTT1null and GSTM1null may be involved in the aetiology of UC, 
where in Caucasians only the GSTT1null genotype is associated with UC. This 
distinction might result from differences in life style, environmental factors, 
and the microbiome, requiring a different utilisation of GST subclasses. Ideally 
subgroup analyses for different races are included, however absolute numbers of 
Asian IBD patients are insufficient for a reliable estimation. This accentuates the 
need for larger studies in the Asian IBD population exploring GSTM1null as well 
as GSTT1null genotypes.
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Single nucleotide polymorphisms (SNPs) Genetic variations in the neighbour of the 
deletion polymorphism may be in linkage disequilibrium and subsequently might be 
used as a tag SNP. However, this method is limited by inter population differences 
in the degree of linkage disequilibrium. Most SNPs in linkage disequilibrium with 
GSTM1 and GSTT1 (31), were not included in the most recent GWAS (1). This can 
partly be explained by the fact that some of these tagSNPs such as rs407257 lie 
in the deletion area.
As previous studies with comparable or smaller sample sizes were able to show 
significant associations we assumed to have sufficient power with the patient 
numbers included in our case-control study. In the present meta-analysis 
heterogeneity between studies was observed, which besides differences in race 
could have been originated from differences in study design. For example, patient 
enrolment in academic hospitals could be confounded by more severe disease 
phenotypes included in academic hospitals. Also the selection of healthy controls 
might have an impact and could be a possible cause for heterogeneity. Considering 
these potential differences, we used a random effect model for computing pooled 
odds ratios, with the knowledge that in case of low heterogeneity results of a random 
model will approach values of a fixed model, but preventing poorly substantiated 
significant outcomes (32). The funnel plot of GSTT1null in UC contains one outlier 
(the study of Mittal with an OR of 51.09), though as mentioned above, with exclusion 
of this study still a significant effect of GSTT1null and UC was observed. It has to 
be mentioned that the number of studies published on this topic is limited, which 
makes correct interpretation of the funnel plot difficult. Therefore, influence of 
publication bias should be considered, as studies showing a significant influence 
of specific polymorphisms might be published more often (33). Furthermore, the 
PCR techniques used in our case control study, and the other included studies, can 
only detect homozygous (null) genotypes of the GSTM1*0 and GSTT1*0 alleles, 
failing to detect heterozygous individuals. One study measured GSTM1 enzyme 
activity instead of the GSTM1null genotype (12). We decided to include this study 
in the meta-analyses since this method is validated against the GSTM1 genotype 
and their findings showed that 50% of controls had no GSTM1 activity, which is in 
line with the GSTM1null genotype frequency in that geographical area (8, 34). In 
addition, this method also lacks the capability to identify GSTM1null heterozygotes.
In conclusion, in this meta-analysis we show that the GSTT1null genotype is 
associated with an increased the risk for UC, but not for CD.
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ABSTRACT
Background: The use of thiopurines is frequently accompanied by hepatotoxicity. 
Studies on hepatocyt cultures showed a time and dose dependent increase of 
thiopurine toxicity. 5-aminosalicylic acid (5-ASA) and allopurinol can influence 
thiopurine metabolism, however it is unknown whether this affects in vitro 
cytotoxicity.
Methods: Human hepatoma cells (Huh7, HepG2 and HepaRG) were incubated 
with increasing concentrations of thiopurines, 5-ASA or allopurinol. WST-1 
cytotoxicity assays were used to calculate cell survival curves and half maximal 
inhibitory concentrations (IC50). Combination experiments with thiopurines with 
a fixed dose of 200 µM 5-ASA or 100 µM allopurinol were conducted in HepaRG 
cells. Caspase-3/7 activation was evaluated and single cell electrophoresis analysis 
was performed.
Results: A time and dose related cytotoxic effect was seen with azathioprine 
(AZA) in all hepatoma cells, whereas Huh7 and HepG2 cells did not show toxicity 
to mercaptopurine (MP). HepaRG cells expressed the highest levels of drug 
metabolising enzymes and therefore combination experiments were conducted 
in HepaRG cells. Addition of a non-toxic dose of allopurinol resulted in a two- to 
three-fold increased cytotoxicity of all thiopurines, which seemed to be mediated 
by apoptosis / DNA-damage.
Conclusion: The addition of allopurinol to thiopurines leads to a two- three fold 
increased cytotoxicity in HepaRG cells.
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INTRODUCTION
The metabolism of azathioprine (AZA) and mercaptopurine (MP) is complex and 
involves multiple enzymatic steps, before the pharmacologically active substrate 
6-thioguanine nucleotide (6-TGN) is produced (see Figure 1). During this process 
side products such as 6-methylmercaptopurine ribnucleotides (6-MMP) and 
thiouric acid are also formed. The metabolism of thioguanine (TG) is less complex 
with the main pathway resulting in a more direct conversion to 6-TGN. Several 
factors may influence thiopurine metabolism such as genetic variants in the 
thiopurine-S-methyltransferase (TPMT) gene and the use of concomitant drugs.(1)
With respect to inflammatory bowel disease (IBD), the most relevant drugs 
that can influence thiopurine metabolism are 5-aminosalicylic acid (5-ASA) and 
allopurinol. Allopurinol, a strong xanthine oxidase (XO) and TPMT inhibitor, reduces 
6-MMP formation (2). The combination of allopurinol with a tailored dosage of 
AZA or MP is a potent strategy in patients with a skewed metabolism towards 
the cytotoxic 6-MMP formation. Hoentjen et al. showed a significant reduction of 
6-MMP levels from 10110 pmol/8 × 10^8 Red blood cell (RBC) with monotherapy 
to 265 pmol/8 × 10^8 RBC with combination therapy and significant increase of 
6-TGN levels from 145 to 271 pmo1/8 × 10^8 RBC (3). Thiopurines and 5-ASA 
Figure 1. Simplified overview of thiopurine metabolism. Azathioprine (AZA) is converted 
by glutathione S-transferase (GST) in mercaptopurine (MP). MP can be methylated by thio-
purine S-methyl transferase (TPMT) into 6-methyl mercaptopurine (6-MMP), oxidised by 
xanthine oxidase (XO) into 6-thiouric acid (6-TU) or metabolised by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) into 6-thioinosine monophosphate (6-TIMP). Next, 
6-TIMP can be phosphorylated into 6-thioinosine triphosphate (6-TITP) or metabolised 
into the pharmacological active 6-thioguanine nucleotides (6-TGN). Besides metabolised 
into 6-TGN by HPRT, 6-Thioguanine (TG) can be oxidised by XO into 6-TU or methylated 
by TPMT into 6-methyl thioguanine (6-MTG).
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exert their disease modifying effect by different mechanisms, yet 5-ASA can 
interfere in thiopurine metabolism by a non-competitive inhibition of TPMT (4). 
Therefore, co-administration can lead to a decreased production of 6-MMP and 
increase of the therapeutic active 6-TGN (5-7).
Studies to explore hepatotoxicity in humans on a cellular level are costly and have 
major ethical considerations. In vitro studies with primary cultures of hepatocytes 
or hepatoma cell lines are an ethical and feasible alternative for exploring drug 
toxicity. Previous in vitro studies demonstrated a time and dose-dependent toxicity 
of AZA, MP and 6-TG in HepaRG and HepG2 cells (8, 9). In this study we aim to 
explore the effects of the addition of 5-ASA or allopurinol on thiopurine-induced 
hepatotoxicity.
MATERIALS AND METHODS
HepG2 and Huh7 cells have been used extensively in in vitro experiments so far, 
therefore we tested cytotoxicity in these hepatoma cell lines as well as in the more 
recently developed HepaRG cell line (10). First we assessed individual cytotoxicity 
of AZA, MP, TG in all three cell lines. Next, we tested these cell lines for the 
expression of important drug metabolising enzymes and used the hepatoma cell 
line with the highest expression of drug metabolising enzymes to explore the 
influence of 5-ASA and allopurinol on cytotoxicity of thiopurines.
Cell culture
Hepatocyte differentiated HepaRG cells (Invitrogen™, Paisly, UK), HepG2 (HB-
8065™, American Type Culture Collection, Rockville, USA) and Huh7 cells 
(JCRB0403, Cell Resource Center for Biomedical Research, Tohoku University, 
Japan) were used and cultured as described previously (9, 11). Cells were seeded 
into 96-well flat bottom microplates at a density of 1.48 x 105 cells / cm² for the 
HepG2 and Huh7 cells and 4.5 x 105 cells / cm² for the HepaRG cells according to 
the manufacturer’s protocol. After 24 hours incubation, the medium was replaced 
by differentiation medium, being growth medium supplemented with 2.0% (v/v) 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich B.V.). Addition of DMSO is according to 
the protocol of growing HepaRG cells. To increase uniformity of the experiments 
we also used differentiation medium in HepG2 and Huh7 cell cultures.
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Incubations with drugs
On the fourth day after seeding, cells were incubated with one of the following 
test substances; AZA, MP, 5-ASA, allopurinol (all from Sigma-Aldrich B.V.) or TG 
(Alfa Aesar GmbH & Co KG, Karlsruhe, Germany) in concentrations ranging from 
0.5 µM to 4 mM. For the combination experiments, a fixed non-toxic dose of 200 
µM 5-ASA or 100 µM allopurinol was used in combination with the same range 
(3.9 µM - 4 mM) of thiopurines for 24, 48 or 72 hours. In order to mimic daily drug 
administration medium with drugs was refreshed every 24 hours.
Evaluation of cytotoxicity
Water-soluble tetrazolium salt-1 (WST-1) assays (Roche Diagnostics Nederland BV, 
Almere, the Netherlands) were performed after 24, 48 or 72 hours of incubation 
with the drugs. The WST assay is based on the ability of viable cells to cleave 
the tetrazolium salt WST, which was measured with a Tecan Infinite m200PRO 
plate reader (Tecan, Giessen, the Netherlands) as described previously (9). Three 
independent experiments were conducted in triplicate.
Evaluation of drug metabolising enzymes
Protein expression of important drug metabolising enzymes was measured 
for two purposes. First to select the cell line with the highest expression (and 
therefore best comparability with human hepatocytes) and second to quantify 
any influence of adding DMSO to the culture medium of HepG2 and Huh7 cells. 
The following enzymes were analysed: UDP-glucuronosyltransferase 1A (UGT1A), 
cytochrome-P450 3A4 (CYP3A4), glutathione S-transferase alpha (GSTAlpha), 
mu (GSTMu) and theta (GSTTheta) (12). These enzymes were chosen because 
of their role in thiopurine metabolism (GSTAlpha and GSTMu), or their important 
role in drug metabolism in general. Cells were seeded in 25 cm2 flasks and after 
24 hours of culturing half of the flasks were supplemented with differentiation 
medium (group DMSO+), while the other half received standard William’s E 
growth medium (group DMSO-). On days 0, 3, and 7 cells were harvested and 
homogenised using lysis buffer, consisting of 0.25 M saccharose, 20 mM Tris-
HCl pH 7.4, 1 mM dithiothreitol (DTT) and 1 % Triton X-100 and lysates frozen 
at -200C until use. Total amount of protein was assessed according to the Lowry 
procedure (13). Homogenates (25 µg protein) were loaded on 8%, 10% or 12% 
SDS polyacrylamide gels for UGT, CYP3A4 or GST analyses, respectively. After 
electrophoresis, proteins were transferred to nitrocellulose (Whatman GMBH, 
5
517689-L-sub01-bw-Broekman
Processed on: 7-3-2018 PDF page: 110
110
Chapter 5
Dassel, Germany) using a semi-dry blotter (V20-SDB, Scie-Plas, Cambridge, UK). 
Nonspecific binding was blocked with 1% gelatine in phosphate buffered saline 
(PBS)/Tween 20 (0.05%, v/v). The following primary monoclonal antibodies were 
added: CYP3A4 (kind gift from dr. P. Kremer, Université de Liège, Belgium), GST 
class Theta T1-1 (purchased from dr. E. Juronen, Tartu, Estonia), UGT1A, GSTAlpha 
(A1-2) and GSTMu (all developed in our laboratory) (14-16). β-Actin (1:10,000, 
Sigma-Aldrich B.V.) was used as protein loading control. After incubation and 
washing, polyclonal rabbit anti mouse peroxidase-conjugated second antibodies 
(Dako Diagnostics, Glostrup, Denmark) were added. Immunoreactive proteins 
were visualised with 0.1 % (w/v) 3,3-diaminobenzidine, 5 mM imidazole, 2 mM 
cobalt chloride hexahydrate and 8 µl 30 % hydrogen peroxide in 50 ml PBS.
TPMT enzyme activity and polymorphism
To establish influence caused by variation in TPMT activity we analysed TPMT 
polymorphisms as well as TPMT enzyme activity. TPMT enzyme activity was 
assessed by high-performance liquid chromatography (HPLC) as described 
previously (17). Genotyping of the three common variants in the TPMT gene 
(TPMT*2, *3A and *3B) was performed according to the manufacturer’s 
protocol using Taqman SNP genotyping assays (Life Technologies, Bleiswijk, 
the Netherlands, (TPMT*2: rs1800462, assay ID C__12091552_30; TPMT*3B: 
rs1800460, assay ID C__30634116_20; TPMT*3A: rs1142345, assay ID 
C_____19567_20). Signals were detected with 7500 Fast Real-Time PCR system 
(Life Technologies) and subsequently analysed using the Allelic Discrimination 
software version 1.4 (Life Technologies).
Thiopurine metabolite assessment
6-MMP and 6-TGN were assessed in cell lysates by a high-performance liquid 
chromatography method as described by Dervieux et al. (18). Metabolite analysis 
was only done for AZA, since the pharmacological action is based on the release 
of MP, which is primarily catalysed by GST (12). We assumed that if AZA is 
intracellular metabolized, MP will be too. For this purpose, HepaRG cells were 
incubated with 600 µM AZA for 10 hours, subsequently the cells were washed 
with PBS 0.9%, harvested, homogenised and stored at -20 °C until use.
Caspase-3/7 activation
Caspase-3/7 activation was tested in HepaRG cells treated with AZA with and 
without 5-ASA or allopurinol with the Apo-ONE® Homogeneous Caspase-3/7 
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Assay (Promega) according to the manufacturer protocol. Briefly, HepaRG cells 
were seeded in a flat-bottom 96 wells plate in a density of 20.000 cells/well. 
Cells were incubated with only medium (control), AZA (70 µM), 5-ASA (200 µM), 
allopurinol (100 µM), a combination of AZA + 5-ASA, a combination of AZA + 
allopurinol or staurosporine (2 µM) (positive control). After 24 hours Apo-one 
reagent was added. Caspase-3/7 activation was measured after 6 hours on a 
Tecan Infinite m200PRO plate reader (Tecan, Giessen, the Netherlands). Two 
experiments were performed in triplicate. The control was set as reference to 
calculate differences in caspase-3/7 activation.
Comet assay
The comet assay was used to identify the mechanisms behind the increased 
toxicity with allopurinol co-administration. This assay was performed according 
to the manufacturer instructions (Trevigen Inc., Gaithersburg, MD). HepaRG cells 
were seeded in 25 cm2 flasks and treated 24 hours with allopurinol (100 µM), 
AZA (70 µM), AZA (70 µM) + allopurinol (100 µM) or untreated (control). After 24 
hours cells were harvested and the cell suspension was mixed with 75 µL low 
melting agarose (Trevigen Inc.) in a density of 2x 104 cells/ml and directly pipetted 
on magarose-precoated slides. Slides were stored at 4°C for 30 minutes and 
subsequently submerged in lysis solution. After 60 minutes lysis they were treated 
with alkaline unwending solution (pH>13) for 60 minutes, followed by 30 minutes 
electrophoresis at 25 Volt. Slides were stained with SYBR green (Trevigen Inc.) 
and visualized and photographed by a digital camera (AxioCam MRm) attached to 
a fluorescent microscope (Axio imager.M1) using a 20x magnification.
Statistical analysis
For the cytotoxicity analyses, the mean absorption of the empty wells was used 
to correct for background staining. The mean of three experiments was used 
for further calculations. Cell survival (in percentage of control) was calculated by 
dividing the mean of each concentration by the mean of the control wells (cells 
without drugs). Half maximal inhibitory concentrations (IC50) were calculated and 
subsequently tested among experiments using the extra sum of squares F-test. 
Differences in caspase-3/7 activation were compared means of the by Mann-
Whitney U test. Analyses were performed with GraphPad Prism (version 5.03 for 
Windows, GraphPad Software, San Diego California USA; www.graphpad.com).
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RESULTS
Single drug tests
AZA showed a steep decline in cell survival at concentrations above approximately 
200 µM in all cell lines (Figure 2), with a time-dependent effect (Table 1). With 
respect to MP, cell survival was not affected in the HepG2 and Huh7 cells, 
however in the HepaRG cells a decline in cell survival was seen when incubating 
for 48 or 72 hours (Table 1). Incubation with TG resulted in a dose-dependent 
decline of cell survival observed in all cell lines, with the most pronounced decline 
in HepaRG cells. The lowest IC50 value (i.e. most cytotoxicity) was found in the 
HepaRG cells incubated for 72 hours with TG, with an IC50 of 19 µM (Table 1).
Expression of drug metabolising enzymes
Large differences were seen between the three cell lines regarding the expression 
of UGT1A, CYP3A4, GSTAlpha, GSTMu and GSTTheta (Figure 3). Huh7 and 
HepaRG cells showed CYP3A4 expression, whereas HepG2 cells did not. The 
HepaRG cells showed the highest expression of GSTAlpha and GSTMu. GSTTheta 
was expressed in both HepaRG and HepG2 cells, but not at all in Huh7 cells. The 
latter was confirmed by PCR analysis, which showed a GSTT1 gene deletion in 
Huh7 cells (data not shown). In HepG2 and Huh7 cells, addition of DMSO to the 
culture medium increased the expression of GST and UGTA1 enzymes. Overall 
HepaRG cells showed the highest expression of all enzymes.
Figure 2. Cell survival after incubation of Huh7, HepG2 and HepaRG cells with azathioprine 
(AZA), mercaptopurine (MP) or thioguanine (TG) for 72 hours. In the HepaRG cells 5-Ami-
nosalicylic acid (5-ASA) and allopurinol were also tested. Values are means with SEM from 
three independent experiments, performed in triplicate. SEM: Standard error of the mean.
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Table 1. IC50 values in HepG2, HepaRG and Huh7 cells after 24, 48 or 72 hours exposure 
to thiopurines, 5-ASA or allopurinol
24 hours 48 hours 72 hours
IC50 (95% CI) IC50 (95% CI) IC50 (95% CI)
HepG2 AZA 572 (520-628) 406 (333 - 495)** 363 (315 - 419)
MP n.r. n.r. n.r.
TG n.r. 1746 (1258 - 2422)** 1134 (812 - 1585)
Huh7 AZA 464 (431 - 501) 400 (314 - 509) 307 (188 - 501)
MP n.r. n.r. n.r.
TG 2069 (856 - 5004) 172 (105 - 280)** 242 (120 - 486)
HepaRG AZA 514 (460 - 574) 317 (289 - 347)** 266 (237 - 298)*
MP n.r. 679 (502 - 920) 412 (321 - 530)
TG  1949 (993-3827)  100** (80 - 125)  19** (16 - 22)
5-ASA n.r. n.r. n.r.
Allopurinol n.r. 999 (766 – 1302)** 509 (411 – 631)**
Values are expressed in µM with 95% confidence interval. Significant difference (P < 
0.05)* or (P<0.01)** compared to 24 hour shorter incubation. AZA: azathioprine; MP: 
mercaptopurine; TG: thioguanine; 5-ASA: 5-aminosalicylic acid; IC50 half maximal inhibitory 
concentrations; n.r.: IC50 not reached; 95% CI: 95% confidence interval
Figure 3. Expression of β-actin, GSTAlpha, GSTMu, GSTTheta, CYP3A4 and UGT1A in 
HepG2, Huh7 and HepaRG cells at day 0, after three days of incubation with William’s 
E medium without DMSO(3-) or William’s with DMSO 2% (3+), and after seven days of 
incubation without (7-) and with (7+) DMSO. M: rainbowmarker (Precision Plus Protein™ 
Kaleidoscope™) or antigen for the specific antibody (GST Alpha, Mu and Theta).GSTAl-
pha: glutathione S-transferase alpha, GSTMu: glutathione S-transferase Mu, GSTTheta: 
glutathione S-transferase Theta, CYP3A4: cytochrome-P450 3A4, UGT1A: UDP-glucu-
ronosyltransferase 1A. DMSO: dimethyl sulfoxide.
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Combination tests of thiopurines with 5-ASA or allopurinol
Based on the highest expression of drug metabolising enzymes HepaRG cells 
were used for the combination experiments with 5-ASA and allopurinol. 5-ASA did 
not influence cell survival of HepaRG cells at all, while incubation with allopurinol 
gave a decline in cell survival after 48 and 72 hours with concentrations above 300 
µM (Figure 2 and Table 1). As can be seen in Figure 4 and Table 2 incubation 
of thiopurines in combination with a fixed, non-toxic dose of 100 µM allopurinol 
had a larger influence on cytotoxicity than concomitant incubation with 200 µM 
5-ASA. Co-administration of allopurinol with all thiopurines consistently resulted 
in an increased cytotoxicity, with the most pronounced cytotoxic effects emerging 
after 48 or 72 hours. The combination of MP and 5-ASA, but not AZA and 5-ASA 
showed an increase in IC50 (i.e. decreased cytotoxicity) after 48 or 72 hours 
incubation.
TPMT activity and genotype
No mutations were found for the three most common allele variants in TPMT. 
TPMT activity was expressed as nmol 6-methylthioguanine/mg protein per hour 
and was lowest in HepG2 cells (0.08 nmol/mg protein per hour), followed by 
HepaRG cells (0.28 nmol/mg protein per hour) and Huh7 cells (0.47 nmol/mg 
protein per hour). Values were comparable with these found in other cell lines 
(19). TPMT activity was not correlated with the cytotoxicity.
Figure 4. Cell survival curves after incubation of HepaRG cells with AZA, MP or TG for 
72 hours with and without a fixed non toxic concentration of 200 µM 5-ASA or 100 µM 
allopurinol. Values are means with SEM from three independent experiments, performed 
in triplicate. AZA: azathioprine, MP: mercaptopurine, TG: thioguanine, 5-ASA: 5-Amino-
salicylic acid, SEM: Standard error of the mean.
517689-L-sub01-bw-Broekman
Processed on: 7-3-2018 PDF page: 115
115
Thiopurine-induced hepatotoxicity in vitro
Ta
b
le
 2
. I
C
50
 v
al
ue
s 
in
 H
ep
aR
G
 c
el
ls
 a
ft
er
 2
4,
 4
8 
an
d 
72
 h
ou
rs
 e
xp
os
ur
e 
to
 th
io
pu
rin
es
 w
ith
 a
nd
 w
ith
ou
t 2
00
 µ
M
 5
-A
S
A
 o
r 1
00
 µ
M
 a
llo
pu
rin
ol
.
24
 h
o
u
rs
48
 h
o
u
rs
72
 h
o
u
rs
si
ng
le
 d
ru
g
+
 5
-A
S
A
+
 
al
lo
pu
rin
ol
si
ng
le
 d
ru
g
+
 5
-A
S
A
+
 
al
lo
pu
rin
ol
si
ng
le
 d
ru
g
+
 5
-A
S
A
+
 
al
lo
pu
rin
ol
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
 (9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
IC
50
(9
5%
 C
I)
A
Z
A
51
4
(4
60
-5
74
)
53
8
(4
74
-6
11
)
50
2
(4
65
–5
42
)
31
7
(2
89
-3
47
)
27
1
(2
35
-3
12
)
20
1^
(1
68
–2
41
)
26
6
(2
37
-2
98
)
20
0*
(1
67
-2
39
)
10
1^
(8
8
–1
16
)
M
P
n.
r.
n.
r.
n.
r.
67
9
(5
02
-9
20
)
n.
r.*
40
3*
(2
57
–6
32
)
41
2
(3
21
-5
30
)
91
8*
(7
53
-1
11
8)
17
0^
(1
23
–2
36
)
TG
19
49
(9
93
-3
82
7)
n.
r. 
*
 9
87
*
(7
30
 1
33
5)
75
(5
9
-9
4)
 1
00
(8
0 
- 1
25
)
 6
8
(4
8 
- 9
5)
 1
9
(1
6 
- 2
2)
 2
1
(1
9 
- 2
4)
 9
^
(7
 –
 1
1)
Va
lu
es
 a
re
 e
xp
re
ss
ed
 in
 µ
M
 w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
. C
om
bi
na
tio
n 
ex
pe
rim
en
ts
 w
er
e 
si
m
ila
r t
o 
th
e 
si
ng
le
 d
ru
g 
ex
pe
rim
en
ts
, b
ut
 w
ith
 
th
e 
ad
di
tio
n 
of
 2
00
 µ
M
 5
-A
S
A
 o
r 
10
0 
µM
 a
llo
pu
rin
ol
. S
ig
ni
fic
an
t 
di
ff
er
en
C
E
 (P
 <
 0
.0
5)
* 
or
 (P
<
0.
00
01
)^
 c
om
pa
re
d 
to
 t
he
 s
am
e 
ex
pe
rim
en
t 
w
ith
ou
t 
5
-A
S
A
 o
r 
al
lo
pu
rin
ol
. 
A
Z
A
: 
az
at
hi
op
rin
e;
 M
P
: 
m
er
ca
pt
op
ur
in
e;
 T
G
: 
th
io
gu
an
in
e;
 5
-A
S
A
: 
5
-A
m
in
os
al
ic
yl
ic
 a
ci
d;
 I
C
50
 h
al
f 
m
ax
im
al
 
in
hi
bi
to
ry
 c
on
ce
nt
ra
tio
ns
; n
.r.
: I
C
50
 n
ot
 re
ac
he
d,
 9
5%
 C
I: 
95
 %
 c
on
fid
en
ce
 in
te
rv
al
5
517689-L-sub01-bw-Broekman
Processed on: 7-3-2018 PDF page: 116
116
Chapter 5
Metabolite formation
Support for in vitro metabolism of the thiopurines was obtained by HPLC. The 
retention time of 6-TGN was comparable to AZA and MP, therefore only 6-MMP 
metabolites could be identified by HPLC. In the culture medium of HepaRG cells 
incubated with AZA, we demonstrated the presence of 6-MMP metabolites, 
providing evidence for in vitro metabolism of AZA in HepaRG cells (Figure 5).
Mechanisms behind the increased cytotoxicity of allopurinol co-
administration
DNA damage by AZA with or without allopurinol was visualized with single cell 
electrophoreses (Figure 6). With levels of AZA (70 µM) not affecting cell viability, 
the combination of AZA + allopurinol resulted in larger comet tails (more DNA 
damage) than incubation with AZA alone. In addition, caspase-3/7 activation was 
significantly increased (P< 0.01) when allopurinol (100 µM) was co-administered 
with AZA (70 µM), while allopurinol alone did not increase caspase-3/7 activation 
(Figure 7). Co-administration of 5-ASA (200 µM) with AZA (70 µM), did not 
influence caspase-3/7 activation (P=0.17).
Figure 5. Formation of 6-MMP (RT: 5.935) metabolites, measured by HPLC in culture 
medium of HepaRG cells after incubation with AZA for 10 hours. The RT of AZA and MP 
is equal to that of 6-TGN, therefore only 6-MMP metabolites could be distinguished. Other 
peaks are substances of culture medium. 6-MMP: 6-methylmercaptopurine, RT: retention 
time, AZA: azathioprine, MP: mercaptopurine, 6-TGN: thioguanine nucleotide
517689-L-sub01-bw-Broekman
Processed on: 7-3-2018 PDF page: 117
117
Thiopurine-induced hepatotoxicity in vitro
Figure 6. Single cell gel electrophoresis (Comet assay) of HepaRG cells incubated with 
A. medium serving as control, B. Allopurinol (100 µM), C. AZA (70 µM), D. AZA 70 (µM) 
and Allopurinol (100 µM). HepaRG cells were embedded in low melting agarose on a 
slide, then lysed, and treated with alkaline for DNA unwending followed by alkaline elec-
trophoresis (pH > 13). Following SYBR Green I staining, nuclei were visualized under an 
epifluorescence microscope. Damaged DNA migrates towards the anode, resulting in a 
comet tail. AZA: Azathioprine.
Figure 7. Caspase-3/7 activation of HepaRG cells incubated 24 hours with medium (con-
trol), 5-ASA (200 µM), allopurinol (100 µM), AZA (70 µM) or a combination of both. Stau-
rosporine (2 µM) was used as positive control. Activation of cells incubated only with 
medium was set as control. Values are presented as mean of 2 experiments with the SEM. 
Differences were compared with the Mann-Whitney U test. AZA: Azathioprine, 5-ASA: 
5-Aminosalicylic acid, SEM: Standard error of the mean.
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DISCUSSION
In this study we showed that the combination of a non-toxic dose of 100 µM 
allopurinol with AZA, MP or TG led to a two- to threefold increase in thiopurine 
induced cytotoxicity in HepaRG cells. The most likely explanation for the increased 
cytotoxicity with allopurinol is an elevation of 6-TGN levels, which are incorporated 
into DNA as fraudulent bases, resulting in strand breakage and apoptosis(1).
Previous studies in cultures of rat hepatocytes showed a positive effect on cell 
viability when allopurinol was co-administered with AZA, due to its anti-oxidant 
capacities (20-22). The contrasting findings of our study might be explained 
by differences in the experimental settings. Isolated rat hepatocytes exert 
no mitotic activity in contrast to human hepatoma cells. Because 6-TGNs act 
through incorporation into the DNA, this effect may be more pronounced in 
mitotically active cells. We hypothesise that the higher levels of 6-TGNs with 
allopurinol co-administration are responsible for the increased cytotoxicity. This 
is supported by our findings that allopurinol co-administration resulted in more 
single strand breakages and significant increased caspase-3/7 activation. In 
vivo, co-administration of allopurinol results in a significant reduction of 6-MMP 
metabolites and increase of 6-TGN metabolites. (3). Unfortunately, we were not 
able to analyse 6-TGN levels by HPLC, because of equal retention times of AZA, 
MP and 6-TGN. A direct comparison of our in vitro study with in vivo situation 
is difficult because of low mitotic activity of human hepatocytes compared with 
our human hepatoma cells. However, Heparg cells are known to have decreased 
mitotic activity when they are confluent, resembling the in vivo situation as best 
as possible. (10).
Theoretically, addition of 5-ASA may lead to decreased hepatotoxicity in vivo 
by inhibition of TPMT, leading to a decline in 6-MMP levels (4, 5, 23). However, 
there is much debate about the clinical significance of this interaction (24). The 
interaction between 5-ASA and thiopurines is non-competitive and long-term 
5-ASA therapy did not affect TPMT enzyme activity in a prospective study in 
CD patients (4, 25). Unfortunately, measurement of 5-ASA influences on TPMT 
activity is technically not feasible to our knowledge, because 5-ASA is removed 
in the washing steps(25). In our in vitro study, the effects of 5-ASA on cytotoxicity 
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were limited compared to allopurinol. This is supported by the finding that 5-ASA 
co-administration did not increase caspase-3/7 activation.
In this study we showed that concentration based TG is more cytotoxic than 
AZA or MP, with IC50 values of 18 µM in HepaRG cells after 72 hours incubation. 
This probably results from a direct conversion of 6-TG to 6-TGN, resulting in 
higher 6-TGN levels and less other metabolites. The increased cytotoxicity of 
TG with allopurinol co-administered can be explained by XO involvement in TG 
metabolism (Figure 1). Our results of single drug assessments of AZA and MP in 
HepaRG cells are in accordance with those of Petit et al, who compared HepaRG 
cells with human hepatocytes (8). Furthermore, we showed a different toxicity 
profile of AZA and MP in Huh7 and HepG2 cells. On the other hand in HepaRG 
cells this difference was not that prominent. It might be explained by depletion 
of glutathione, caused by the conversion of AZA to MP, as previously shown by 
Lee and Farrell (20).
We measured both TPMT activity as well as the most prevalent polymorphisms in 
the TPMT gene (TPMT*2 and TPMT*3A, *3B), because TPMT activity still varies 
in patients without these polymorphisms (26). Low TPMT activity is associated 
with high 6-TGN levels, which may cause leukopenia (26, 27). The three hepatoma 
cell lines tested had identical TPMT genotypes, but a variance in TPMT activity 
was noticed. Hence, no direct relation with cytotoxicity was found. It is difficult 
to compare TPMT activity we measured with those in clinical studies as herein 
TPMT activity is measured in erythrocytes (17).
Unfortunately, our HPLC method could not discriminate 6-TGN from AZA or MP. 
This would be of particular interest, as that would allow the production of a dose 
response curve comparing the association between 6-TGN levels and cytotoxicity. 
Despite the fact that the used HPLC protocol was not intended and validated 
for cell line research, our study is still unique, providing direct evidence of the in 
vitro metabolism of AZA in the HepaRG cell line demonstrated by the formation 
of 6-MMP. Another limitation of this study is the lack of comparison with human 
hepatocytes. It has to be stressed, that incubation experiments with human 
hepatocytes also have their limitations, as human hepatocytes are difficult to obtain 
and their metabolic activities rapidly decline during culturing (28-30). HepaRG 
cells are currently considered as the best surrogate for human hepatocytes for 
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use in drug toxicity studies and are closer related to human hepatocytes than rat 
hepatocytes because of the high conservation of metabolic enzymes and the 
absence of interspecies differences (10, 11, 29-31). With the notion that HepG2 
and Huh7 cells have been used more extensively in in vitro experiments so far, we 
also used these cell lines for comparison (32). In accordance with previous studies 
(8, 10, 31), we showed that HepaRG cells express the highest levels of important 
drug metabolising enzymes. In order to create similar experimental conditions for 
the three cell lines, we used the same culture medium for all three cell lines, which 
includes addition of 2% DMSO according to the HepaRG culturing protocol (33). 
DMSO is used to induce or maintain cell differentiation in HepaRG cells (33-36). 
Because previous studies with HepG2 and Huh7 cells did not use DMSO, this 
can be considered as a limitation. However, our results demonstrate that the up 
regulation of drug metabolising enzymes by DMSO is not limited to HepaRG cells, 
results which are in accordance with those of Choi et al. (35).
In conclusion, in this in vitro study we could demonstrate a considerable increase 
of thiopurine induced cytotoxicity by co-treatment with a non toxic dose of 
allopurinol. Further studies are required to explore the underlying mechanism of 
cytotoxicity due to this combination therapy.
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ABSTRACT
Background: Patients’ beliefs about medicine may either reflect the necessity 
for treatment or concerns regarding the treatment. We explored the extent to 
which these beliefs have an effect on thiopurine metabolite levels and premature 
discontinuation in patients with inflammatory bowel disease (IBD).
Methods: Patients enrolled in the ‘Thiopurine response Optimization by 
Pharmacogenetic testing in IBD Clinics’ (TOPIC) trial were asked to complete the 
Beliefs about Medicine Questionnaire (BMQ) four weeks after thiopurine initiation. 
The BMQ measures perceptions about treatment necessity and concerns about 
treatment. On the basis of the necessity and concern scores, patients can be 
categorized as accepting, ambivalent, indifferent or skeptical. The thiopurine 
discontinuation rates for these belief subgroups were compared by Kaplan-Meier 
curves. Furthermore, clinical response and metabolite levels were compared 
between the belief subgroups.
Results: A total of 767 patients with IBD started thiopurine treatment, of whom 
576 (75%) completed the BMQ. Patients could be classified as accepting (34%), 
indifferent (17%), ambivalent (34%), or skeptical (15%). Compared with patients in 
the accepting group (discontinuation rate 22%), patients with an indifferent (35%; 
p=0.02), ambivalent (37%; p<0.01) or skeptical believe (54%; p<0.01) had higher 
thiopurine discontinuation rates. No differences were observed in steady-state 
thiopurine metabolite levels between the different belief subgroups.
Conclusion: Patients with a low perceived treatment necessity or high concerns 
towards IBD treatment were more likely to discontinue thiopurine treatment 
prematurely. Extra attention towards these patients might prevent them from 
premature discontinuation.
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INTRODUCTION
Thiopurines are seen as the cornerstone in the maintenance treatment of 
inflammatory bowel disease (IBD). Although thiopurines are effective in the 
treatment of ulcerative colitis (UC) and Crohn’s disease (CD), up to 40% of 
patients discontinue treatment within one year.(1, 2) Several factors may result 
in early treatment discontinuation, such as occurrence of side effects or the lack 
of effectiveness. Apart from the actual occurrence of side effects or the lack of 
effectiveness, patients’ beliefs about the necessity for the treatment (e.g. the 
personal need for the prescribed drug) and concerns regarding potential drawbacks 
of treatment (e.g. side effects, long-term effects or dependence) may influence 
the motivation to start and continue medication.(3, 4)
Patients with IBD have relatively high levels of necessity, which suggest a high 
need for medical treatment.(3, 5) Nevertheless, non-adherence to medication is 
reported in 30-60% of patients.(3, 6) This results in an increased flare risk and a 
lower quality of life.(6) Nonadherence to thiopurines might seduce the attending 
physician to an unjustified switch to expensive biologic drugs in an effort to control 
disease, thereby placing an increased burden on healthcare resources. In IBD, as 
in other diseases, nonadherence is more frequently encountered in patients with 
stronger concerns or lower perceived necessity of treatment.(7-11)
Evaluation of treatment adherence is a challenge. Objective methods to assess 
treatment adherence such as drug tests in blood or urine are cumbersome and not 
available for all drugs; therefore, adherence is frequently assessed by indirect and 
subjective methods.(12, 13) Unfortunately, significant discrepancies exist between 
self-reported adherence and more objective parameters of adherence.(14) In 
thiopurine treatment, assessment of 6-methylmercaptopurine ribonucleotides 
(6-MMPR) and 6-thioguanine nucleotide (6-TGN) levels is becoming increasingly 
available in daily clinic for optimization and evaluation of thiopurine treatment. The 
presence of low levels of 6-MMPR and 6-TGN may suggest noncompliance and 
can therefore be used as a tool to assess treatment adherence.(15) Manipulation of 
adherence by taking pills just for the visit is less relevant with thiopurines, because 
it takes several weeks to achieve steady-state metabolite levels.
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Identification of patients at risk for nonadherence or early treatment discontinuation 
would be useful in designing a targeted approach to improve adherence. Apart 
from the influence of personal beliefs on self-reported treatment adherence and 
factors associated with adherence, little is known on the effect of beliefs about 
medicine on steady-state thiopurine metabolite levels and, more importantly, 
how these beliefs may foresee treatment discontinuation.(5, 13) To this end, we 
explored whether beliefs about IBD drugs could be associated with metabolite 
levels or premature treatment discontinuation of thiopurines.
PATIENTS AND METHODS
Patients
The current study is a post-hoc analysis of the Thiopurine response Optimization 
by Pharmacogenetic testing in Inflammatory bowel disease Clinics (TOPIC) trial. In 
the TOPIC trial, thiopurine-naive patients with IBD were randomized for standard-
of-care thiopurine dosing versus a genotype-based dose to evaluate the efficacy 
of pre-treatment thiopurine S-methyltransferase genotyping on the occurrence 
of myelosuppression.(16) Patients were followed for 20 ± 6 weeks. Physicians 
were free to use either azathioprine or mercaptopurine. The main exclusion criteria 
were previous use of thiopurines, laboratory test abnormalities, known thiopurine 
S-methyltransferase enzyme activity or genotype. The study protocol of the TOPIC 
trial was approved by the Institutional review board of the Radboud University 
Medical Center. All patients provided written informed consent (clinicaltrials.gov, 
NCT00521950). The TOPIC trial complies with the Declaration of Helsinki. For a 
detailed description of the study design, patient selection and patient data, we 
refer to Coenen et al.(16)
Beliefs about Medicine Questionnaire
Patients participating in the TOPIC trial were asked to complete the Beliefs about 
Medicine Questionnaire (BMQ) and the Medication Adherence Report Scale 
(MARS) four weeks after thiopurine initiation. Personal needs and concerns 
regarding a treatment can be quantified with the BMQ.(17) The BMQ was 
developed by R. Horne and J. Weinman to assess both disease-specific beliefs 
as well as beliefs to medication in general and is validated in patients with various 
chronic diseases such as asthma, rheumatoid arthritis, diabetic, renal dialysis, 
chronic heart disease, IBD and psychiatric diseases.(17, 18)
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For this study, the BMQ included statements about IBD treatment in a random 
order regarding the necessity (5 questions; e.g. My future health depends on 
the use of my IBD medication) and concerns (6 questions; e.g. the use of these 
IBD drugs disrupt my life). Statements are scored on a Likert-type scale (ranging 
from 1= strongly disagree to 5= strongly agree). The sum of answers for the five 
statements about necessity leads to a score between 5 and 25. For concern 
statements, the sum of answers was divided by six (the number of statements) 
and multiplied by five to generate a score between 5 and 25. Plotting the necessity 
score at the y-axis and the concerns score at the x-axis, with a split at the midpoint, 
enables a classification into four belief subgroups (Table 1).(7)
Self-reported adherence
Self-reported adherence was assessed with the 5-item MARS questionnaire 
(Medication Adherence Report Scale).(17) Questions are related to several 
statements concerning adherence (e.g. I forget to take my medication or I take 
fewer pills than prescribed). Answers were provided on a 5-point Likert-scale. The 
sum of answers was used as a subjective marker of adherence, with a maximum 
score of 25, which can be considered as full (self-reported) adherence.
6-MMPR and 6-TGN metabolite measurements
By protocol, 6-TGN and 6-MMPR levels at week eight were assessed at a routine 
check-up in the first 301 patients included in the TOPIC trial. 6-TGN and 6-MMPR 
levels were determined in red blood cells (RBCs) by high performance liquid 
chromatography according to the Lennard method.(16) Thiopurine metabolite 
concentrations are presented in pmol/8x108 RBCs. For analyses with metabolite 
levels, we used data from patients without dose adjustments in the first eight 
Table 1. Classification of patients into four belief subgroups based on scores of the Beliefs 
about Medicine Questionnaire on the domains necessity and concerns regarding IBD 
treatment.
Belief subgroup Necessity score Concern score
Accepting High Low
Ambivalent High High
Indifferent Low Low
Skeptical Low High
A high score on both the necessity and concern subscale is defined as a score of more 
than 15 points and a low score is defined as 15 points or lower.
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weeks. Subtherapeutic levels were defined as 6-TGN levels below 230 pmol/8x108 
RBCs, whereas therapeutic levels were defined as 6-TGN levels between 230 
and 490 pmol/8x108 RBCs.(19)
Clinical response
Clinical response was evaluated by means of the Harvey-Bradshaw Index in 
patients with CD and the partial Mayo score in patients with UC. The partial 
Mayo score uses the three non-invasive components of the Mayo Score (stool 
frequency, rectal bleeding and the physician’s global assessment).(20) Disease 
activity was measured at baseline, week 0, and at the end of the clinical trial, week 
20. Treatment response was defined as a reduction of three or more points at 
week 20 compared to week 0 on either the Harvey-Bradshaw Index or the partial 
Mayo score.
Data analysis
For this study, all patients who completed the BMQ were included. One 
missing answer per subscale (necessity, concerns or self-reported adherence 
part) was accepted; in that case the missing value was replaced by the mean 
of the other answers on that subscale. Patients were excluded from this study 
if more than one answer per subscale was missing. Scores are presented as 
mean ± SD, unless mentioned otherwise. Differences between respondents and 
nonrespondents were compared by parametric and nonparametric test, where 
appropriate. Necessity and concerns scores were compared for CD and UC using 
an independent-samples t-test. In the same way, necessity and concerns scores 
were compared between patients who continued and discontinued their thiopurine 
during the five months after treatment initiation. Treatment discontinuation was 
defined as a patient who stopped the initial prescribed thiopurine within five 
months. Dose reductions and temporary interruptions were accepted, provided 
that interruption was not longer than one month.(21) Kaplan-Meier curves were 
plotted to illustrate the time to discontinuation for the four belief subgroups 
and the log-rank test was used to compare discontinuation rates. Self-reported 
adherence rates were compared between the different belief subgroups with the 
Kruskal-Wallis test. The Kruskal-Wallis test was used to compare 6-MMPR and 
6-TGN levels between the different belief subgroups and the chi-squared test was 
used to compare the number of patients with 6-TGN levels within the therapeutic 
range. The degree of correlation between self-reported adherence scores and 
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metabolite levels was examined by Spearman’s correlation coefficient. Differences 
in treatment response for the belief subgroups were compared by chi-squared 
test. A p-value of <0.05 was considered significant. All analysis were performed 
in SPSS version 22.0.0.1 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Patients
Of the 796 randomized patients in the TOPIC trial, 767 patients actually started 
with thiopurines and 601 (78%) returned the BMQ. A total of 25 returned 
questionnaires were excluded because of more than one missing answer in 
one of the three subscales, leaving 576 (75%) patients, the respondents, who 
successfully completed the questionnaires for further analysis. Patients who did 
not return the questionnaire (n=166) or who were excluded because of missing 
answers (n=25) were classified as non-respondents. The characteristics of 
respondents and non-respondents are depicted in Table 2.
Table 2. characteristics of respondents and non-respondents
Total 
(n=767)
Respondents 
(n=576)
Non-
respondents 
(N=191)
P-value
Age, years, median (IQR) 41 (27-53) 43 (28-55) 37 (24-47) <0.01
Gender, female, n(%) 421 (55) 323 (56) 98 (51) 0.25
Disease type, CD, n (%) * 463 (60) 336 (59) 127 (66) 0.05
Disease duration, years, mean(SD) 5.3 (8.2) 5.7 (8.6) 4.1 (6.9) 0.01
Baseline disease severity**
 CD (HBI), mean (SD) 3.5 (3.0) 3.2 (2.7) 4.3 (3.8) 0.01
 UC (partial Mayo), mean (SD) 3.8 (1.7) 3.8 (1.7) 4.3 (1.7) 0.10
Type of thiopurine, AZA, n (%) 494 (64) 380 (66) 114 (60) 0.12
Discontinuation before week 20, n (%) 296 (39) 197 (34) 99 (52) <0.01
The non-respondents group is composed of patients who did not return the questionnaire 
(n=166) and patients with more than 1 missing answer in one of the three subscales 
(n=25). *7 patients were diagnosed with indeterminate colitis. ** HBI was known for 
349 patients with CD and partial mayo score was known for 251 UC patients. AZA; 
azathioprine, CD; Crohn’s disease, HBI; Harvey-Bradshaw Index; UC, ulcerative colitis
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Patients with IBD scored (17.1 ± 4.2) on the necessity subscale. Necessity scores 
were higher in patients with UC (17.8 ±4.2) than CD (16.6 ±4.1) (p<0.01). Concern 
scores were not different between UC (15.6 ± 3.4) and CD (15.1 ± 3.4) (p=0.07). 
Categorization of patients according to the combination of necessity and concerns 
score showed that 34% of the patients could be defined as accepting, 34% as 
ambivalent, 17% as indifferent and 15% as skeptical (Figure 1).
Thiopurine discontinuation rates
Of the 576 respondents, 197 (34%) discontinued the initial prescribed thiopurine 
within the first 5 months. Patients who discontinued treatment had higher concerns 
(16.3±3.6 versus 14.8±3.2, p<0.01) and lower necessity scores (16.1±4.9 versus 
17.7±3.6, p<0.01) than patients who continued thiopurine treatment. Compared 
with patients in the accepting group (discontinuation rate 22%), patients classified 
as either indifferent (35%; p=0.02) , ambivalent (37%; p<0.01) or skeptical (54%; 
p<0.01) all had higher discontinuation rates (Figure 2). Moreover, discontinuation 
rates of patients with a skeptical profile were also higher compared with patients 
classified as either indifferent or ambivalent (p<0.01).
Self reported adherence
Self-reported adherence scores, measured with the MARS questionnaire, 
were very high with an median score (IQR) of 25.0 (24.0-25.0). Self-reported 
adherence scores were not different between the belief subgroups (p=0.88). 
6-MMPR metabolite levels (p=0.29) and 6-TGN metabolite levels (p=0.34) were 
not correlated with the self-reported adherence.
Thiopurine metabolite levels
Overall, 196 (65%) of the 301 patients in whom the week eight 6-MMPR and 
6-TGN levels were assessed were considered as steady state (i.e. had no 
dose adjustments during the first eight weeks) and were included for further 
analyses. The number of patients per belief subgroup with 6-TGN levels within 
the therapeutic range varied between 43 and 48%. 6-MMPR (p=0.99), 6-TGN 
(p=0.97) levels and the percentage of patients within the therapeutic range 
(p=0.97) were not different between the four belief subgroups (Table 3).
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Clinical response
Clinical response was known for 338 (58.7%) of the 576 respondents. 
Categorisation of these 388 patients in belief subgroups showed that 35% of the 
patients could be classified as accepting, 35% as ambivalent, 16% as indifferent 
and 14% as sceptical, which is in line with the numbers of the entire group (Figure 
1). Treatment response rates per belief subgroup were 26% (30 out of 117) in 
patients classified as accepting, 26% (31 out of 121) in ambivalent patients, 17% (9 
out of 54) in indifferent patients and 34% (16 of 47) in skeptical patients (Figure 3). 
Treatment response was not different between the four belief subgroups (p=0.26).
High necessity
Low necessity
High
concerns
Low 
concerns
Accepting
n=198
(34%)
Indifferent
n=96
(17%)
Skeptical
n=84
(15%)
Ambivalent
n=198
(34%)
Figure 1. Categorization of patients in four belief subgroups based on their necessity and 
concerns score, including the discontinuation rate per belief subgroup.
 
Figure 2. Kaplan-Meier curve in which treatment discontinuation is plotted for the four 
belief subgroups: accepting group (n =198), ambivalent group (n =198), indifferent group 
(n =96), and skeptical group (n=84).
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DISCUSSION
The present study shows that patients with IBD who perceive a low necessity 
or high concerns for IBD treatment were more likely to discontinue thiopurine 
treatment prematurely. Categorization into four belief subgroups showed that most 
patients could be classified as accepting or ambivalent. We found no association 
between belief subgroups and 6-MMPR and 6-TGN metabolite levels.
Table 3. Steady state week eight 6-MMPR, 6-TGN levels and percentage of patients within 
the therapeutic range per belief subgroup
Belief subgroup
6-MMPR
(pmol/8x108 RBCs)
6-TGN
(pmol/8x108 RBCs)
% of patients 
within the 
therapeutic range
Accepting (n=76; 38%) 3068 (918-7352) 259 (204-381) 47
Ambivalent (n=63; 32%) 3141 (681-7363) 271 (196-343) 48
Indifferent (n=36; 18%) 3639 (867-6219) 271 (195-378) 44
Skeptical (n=21; 11%) 4101 (613-8024) 264 (171-508) 43
Week eight metabolite levels were presented as median (interquartile range). Therapeutic 
range was defined as 6-TGN levels between 230 and 490 pmol/8x108 RBCs. 6-MMPR 
(p=0.99), 6-TGN levels (p=0.97) and therapeutic range (p=0.97) were not different between 
the different belief subgroups. 6-MMPR; 6-methylmercaptopurine ribonucleotides, 6-TGN; 
6-thioguanine nucleotide, RBCs; red blood cells
Figure 3. Percentage of patients with a reduction of three or more points on the Har-
vey-Bradshaw Index or partial Mayo score after 20 weeks for the four belief subgroups. 
Treatment response was not different between subgroups (p=0.26).
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The proportion of patients per belief subgroup corroborates with those found 
in previous studies in IBD patients.(3, 22) As such, impact on necessity and 
concerns scores created by study participation appears to be limited. The relative 
high scores of patients towards the necessity for treatment probably follow from 
a high level of disease burden in patients with IBD.(23, 24) Application of the 
BMQ in diseases with a lower disease burden, such as atrial fibrillation, indeed 
results in lower necessity scores than thrombosis which has more impact.(25) The 
higher necessity scores of UC patients compared with patients with CD might be 
explained by the fact that UC exacerbations with frequent bloody diarrhea may 
be perceived as more severe compared with CD, which can be more subtle in 
presentation.(26) The fact that a third of the patients still had IBD scores low on 
necessity for treatment may have resulted from the cyclical disease manifestation 
with episodes of no or only minimal disease symptoms.(13)
A novel aspect of this study is that we correlated BMQ scores with treatment 
discontinuation rates. To date, studies using the BMQ in patients with IBD 
mainly focused on the exploration of factors associated with drug adherence.
(13) Knowledge of who discontinues treatment is of high relevance, given the 
limited alternative options in the treatment of IBD. We showed that IBD patients 
with high concerns or low needs are at risk for premature discontinuation of 
thiopurines in the first months of treatment. Moreover, the combination of both 
even further increases this risk. Our findings corroborate studies in patients 
with IBD that showed a positive relation between the patients’ necessity and 
medication adherence and a negative relation in case of high concerns.(13) In 
the current study, the BMQ was collected four weeks after thiopurine initiation, 
which is in line with comparable study designs.(25, 27) Although studies showed 
that patients’ beliefs are considered stable over time, occurrence of side effects 
within the first weeks may have resulted in increased concern feelings at the time 
that the questionnaire was completed.(28) Identification of patients at risk for 
treatment discontinuation in an early stage might help in the design of strategies 
to prevent patients from discontinuing treatment. Special attention should be 
paid to patients with high concerns as within the spectrum of IBD drugs, patients 
consider thiopurines as drugs with the highest risks as a result of fear for side 
effects and long-term drug-induced comorbidities.(29) This leads to significant 
lower adherence rates for thiopurine use.(30) A comprehensive education at start 
and at follow-up phone calls by an IBD nurse or pharmacist seem to be a promising 
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approach to evaluate and anticipate on the negative perceptions and expectations 
towards thiopurine treatment.(6, 31-33)
This study is unique as thiopurine metabolite levels were used as an indicator 
for treatment adherence in conjunction with self-reported adherence scores.(3, 
10) Most studies only used self-reported adherence or pill count as a proxy for 
treatment adherence. In our study, patients scored very highly on self-reported 
adherence, whereas the number of patients in the therapeutic range varied around 
45%. Previous studies reported lower self-reported adherence scores, suggesting 
that self-reported adherence scores in this study might be biased because of 
the setting of a clinical trial.(3, 7, 10, 24) Only a few studies have compared self-
reported adherence with thiopurine metabolite levels measured in blood. In one of 
these studies, self-reported nonadherence was limited to 10% of thiopurine users, 
whereas in practice only 14% had 6-TGN levels within the therapeutic range.
(14) It must be stressed that many genetic and environmental factors influence 
thiopurine metabolism, which limits analyses between necessity or concern 
scores and metabolite levels.(34) This underscores the relevance, but also the 
difficulty, of more objective outcome measures. We found no association between 
the four belief subgroups and 6-MMPR and 6-TGN metabolite levels at week 
eight. Furthermore, there were no differences in treatment response between 
the belief subgroups, which seems logical, given the similar 6-MMPR and 6-TGN 
levels across the belief subgroups. This indicates that, at least at short term, the 
BMQ does not allow to predict adherence or treatment response in patients with 
IBD, but only who will discontinue treatment.
A limitation of our study is that obtaining metabolite levels at week eight might 
be too early in the follow up to identify differences in levels between the belief 
subgroups. Nonadherence risk increases with length of treatment, whereas in this 
study, patients just started treatment and might still be motivated to take their pills.
(35) This is supported by a study in 65 patients with IBD with an average thiopurine 
usage of almost three years, in which metabolite levels were significantly lower 
in patients with a low self-reported adherence.(36). Furthermore, we only used 
data from patients with steady-state week eight metabolite levels. Patients with 
dose adjustments, frequently because of side effects, were excluded. Importantly, 
proportions of the four belief subgroups of patients with steady state metabolite 
levels merely correspond with numbers of the entire study group, which makes 
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selection bias unlikely. Another limitation is that selection bias occurred, given the 
differences between respondents and nonrespondents in age, disease duration 
and discontinuation rates.(37, 38) The latter can partially be explained by patients 
who discontinued treatment before week four and subsequently did not return the 
questionnaire. Finally, questions in the BMQ and MARS questionnaire contained 
the term ‘IBD treatment’ rather than ‘thiopurine treatment’ to avoid confusion 
with complicated chemical drug names (azathioprine or mercaptopurine) or brand 
names. Therefore, it might be that patients did not answer the questions with 
reference to thiopurine use. However, we foresee that this influence is minimal 
as patients were asked to participate in a trial that focused on the initiation of 
thiopurines.
In conclusion, the use of the BMQ helps to identify IBD patients who are likely to 
discontinue thiopurines in the first months of treatment. Attention and education 
in the consulting room or by telephone should be given to patients with low 
needs and high concerns towards IBD treatment to withhold them from premature 
discontinuation.
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ABSTRACT
Background: Leukopenia is a common side effect in patients treated with 
thiopurines. Variants in the thiopurine S-methyltransferase (TPMT) gene are the 
best-known risk factor, but only explain up to 25% of leukopenia cases. Our aim 
was to identify clinical risk factors for thiopurine-induced leukopenia in patients 
without a common TPMT variant and explore if these patients are at increased 
risk for infections.
Methods: Post-hoc analysis of the Thiopurine response Optimization by 
Pharmacogenetic testing in Inflammatory bowel disease Clinics (TOPIC) trial. For 
this analysis, patients without a variant in TPMT (*2, *3A or*3C) were included. 
Uni- and multivariate Cox-proportional hazard models were used to identify risk 
factors for leukopenia and infections. Leukopenia was defined as a white blood cell 
(WBC) count <3.0 x109/L and infections were classified according to the Common 
Terminology Criteria for Adverse Events (CTCAE).
Results: 695 patients (90.6%) included in the TOPIC-trial had no variant in TPMT, 
of which 45 (6.5%) developed leukopenia. Median time to leukopenia was 56 (29-
112) days. Multivariate analysis showed that use of mercaptopurine compared to 
azathioprine was associated with leukopenia (Hazard ratio (HR) 2.61 [95% CIs, 
1.39-4.88; p<0.01]) and a higher baseline WBC count was protective (HR 0.80 
[95% CIs, 0.71-0.89; p<0.01]). Risk factors for infections were older age (per 10 
year; HR 2.07 [95% CIs, 1.18-3.63; p=0.01]) and concomitant use of biologic drugs 
(HR 2.15 [95% CIs, 1.14-4.07; p=0.02]).
Conclusion: Low baseline WBC count and mercaptopurine, due to a relatively 
higher dose, were risk factors for thiopurine-induced leukopenia in patients without 
a TPMT variant.
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INTRODUCTION
Thiopurines are immunosuppressive drugs that have an important role in the 
treatment of inflammatory bowel diseases (IBD), both as monotherapy and as 
combination treatment with biologics. (1-3) Yet, many patients have to discontinue 
treatment in an early phase due to ineffectiveness or side effects. Leukopenia 
as a result of thiopurine use is a frequent reason for dose reductions and/or 
(temporary) treatment discontinuation in patients with IBD, leading to suboptimal 
treatment conditions. (4, 5) Dose reductions or treatment discontinuation in case 
of leukopenia are mainly driven by fear for infectious complications.(4)
The best-known risk factor for the development of thiopurine-induced leukopenia 
is the presence of genetic variants in the thiopurine S-methyltransferase (TPMT) 
gene, which leads to a reduced or negligible TPMT activity and subsequently to 
excessive cytotoxic 6-thioguanine nucleotide (6-TGN) metabolite formation.(6, 7) 
In the Caucasian population 95% of the decreased TPMT enzyme activity follows 
from three common variants (TPMT*2, TPMT*3A or TPMT*3C).(7) Especially 
patients with a homozygous genetic variant in TPMT (~0.3% of the population), 
and to a lesser degree patients with a heterozygous variant in TPMT (~10% of 
the population) are at increased risk for severe, life-threatening, myelosuppression 
when treated with the standard recommended dose of azathioprine (AZA) or 
mercaptopurine (MP).(8-10) Leukopenia can be prevented by genotyping for 
these variants prior to initiation of thiopurine treatment and subsequently taper 
the thiopurine dose to 50% of the original dose in those heterozygous for a variant 
in TPMT and 0-10% of the original dose in patients with a homozygous variant. 
(11-13) However, only up to 25% of the leukopenia cases can be explained by 
variants in TPMT, which makes that leukopenia is frequently observed in patients 
without a TPMT variant. (1, 5, 14-16) This suggests that also other genes and 
environmental or clinical factors may contribute to the risk of leukopenia during 
thiopurine treatment.(17-21)
It is unknown to what degree leukopenia attributes to the risk for infections. 
Recent studies in the treatment of hepatitis C did not reveal a relation between 
interferon-induced leukopenia and infectious complications. (22, 23) If this also 
applies for thiopurine treatment in IBD, strict dose reductions in case of leukopenia 
might be redundant.
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In the present post-hoc analysis of the ’Thiopurine response Optimization by 
Pharmacogenetic testing in Inflammatory bowel disease Clinics’ (TOPIC) trial, we 
aimed to (i) identify clinical risk factors for the development of TPMT-independent 
leukopenia in patients with IBD treated with thiopurines and (ii) evaluate whether 
TPMT-independent leukopenia is a risk factor for the occurrence of infections in 
these patients.
PATIENTS AND METHODS
Patients
We designed a case-control study with patient data from the TOPIC trial, which 
evaluated the efficacy of pre-treatment TPMT genotyping on the occurrence of 
myelosuppression during thiopurine treatment.(14) In brief, in the TOPIC trial 
thiopurine-naive patients with IBD with an indication for thiopurine treatment 
(indicated by the treating physician) were randomised 1:1 for the intervention group 
with prior to treatment genotyping of the three most common genetic variants (*2, 
*3A and *3C) in TPMT versus the standard of care group with thiopurine dosing 
according to current standard of care; AZA (2.0-2.5 mg/kg) and MP (1.0-1.5 mg/kg). In 
patients allocated to the intervention arm a 50% dose reduction was recommended 
in case of a heterozygous TPMT variant and in case of a homozygous TPMT variant 
10% of the standard dose or an alternative treatment was advised. Patients were 
followed for 20 ± 6 weeks with laboratory measurements including white blood cell 
(WBC) count at week 0, 1, 2, 4, 6, 8, 20 and when indicated by the treating physician. 
Neutrophil count was not routinely measured in the TOPIC-trial. Physicians were 
free in their choice for AZA or MP and were advised to start full dose. After the 
follow-up period, TPMT genotype was assessed in patients randomised to the 
standard of care arm and in addition TPMT activity was assessed in all patients. 
Main exclusion criteria of the TOPIC-trial were previous use of thiopurines, co-
treatment with allopurinol, baseline WBC count <3.0*109/L, baseline liver test 
abnormalities (alanine transaminase, aspartate transaminase, alkaline phosphatase, 
and/or gamma glutamate transpeptidase ≥ two times the normal upper limit), known 
TPMT enzyme activity or TPMT genotype. 6-Methylmercaptopurine ribonucleotides 
(6-MMPR) and 6-TGN levels were assessed at week eight in the first 301 patients 
included in the trial. For a detailed description of the study design, patient selection 
and patient data, we refer to Coenen et al.(14) The TOPIC trial was approved by the 
institutional ethics committee and all patients provided written informed consent 
(clinicaltrials.gov, NCT00521950).
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The primary aim of the current study was to indentify risk factors for leukopenia 
in patients without one of the tested genetic variants in TPMT. All randomised 
patients who started with a thiopurine and tested negative for a variant in TPMT 
were included in an intention-to-treat analysis (Figure 1). Patients allocated to 
the genotyping arm with a TPMT variant (treated with 50% of the regular dose), 
as well as patients assigned to the standard of care arm with a TPMT variant 
(treated with 100% of the regular dose) were excluded. The Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 was used to classify the severity 
of leukopenia.(24) According to these criteria mild leukopenia (grade 1) is defined 
as a WBC count between the lower limit of normal and ≥3.0*109/L, moderate 
leukopenia (grade 2) was defined as a WBC count between ≥2.0*109/L and 
<3.0*109/L and severe leukopenia (grade 3) if the WBC count was <2.0*109/L. 
For the current analysis, only cases of moderate and severe leukopenia were 
included. Leukopenia which developed two weeks or later after discontinuation 
of the thiopurine was not considered to be associated with thiopurine use.
The second goal of this study was to explore if patients with TPMT-independent 
leukopenia during thiopurine treatment were at increased risk for infections. For 
this analysis, infections were classified according to the CTCAE.(24) The source 
of infection was reported and severity was subdivided in grade 1 to 5, in which 
grade 1 means no indication for infection treatment, grade 2: oral intervention 
(antibiotics, antifungal or antiviral) treatment indicated, grade 3: intravenous 
treatment (antibiotics, antifungal or antiviral) or operative intervention indicated, 
grade 4: life-threatening consequences and grade 5 indicates death from the 
infection. Only clinical relevant infections, grade 2 or higher, were included in 
the analysis, i.e. infections for which oral or intravenous antibiotic, antifungal, or 
antiviral treatment was indicated. Infections up to two weeks after thiopurine 
treatment discontinuation were included. Infections were classified as ‘leukopenia-
associated infection’ when the infection occurred while the patient was leukopenic 
(WBC count <3.0*109/L) or within two weeks after the leukopenia was resolved.
Covariates included in the analysis were baseline (week 0) WBC count and week 
one decrease in WBC count, defined as the decrease in WBC level after 7 (± 
1) days of thiopurine use. Furthermore, use of concomitant drugs, i.e. use of 
5-aminosalicylic acid (5-ASA), steroids, biologics and ACE-inhibitors at baseline or 
initiated during the use of the initial thiopurine was reported. Steroids with limited 
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systemic bioavailability, such as budesonide were not included. Information about 
co-morbidities (diabetes mellitus, chronic pulmonary disease and rheumatoid 
diseases) was reported. Patients were classified as active smoker or non-smoker, 
determined at baseline. Disease severity at baseline was classified according to 
the Harvey-Bradshaw Index (HBI) in patients with Crohn’s disease (CD) and partial 
Mayo score for ulcerative colitis (UC). AZA dose in mg/kg was divided by 2.08 for 
comparison with MP dose.(12, 25)
TPMT enzyme activity and TPMT genotyping
TPMT enzyme activity was measured in red blood cells (RBCs) using a high-
performance liquid chromatography method described previously.(14) Genotyping 
of variants *2, *3A and *3C in TPMT was described previously.(14) Possible cases 
of TPMT-induced leukopenia caused by rare variants, other than *2, *3A and 
*3C in TPMT, might have been missed. For this reason, we sequenced all exons 
including splice sites in the TPMT gene in patients with a low TPMT activity 
(<60 mg 6-methylguanine / mmol Hb.h) or who developed leukopenia (WBC 
<3.0*10^9/L). Polymerase chain reaction was performed on 10 ng DNA using 
AmpliTaq Gold 360 mastermix (Life Techologies, Bleiswijk, The Netherlands). 
Primers are described elsewhere.(14) Annealing temperature was 56°C for all 
exons. Polymerase chain reaction products were purified using Multiscreen filter 
plates (Millipore Carrigtwohill, Cork, Ireland). Purified products were used for 
Sanger sequence analysis (bidirectional) with dye-termination chemistry (BigDye 
Terminator, version 3) on a 3730 DNA analyzer (Applied Biosystems, Inc., Foster 
City, CA, USA.
6-MMPR and 6-TGN metabolite measurements
By protocol, 6-TGN and 6-MMPR levels at week eight were assessed at a routine 
check-up in the first 301 patients included in the TOPIC trial. 6-TGN and 6-MMPR 
levels were determined in red blood cells (RBCs) by high performance liquid 
chromatography according to the Lennard method.(14) Median (IQR) thiopurine 
metabolite concentrations are presented in pmol/8x108 RBCs.
Statistical analysis
All analyses were performed using SPSS version 20.0.0.1 (SPSS Inc., Chicago, IL, 
USA). First, leukopenia rate was calculated for patients without one of the tested 
TPMT variants. Characteristics of patients with and without TPMT-independent 
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leukopenia were compared by chi-squared test (categorical data) or independent 
t-test (continuous data). Non-parametric tests were used when data were not 
distributed normally. In a similar fashion, characteristics of patients with and 
without an infection during the use of the initial thiopurine were analysed. In 
patients with steady state metabolite levels at week 8, the 6-MMPR, the 6-TGN 
levels and the 6-MMPR/6-TGN ratio were compared by Mann–Whitney U test in 
patients with and without TPMT-independent leukopenia.
Univariate Cox-proportional hazard models were used to identify clinical factors 
associated with the development of leukopenia in patients without one of the 
tested TPMT variants. The time to leukopenia and in patients without leukopenia 
the number of days of thiopurine use served as reference. Variables with a p-value 
<0.2 were included in a multivariate Cox-proportional hazard model with backward 
elimination to explore which factors were independently associated with the 
development of TPMT-independent leukopenia during thiopurine treatment. In 
the same way uni- and multivariate Cox-proportional analysis were performed to 
indentify factors associated with the occurrence of infections during thiopurine 
treatment. The variable leukopenia was retained in this model, since we wanted 
to explore whether these patients were at increased risk for infections. A p-value 
of <0.05 was considered as statistically significant.
RESULTS
Patients
Of the 796 patients with IBD randomised in the TOPIC trial, 29 patients were 
excluded because they did not start with a thiopurine or were lost to follow up. 
Of the remaining 767 patients who actually started with thiopurine treatment, 72 
(9.4%) carried a genetic variant in TPMT and were excluded, which leaves 695 
patients with IBD for this analysis (Figure 1). Of the 695 included patients, 247 
patients (35.5%) were treated with MP (mean dose ± SD 1.20 ± 0.15 mg/kg) and 
448 patients (64.5%) were treated with AZA (mean dose ± SD 2.19 ± 0.20 mg/
kg). To compare the AZA dose with the MP dose, a conversion rate of 2.08 was 
applied, resulting in a mean converted dose of 1.05 ± 0.09 mg/kg. T-test showed 
that the difference was significant (p<0.001).
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Leukopenia
Of the 695 patients without a variant in TPMT, 45 (6.5%) developed leukopenia 
in the first five months of treatment; 41 (5.9%) patients developed moderate 
leukopenia and four (0.6%) patients developed severe leukopenia. See 
Supplementary table 1 for detailed information of the 45 patients with TPMT-
independent leukopenia. Median time (IQR) to onset of leukopenia was 56 (29-112) 
days. In 11 patients (24.4%) with TPMT-independent leukopenia the thiopurine 
Figure 1. Flowchart of patient selection for this post-hoc analysis. All patients 
who participated in the TOPIC trial, without a genetic variant in TPMT, were includ-
ed. AZA, azathioprine; MP, mercaptopurine; TPMT; thiopurine S-methyltransferase 
Figure 2. Thiopurine S-methyltransferase (TPMT) activity in patients with and without 
TPMT-independent thiopurine-induced leukopenia. Leukopenia was defined as white blood 
cell count of <3.0 x109/L.
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treatment was discontinued, while in 20 patients (44.5%) the thiopurine dose was 
reduced, in 12 patients (26.7%) leukopenia recovered without an intervention and 
in two patients (4.4%) the intervention was unknown. TPMT enzyme activity mean 
(±SD) was not different between patients with and without leukopenia (95.8 ± 
21.8 versus 94.4 ± 18.8 mg/mmol Hb.h, p=0.65) (Figure 2).
Table 1 shows the characteristics of patients with and without TPMT-independent 
leukopenia during thiopurine treatment. Table 2 provides the results of the uni- 
and multivariate Cox-proportional hazard model and shows that the choice for MP 
compared to AZA, Hazard ratio (HR) 2.61 (95% CIs 1.39-4.88; p<0.01) was and 
independent risk factor for TPMT-independent thiopurine-induced leukopenia. 
Furthermore, a higher baseline WBC count protected the patient from TPMT-
independent thiopurine-induced leukopenia, HR 0.80 (95% CIs 0.71–0.89; p<0.01): 
for every increase of WBC at baseline with 1.0x10^9/L the risk of leukopenia 
decreased with 0.80.
In 17 patients who developed leukopenia after eight weeks, steady state 6-MMPR 
and 6-TGN levels were assessed. Neither 6-TGN levels, nor 6-MMPR levels, 
nor the 6-MMPR/6-TGN ratio were different from patients without leukopenia in 
whom steady state week eight levels were assessed; 267 (205-364) pmol/8×108 
red blood cells (RBCs) versus 242 (186-341) pmol/8×108 RBCs, p=0.39 and 3596 
(1304-12824) pmol/8×108 RBCs versus 3600 (1326-7415) pmol/8×108 RBCs, 
p=0.63. The 6-MMPR/6-TGN median (IQR) ratio was 13 (6-35) in patients with 
leukopenia and 14 (6-32) in patients without leukopenia, p=0.80.
Infections
Sixty-five (9.4%) of the 695 patients developed an infection while being treated 
with a thiopurine during the study period of five months. Fifty-nine (8.5%) 
infections were classified as grade 2 or higher according to the CTCAE, of these, 
32 patients had a grade 2 infection, 25 patients a grade 3 infection and 2 patients 
were classified as grade 4 infection. Two patients died during the TOPIC trial, 
both were excluded from this analysis, one patient had a heterozygous TPMT 
variant and the other patient developed an infection while he was treated with 
steroids, infliximab and methotrexate, more than two weeks after thiopurine 
treatment was discontinued.(14) Median (IQR) time after the start of thiopurine 
treatment to an infection grade 2 or higher was 54 (18-88) days. Of the 45 patients 
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Table 1. Characteristics of the patients with and without TPMT-independent thiopurine-
induced leukopenia
Characteristics
Leukopenia
Yes (n=45) No (n=650) P-value
Male sex, n (%) 21 (47) 289 (45) 0.77
Age, y, median (IQR) 43 (28-51) 40 (26-53) 0.52
BMI, mean (SD) 24.9 (5.6) 24.8 (4.8) 0.89
Current smoker, n (%) 4 (9) 156 (24) 0.02
Drug, AZA, n (%) 18 (40) 430 (66) <0.01
Thiopurine dose in mg/kg, median (IQR)a 1.15 (1.03-1.31) 1.09 (1.02-1.17) 0.03
TPMT activity, mg/mmol Hb.h, mean (SD) 95.8 (21.7) 94.4 (18.8) 0.65
Disease, CD, n (%)b 24 (53) 399 (61) 0.33
Wk 0 WBC count, 109/L, mean(SD) 8.4 (3.5) 10.6 (3.6) <0.01
Wk 1 decrease WBC count, 109/L, mean (SD)c 1.2 (2.9) 0.8 (2.8) 0.42
Concomitant drugs, n (%)
 5-Aminosalicylic acid 25 (56) 320 (49) 0.41
 Systemic steroids 27 (60) 371 (57) 0.74
 Biologics 9 (20) 66 (10) 0.04
 ACE-inhibitor 2 (4) 20 (3) 0.61
Co-morbidity, n (%) d
 Diabetes mellitus 3 (7) 22 (3) 0.25
 Rheumatic disease 2 (5) 36 (6) 0.75
 Astma / COPD 3 (8) 66 (12) 0.45
Disease severity
 CD, HBI, mean (SD) e 3.7 (3.6) 3.6 (3.1) 0.83
 UC, partial Mayo, mean (SD)f 3.7 (1.5) 3.8 (1.7) 0.83
Leukopenia was defined as a white blood cell count (WBC) of <3.0 x109/L. a AZA dose in 
mg/kg was divided by 2.08 to compare with MP dosage. b Seven patients were diagnosed 
with indeterminate colitis. c Known for 492 patients. d Known for 602 patients. e Known 
for 325 patients with CD. f Known for 225 patients with UC. AZA, azathioprine; BMI, 
body mass index; CD, Crohn’s disease; HBI; Harvey-Bradshaw Index; TPMT, thiopurine 
S-methyltransferase; UC, ulcerative colitis; WBC, white blood cell.
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with TPMT-independent leukopenia five patients (11.1%), of whom three had a 
severe leukopenia (WBC count <2.0*109/L), experienced a ‘leukopenia associated 
infection’, while the infection rate in patients without leukopenia was 54 in 650 
patients (8.3%) (p=0.41). Details about infection localisation are depicted in Table 3. 
Characteristics of patients with and without an infection are presented in Table 4. 
In the multivariate Cox-proportional hazard model only age (per 10 years), HR 
2.07 (95% CIs, 1.18-3.63; p=0.01) and concomitant use of biologic drugs, HR 2.15 
(95% CIs, 1.14-4.07; p=0.02), were associated with the occurrence of infections 
(Table 5).
Table 2. Uni- and multivariate Cox-proportional hazards regression analysis to explore 
factors associated with development of thiopurine-induced leukopenia in the first five 
months of thiopurine treatment in patients without a TPMT variant.
Univariate analysis Multivariate analysis
Hazard ratio  
(95% CIs)
P-value
Hazard ratio  
(95% CIs)
P-value
Drug type, MP versus AZA 2.45 (1.35-4.48) 0.003 2.61 (1.39-4.88) 0.003
Week 0 WBC count, 109/L 0.78 (0.70-0.88) <0.001 0.80 (0.71-0.89) <0.001
Concomitant biologic drugs 1.67 (0.80-3.49) 0.17
Thiopurine dosage (mg/kg) 5.59 (0.68-46.1) 0.11
Active smoking 0.37 (0.13-1.03) 0.06
AZA dose in mg/kg was divided by 2.08 to compare with MP dosage. AZA, azathioprine; 
MP, mercaptopurine; WBC, white blood cell
Table 3. Infection localisation according to the Common Terminology Criteria for Adverse 
Events (version 4.0). Only patients with infections grade 2 or higher were included.
Localisation Frequency
Lung infection 16
Urinary tract infection 8
Skin infection 7
Abdominal infection 5
Infectious enterocolitis 4
Upper respiratory infection 2
Meningitis 1
Unknown 16
Overall 59
7
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Table 4. Characteristics of the patients with and without an infection during thiopurine 
treatment
Characteristics
Infection during thiopurine 
treatment
Yes (n=59) No (n=636) P-value
Male sex, n (%) 21 (36) 289 (45) 0.15
Age,y, median (IQR) 42 (33-60) 40 (26-53) 0.11
BMI, mean (SD) 24.9 (6.1) 24.7 (4.7) 0.82
Current smoker, n (%) 18 (31) 142 (22) 0.16
Drug, AZA, n (%) 42 (71) 406 (64) 0.26
Thiopurine dose in mg/kg, median (IQR)a 1.08 (1.02-1.16) 1.10 (1.02-1.19) 0.50
TPMT activity, mg/mmol Hb.h, mean (SD) 96.2 (19.6) 94.4 (18.9) 0.47
Disease, CD, n (%)b 38 (64) 385 (61) 0.63
Wk 0 WBC count, 109/L, mean(SD) 9.9 (3.5) 10.5 (3.6) 0.21
Wk 1 decrease WBC count, 109/L, mean (SD)c 0.4 (3.0) 0.9 (2.8) 0.29
Leukopenia 5 (9)* 37 (6) 0.41
Concomitant drugs, n (%)
 5-Aminosalicylic acid 28 (48) 317 (50) 0.47
 Systemic steroids 33 (56) 632 (58) 0.79
 Biologics 12 (20) 63 (10) 0.01
 ACE-inhibitor 2 (4) 20 (3) 0.61
Co-morbidity, n (%) d
 Diabetes mellitus 1 (2) 24 (4) 0.41
 Rheumatic disease 8 (16) 61 (11) 0.32
 Astma / COPD 5 (10) 33 (6) 0.28
Disease severity
 CD, HBI, mean (SD) e 3.7 (2.8) 3.6 (3.1) 0.80
 UC, partial Mayo, mean (SD)f 3.9 (1.7) 3.8 (1.7) 0.82
Leukopenia was defined as a WBC count of <3.0 x109/L. Only infections grade 2 or 
higher according to the Common Terminology Criteria for Adverse Events were 
included. a AZA dose in mg/kg was divided by 2.08 to compare with MP dosage. 
b Seven patients were diagnosed with indeterminate colitis. c Known for 492 patients. 
d Known for 602 patients. e Known for 325 patients with CD. f Known for 225 patients 
with UC. * As follows from Table 3, 45 patients experienced leukopenia, however in 
three patients with leukopenia during thiopurine treatment who also had an infection, the 
infection was not considered to be related to leukopenia, either because leukopenia was 
already resolved for more than two weeks (two patients), or the infection was already 
known before the leukopenia occurred (one patient). For the analysis, these cases were 
counted as an infection without leukopenia. AZA, azathioprine; BMI, body mass index; 
CD, Crohn’s disease; HBI; Harvey-Bradshaw Index; TPMT, thiopurine S-methyltransferase; 
UC, ulcerative colitis; WBC, white blood cell
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DISCUSSION
In this study, we showed that in patients with IBD without a variant in TPMT, 
baseline WBC count and the choice of MP compared to AZA, were independent 
risk factors for thiopurine-induced leukopenia during the first five months of 
treatment. However, this did not result in a higher risk for infections. Infections 
during thiopurine treatment were more frequently seen in elderly and in patients 
with concomitant use of biologic drugs.
The overall incidence of thiopurine-induced leukopenia is estimated to be 7%.(4) 
Importantly, in 75% of the patients this is not correlated with a genetic variant 
in TPMT. As shown in this study, leukopenia still occurs in 6.5% of the patients 
without a genetic variant in TPMT, often leading to dose reductions or treatment 
discontinuation.(5) Thiopurine-induced leukopenia is at least partially dose 
dependent.(26) In a previous analysis of all patients included in the TOPIC trial, we 
already showed that patients treated with MP were relatively higher dosed than 
patients treated with AZA and that this resulted in amongst others a higher rate of 
leukopenia.(25) This difference annulled in a secondary analysis with adjustment 
for dose and metabolite levels, therefore an interdrug difference between AZA 
and MP seems unlikely. Also, other studies showed a relatively higher dose and 
leukopenia rate in patients on MP compared to AZA.(20, 21, 27) The difference 
Table 5. Uni- and multivariate Cox-proportional hazards regression analysis to explore 
factors associated with infections during thiopurine treatment.
Univariate 
analysis
Multivariate 
analysis
Hazard ratio  
(95% CIs)
P-value
Hazard ratio 
(95%CIs)
P-value
Sex, male 0.67 (0.40-1.15) 0.15
Age, per 10-year 1.84 (1.06-3.21) 0.03 2.07 (1.18-3.63) 0.01
Active smoker 1.58 (0.90-2.76) 0.11
Week 0 WBC count, 109/L 0.95 (0.88-1.02) 0.17
Leukopenia 1.66 (0.75-3.65) 0.21
Concomitant use of biologics 2.03 (1.08-3.83) 0.03 2.15 (1.14-4.07) 0.02
Infections were classified according to the Common Terminology Criteria for Adverse 
Events 4.0 (version 4.0). Only infections grade 2 or higher were included. WBC, white 
blood cell
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might be attributed to the absence of MP tablets with a content of 25 mg, which 
allow a more personalized dosing. Another explanation might be derived from the 
conversion rate of 2.08, which is used to calculate the MP dose from the AZA 
dose. This conversion rate includes assumptions such as a 100% bioavailability. 
(28) The higher rate of dose-dependent side effects might be prevented with a 
slight reduction of the MP starting dose.(25)
In our study, 6-TGN and 6-MMPR metabolite levels were not increased in patients 
with leukopenia. It must be stressed that most patients with leukopenia were 
subjected to dose reductions or treatment discontinuation before week eight. 
Therefore, steady-state week eight 6-TGN levels were available only in a limited 
number of cases, which most likely explains why we found no difference. Besides 
6-TGN levels, also excessively elevated 6-MMPR levels have been associated 
with leukopenia.(21) The increased risk for leukopenia with a lower baseline WBC 
count has also been reported in the setting of ganciclovir- and chemotherapy-
induced leukopenia. (29, 30) In contrast to a previous study, we did not find a 
correlation between concomitant 5-ASA use and myelosuppression. (31) It has 
been suggested that 5-ASA might increase 6-TGN levels by a weak inhibition of the 
TPMT enzyme activity and therefore may increase the risk of myelosuppression. 
(32) Previous studies using data of the TOPIC trial already showed that 6-TGN 
levels were not significantly higher in patients on 5-ASA, which explains why we 
found no increased leukopenia rate in this group. (33, 34) It is known that smoking 
leads to an increase of white blood cell count of 0.5-1.0x109/L as a result of a low-
grade systemic inflammation.(35) Indeed, in our study univariate analysis showed 
that smokers had less often leukopenia, however, this did not reach significance 
in the multivariate analysis.
Pharmacogenetic testing of TPMT is a cost-effective strategy to prevent severe, 
life-threatening, myelosuppression, in those who are TPMT deficient.(36, 37) 
This strategy is strongly recommended by several guidelines.(9, 11, 38, 39) 
TPMT-related and TPMT-independent leukopenia may be considered as two 
separate entities. Most studies reporting on thiopurine-induced leukopenia 
provide no information regarding the TPMT status, which hampers extrapolation 
to daily clinical practice.(40-42) For this reason, we specifically focused on the 
patients without a variant in TPMT. Thiopurine-induced leukopenia in patients 
without genetic variants in TPMT occurred at any moment during the first five 
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months of therapy, with a slight peak in the first two months. Therefore the 
current routine laboratory tests should remain mandatory to identify patients with 
myelosuppression in an early stage.(1) In more than 90% of the cases leukocyte 
levels did not drop below 2.0x109/L. Yet thiopurine dosage was reduced or 
treatment was discontinued in two-thirds of these patients, probably due to fear 
for infectious complications. Overall, most cases of TPMT-independent leukopenia 
are mild and therefore did not require immediate treatment discontinuation or 
dose-reduction. However in the setting of an unknown TPMT-genotype, all cases 
of leukopenia in the first months of thiopurine treatment should be considered as 
potentially TPMT-induced, because otherwise life-threatening myelosuppression 
might occur in the patients whom actually have a genetic variant in TPMT.(1)
Previous studies estimated a cumulative infection rate of 6.5% among patients 
with thiopurine-induced leukopenia.(4) In the present study, we showed that 
infection rates are comparable for patients with and without TPMT-independent 
leukopenia. Both viral and bacterial infections were seen, however in most of the 
cases no specific pathogen was isolated. The risk for bacterial infections increases 
with neutrophil levels below 0.5 x109/L. (43) These levels are often observed in 
patients with a homozygous variant in TPMT when treated with standard thiopurine 
doses due to the very high 6-TGN levels.(1, 44) In our study, neutrophil levels at 
time of leukopenia were available in ~50% of the patients and a neutrophil count 
below 0.5 x109/L was observed in only one patient, which suggests that severe 
neutropenia is not frequently observed in patients without a TPMT variant. This, 
in combination with the fact that in most cases leukopenia was only moderate 
(WBC count ≥ 2.0*109/L), might explain why we did not find a higher infection 
rate in patients with a thiopurine-induced leukopenia. It must be mentioned that 
in 69% of patients with leukopenia the thiopurine dose was reduced or treatment 
was discontinued. It cannot be excluded that this prevented the aggravation of 
the leukopenia and/or the development of infectious complications, which is an 
important limitation of our study. Yet, our findings corroborate studies exploring 
the risk of infections in hepatitis C treatment. In these studies, interferon-induced 
leukopenia was not a risk factor for infectious complications. (22, 23) The lack 
of association between leukopenia and infections might have great implications 
for clinical practice. Some studies showed a relation between mild leukopenia 
(defined as WBC count ≥3.0 and <5.0x109/L) and treatment efficacy.(45, 46) This 
increased treatment efficacy in case of leukopenia was independent from 6-TGN 
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levels.(45) Therefore, if our observations are correct, a more preserved strategy in 
case of moderate leukopenia would not increase infection risk, prevents a patient 
from under-dosing, and possibly increases treatment efficacy. Future studies are 
needed to evaluate whether such a strategy is safe and does increase the infection 
rate or lead to more patients with severe leukopenia.
Age and concomitant use of biologics were the only factors associated with the 
occurrence of infections. Increasing age is a known risk factor for infections, 
which is thought to result from an impaired immune response in the elderly. 
(47, 48) This has also been reported in patients with IBD.(49, 50) In contrast to 
many clinical trials, there was no upper age limit with inclusion in the TOPIC trial. 
As a consequence, 105 (15.1%) of the patients included in current study were 
60 years or older, of whom 24 patients were 70 years or older. This makes it a 
representative sample for the real life setting in the era of an aging IBD population.
(51) The higher risk for infections with concomitant use of biologic drugs is not 
unexpected, since use of biologics is an independent risk factor for (opportunistic) 
infections.(49, 52) This observation is not limited to IBD, but is also observed in 
other immune-mediated diseases.(53, 54) In contrast to previous studies we 
found no relation with concomitant steroid use (49). A likely explanation is that 
steroid use was not protocolised and as a consequence the group of patients on 
oral steroids was very heterozygous and included patients on low maintenance 
dose, short term use during thiopurine initiation, but also patients on a high dose 
for a longer period. Furthermore, patients currently taking no steroids still have 
an increased infection risk, when treated with steroids in the past two years.(55) 
We found no association between diabetes mellitus or smoking and infection risk, 
probably because of the relatively small study size and short follow-up period.
(56, 57)
This study comes with some limitations. First, current analyses were not included 
in the original study protocol. Second, patients in the TOPIC trial were only tested 
for the three common variants in TPMT (*2, *3A en *3C), which cover more than 
90% of the prevalence of genetic variants in TPMT in Caucasians. Therefore, it 
is possible that we missed some patients with other TPMT variants. (58) This 
was circumvented by sequencing the coding region of TPMT in all patients 
with a low TPMT activity or those who developed leukopenia; which did not 
reveal other variants (unpublished data). Furthermore, we assumed that when 
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the treating physician started anti-infectious therapy there was a true suspicion 
of an infection. This comes with some restrictions, since exacerbations of IBD 
or flu-like side effects (which might include elevation of C-reactive protein) can 
mimic (gastro-intestinal) infections leading to the prescription of antibiotics. Finally, 
(viral) infections may induce leukopenia.(19) However, if this is the case it would 
have resulted in an overestimation of ‘leukopenia-associated infections’ and 
further bolster our findings that (moderate) leukopenia itself is not a risk factor 
for infectious complications.
In conclusion, in the present study we showed that the choice for MP compared 
to AZA (as a result of a relatively higher dose) and baseline WBC count are risk 
factors for the development of thiopurine-induced leukopenia in patients without 
a genetic variant in TPMT, however this was not associated with an increased 
risk for infections. Multivariate analysis showed that older patients and patients 
with concomitant use of biologics had a higher risk for infections during thiopurine 
treatment and should therefore treated with more caution. Our data suggest that 
moderate TPMT-independent leukopenia during thiopurine treatment might be 
accepted in the light of close monitoring of WBC count and metabolite levels.
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Chapter 8
BACKGROUND
Thiopurines have remained a cornerstone in the treatment of inflammatory 
bowel diseases (IBD) in the past decades. Three thiopurines are registered for 
clinical use: azathioprine (AZA) (Imuran®), mercaptopurine (MP) (Puri-Nethol®) 
and 6-thioguanine (Lanvis®). AZA is a nitro-imidazol analogue of MP. Both 
AZA and MP need extensive metabolism to yield the pharmacologically active 
compounds (Figure 1). The exact mechanisms by which thiopurines exert their 
immunosuppressive effects are still not completely understood. 6-Thioguanine 
differs from AZA and MP in metabolism, yet the mechanism of action is considered 
similar. This thesis focuses on the use of AZA and MP in the treatment of IBD.
AZA and MP were developed in the middle of the previous century for the 
treatment of leukaemia. Around 1960, the first clinical trials with thiopurines were 
conducted in patients with ulcerative colitis (UC) and Crohn’s disease (CD).(1, 2) 
Currently, thiopurines are registered for the treatment of several malignancies 
and immune mediated diseases, such as IBD, rheumatoid arthritis and psoriasis. 
Furthermore, thiopurines are applied in the prevention of organ rejection after 
organ transplantation.
AZA 6-MP
6-MMP
6-TU
6-TXMP6-TIMP
6-TITP
6-MMPR
Nitro-
imidazole
6-TGN
GMPSIMPDH
GSTA1 
GSTA2 
GSTM1
XO
TPMT TPMT
HGPRT 6-TG
6-MTG
6-TU
HGPRT
TPMT
XO
Figure 1. Overview of AZA and MP metabolism. Involved enzymes are indicated in grey 
boxes. AZA, azathioprine; 6-MP, mercaptopurine; GSTA, Glutathione transferase alpha; 
GSTM, Glutathione transferase Mu; 6-MMP, 6‐methylmercaptopurine; 6-MMPR, 6‐meth-
ylmercaptopurine ribonucleotides; TPMT, thiopurine S‐methyltransferase; XO, xanthine 
oxidase; 6-TUA, 6‐thiouric acid; HGPRT, hypoxanthine‐guanine phosphoribosyl transferase; 
6-TIMP, 6‐thioinosine monophosphate; 6-TITP, 6‐thioinosine triphosphate; IMPDH, inosine 
monophosphate dehydrogenase; 6-TXMP, 6‐thioxanthosine monophosphate; GMPS, gua-
nosine monophosphate synthetase; 6-TGN, 6‐thioguaninenucleotides; 6-TG, 6-thioguanine; 
6-MTG, 6-methyl thioguanine
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General discussion
Parts of this thesis expand on data obtained from the “Thiopurine response 
Optimization by Pharmacogenetic testing in IBD Clinics” (TOPIC) trial.(3) In this 
large nationwide trial, 796 thiopurine naive patients with IBD were randomized 
to start thiopurine treatment with a standard thiopurine dose versus a genotype 
based dose to study whether the latter strategy resulted in a reduced rate of 
haematological adverse events.
In this chapter, the findings of this thesis are discussed in three sections. First, we 
focus on the choice for AZA or MP as first choice thiopurine in the treatment of 
IBD. The second part discusses the role of glutathione transferases (GST) in IBD, 
and in the third part, we discuss factors that may improve the overall outcome of 
thiopurine treatment.
PART I
The choice between AZA and MP
In general, AZA and MP are considered equally effective, leaving the choice of 
which thiopurine to use at the discretion of the treating physician. This has resulted 
in large global differences in preference for either AZA or MP. These differences 
mainly originate from historical preferences, but are also driven by differences in 
the registration process by local authorities. Current guidelines have no preference 
and therefore use terms such as ‘AZA or MP’ and ‘AZA/MP’. (4, 5)
AZA is a MP molecule with a nitro-imidazolegroup attached to it (Figure 2). 
The physiological difference between AZA and MP consists of the nitro-
imidazolegroup. Around 88% of AZA is converted to MP with the release of the 
nitro-imidazolegroup, while 12% of AZA is not converted to MP, but to methyl-
4-nitro-5-thioimidazole.(6) The remaining metabolic breakdown is similar as with 
the direct administration of MP (Figure 1), therefore potential differences must 
originate from this additional metabolic step. There are no randomized trials 
comparing AZA and MP, and given the cost of such investigations it is unlikely 
that these will ever be performed. Retrospective data on efficacy and safety of 
AZA versus MP are scarce due to the local preferences for one of both agents.
8
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Chapter 8
(7-10) Therefore, in daily clinical use the choice to prescribe either AZA or MP is 
mainly driven by personal preferences rather than by scientific evidence. Despite 
presumed interchangeability, several studies have reported differences in safety 
and efficacy.(11-13) This notion urged us to perform the studies that are described 
below in more detail.
In Chapter 2, we compared AZA and MP for safety and efficacy based on data 
from the TOPIC trial.(3) This study is unique because of the large number of 
thiopurine-naïve patients with IBD assigned to AZA and MP. In this trial, physicians 
were free in the choice for either AZA or MP. There were no differences in patient 
characteristics between AZA and MP users, which makes selection bias unlikely. 
Our most remarkable findings were that patients treated with MP were relatively 
higher dosed and suffered from a higher rate of dose-dependent side effects, 
such as leukopenia and signs of hepatotoxicity. In a secondary analysis in which 
we adjusted for thiopurine dose and metabolite levels these higher rates of side 
effects annulled. Despite the higher rate of side effects with MP, discontinuation 
rates were comparable, which might be explained by a higher frequency of dose 
reductions in patients on MP.
Several explanations can be proposed why patients on MP were relatively higher 
dosed than AZA. The most obvious reason is that in Europe MP is only available 
in 50 mg tablets, while AZA is available in 25 mg, 50 mg and 100 mg tablets. 
Taking into account that treatment with a dose below the recommended dose 
SH
N
N
N
N
H
S
N
N
N
N
H
O2N
CH3
6-mercaptopurineazathioprine
N
N
Figure 2. Molecule structures of azathioprine and mercaptopurine
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General discussion
is undesirable, a patient with a bodyweight of 75 kg would receive 100 mg MP 
(1.33 mg/kg; recommend dose range is 1.0-1.5 mg/kg) or 150 mg AZA (2.0 mg/
kg; recommend dose range is 2.0-2.5 mg/kg). The absence of tablets with a lower 
dose and the fact that treatment with a dose below the recommended dose is 
undesirable makes that patients with MP are relatively higher dosed than patients 
treated with AZA. Furthermore, given that the absolute dose is lower in MP, 
increasing the dose with 50 mg in terms of percentage leads to larger difference 
with MP compared to AZA. Obviously, introduction of 25 mg tablets MP would 
allow more personalized tailored dosing. Current literature suggests a conversion 
rate of 2.08 to calculate the MP dose from an AZA dose. This rate is based on 
the differences in molecular weight and the 88% of AZA which is converted to 
MP, but includes assumptions such as a 100% biological availability for AZA.(14, 
15) When we apply this conversion rate to the recommended AZA dose of 2.0-
2.5 mg/kg, patients with MP should be treated with 0.92-1.20 mg/kg, instead of 
1.0-1.5 mg/kg.
In Chapter 3, another explanation for the difference in metabolite levels between 
patients treated with AZA and patients on MP is discussed. We showed that 
a homozygous gene deletion in Glutathione Transferase Mu1 (GSTM1), an 
enzyme involved in the conversion of AZA to MP, results in significantly lower 
6-MMPR levels. A homozygous GSTM1 gene deletion, GSTM1-null genotype, is 
found in approximately 50% of the population and therefore this genetic variant 
considerably contributes to individual variation in AZA, but not MP metabolism.
(16, 17) Of note, we found that 6-TGN levels were not different between the 
GSTM1 genotypes. An explanation for this finding comes from older studies, 
which suggested that inosine monophosphate dehydrogenase (IMPDH) is a rate-
limiting enzyme in thiopurine metabolism.(18, 19) IMPDH is positioned more 
downwards in thiopurine metabolism and has no role in the conversion of MP to 
6-MMPR (Figure 1). This might explain why 6-MMPR levels are often correlated 
with the dose, while the correlation between the drug dose and 6-TGN levels is 
often not that explicit.(20, 21)
Increased 6-MMPR levels have been associated with the development of 
hepatotoxicity and leukopenia, while 6-TGN levels correlate with efficacy.(21-23) 
In a small study, in which only patients on AZA were included, it was already 
observed that patients with a GSTM1-null genotype had less side effects.(24) In 
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our study, hepatotoxicity rates were similar in patients on AZA with the GSTM1-
null genotype. The absence of a difference in hepatotoxicity in patients treated 
with AZA might be explained by the fact that 6-MMPR levels did not reach a level 
of 5700 pmol x 108/RBCs.(22)
Our results can be interpreted to the clinical practice in two ways. First, our 
findings suggest that MP should be preferred over AZA, since MP is not a subject 
to variation caused by GSTM1 leading to less inter-individual variation in metabolite 
levels. On the other hand, half of patients treated with AZA might have a lower 
risk for side effects due to lower 6-MMPR levels, while efficacy by 6-TGN is not 
impaired. This would suggest a preference for AZA. It is however too preliminary 
to draw such conclusions based on this single study. Before our findings can be 
incorporated in clinical guidelines, new studies are needed to provide additional 
evidence for the effect of the GSTM1-null genotype on side effects and that the 
GSTM1-null genotype affects 6-MMPR metabolite levels but not 6-TGN levels in 
AZA users.
In Chapter 5, we studied the in vitro hepatotoxicity of 5-ASA and allopurinol co-
administration with thiopurines and showed that a non-toxic dose of allopurinol 
resulted in a two- to threefold increased cytotoxicity. The purpose of this study 
was not to compare AZA and MP, though some variation in cytotoxicity between 
both agents was observed in Huh7 and HepG2 cells. It is hard to translate 
these findings to the in vivo situation, because experiments were conducted in 
immortalized human hepatoma cells. On the other hand, in HepaRG cells, which 
have a higher resemblance with human hepatoma cells, differences were less 
explicit.
In summary, patients with MP are relatively higher dosed and therefore 
experienced more dose-dependent side effects compared to patients on AZA. 
Subsequently, these patients were more often subjected to dose reductions than 
patients on AZA. Also, a common gene deletion in GSTMu had a large influence 
on AZA, but not MP, metabolism. Based on our findings, AZA and MP cannot be 
considered as fully interchangeable and additional factors should be taken into 
account in the choice for AZA or MP as first choice thiopurine in the treatment 
of IBD. First, the cost of MP is €2,54 per 50mg tablet, while the prize of a 50 mg 
tablet AZA is €0,12 in The Netherlands (https://www.medicijnkosten.nl, accessed 
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at 23-07-2017). Second, studies have showed a successful trial of MP in patients 
who discontinued AZA due to side effects.(25-27) In contrast, there are no studies 
reporting about successful AZA administration after failing on MP, most likely 
because this strategy has never been investigated. Taking these additional factors 
into account, we would suggest to start with AZA; in case this drug has to be 
discontinued due to side effects, a trial with MP can be considered. However, in 
order to circumvent the pharmacogenetic variation in GSTM1 one can consider 
starting with MP. When MP is preferred as first choice thiopurine, we recommend 
reducing the start dose to 0.92 - 1.20 mg/kg. Increasing the dose above 1.20 mg/
kg should only be performed under guidance of metabolite monitoring when the 
clinical effect is insufficient. Future registry studies focusing on the clinical use of 
AZA and MP are needed with data about drug dose, side effects, clinical effects 
and metabolite levels, to explore if a lower start dose of MP indeed results in a 
reduction of dose-dependent side effects, while efficacy remains similar.
PART II
ROLE OF GLUTATHIONE TRANSFERASE IN 
INFLAMMATORY BOWEL DISEASE
In Chapter 3 and Chapter 4, we described the influence of genetic variants in GST 
on IBD disease susceptibility and metabolism of thiopurines. GSTs comprise an 
enzyme family consisting of eight different classes, which catalyze the conjugation 
of glutathione with endogenous or exogenous electrophile compounds. The 
different classes contain several subclasses of which each possesses exceptional 
substrate affinity.(28, 29) The main biological effects are undoing damage caused 
by reactive oxygen species and processing of compounds that otherwise could 
damage the DNA.(16) In addition, GSTs have an important role in the metabolism 
of numerous drugs. In phase I of drug metabolism, a reactive or polar group is 
attached to xenobiotics by -amongst others- cytochrome P450. Subsequently, in 
the phase II reaction, GSTs catalyze the conjugation of glutathione to these polar 
compounds. In general, genetic variants in GST have limited consequences on 
drug metabolism due to large overlapping substrate affinities between the GST 
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isoforms.(29) However, there are some exceptions, especially relevant in the field 
of anti-cancer drugs.(30)
The most extensively studied genetic variants of GST are the null genotypes of 
GSTM1 and GST Theta subclass 1 (GSTT1). Homozygous presence of a gene 
deletion (null genotype) leads to an absent enzyme and is reported in around 
20% of the population for GSTT1 and a homozygous GSTM1 gene deletion is 
found in approximately 50%.(16) Genetic variants in GST Alpha (GSTA) may 
affect substrate specificity or enzyme expression, though effects are not that 
explicit as with GSTM1 and GSTT1, in which there is no enzyme activity at all. An 
individual with the GSTM1-null or GSTT1-null genotype is expected to have an 
impaired ability of the detoxification and eradication of carcinogenic compounds.
(28, 31) Meta-analyses showed associations between GSTM1-null genotype and 
several cancer types, probably due an increased exposure to oxidative stress.
(32-37) In addition, case-control studies showed a relation between the GSTT1-
null or GSTM1-null genotype and immune related diseases.(38, 39) Also for IBD, 
several case-control studies have been conducted exploring the relation between 
genetic variants in GST and IBD susceptibility.(40, 41) The pathophysiology is not 
completely understood, but might originate from an increased and prolonged 
exposure to oxidative stress in the gut.(42) Both GSTT1 and GSTM1 are expressed 
at substantial level in human colon cells.(43) Given the inconsistent results of 
previous studies, we performed a large case-control study and subsequently 
incorporated our results with existing literature in a meta-analysis. In Chapter 4, 
we showed that with pooling data from literature supplemented with our data, 
individuals with a GSTT1-null genotype had an increased risk for UC compared to 
patients carrying one or two copies of the GSTT1 gene.
Although MP and its pro-drug AZA were developed in the middle of the previous 
century, only recent studies surfaced that the release of MP from AZA is mediated 
by the action of glutathione transferases.(17) Before this discovery, the cleavage 
of the nitro-imidazolegroup was considered to be primarily non-enzymatic. 
GSTM1, GSTA1 and GSTA2 contribute for more than 90% in the conversion of 
AZA to MP.(17) In two studies, which only included patients treated with AZA, 
the relevance of the GSTM1 null genotype on AZA metabolism was already 
illustrated.(24, 44) The absence of an analysis with genetic variants in GSTA1 and 
GSTA2 in these studies, and the lack of a control group (e.g. patients on MP, in 
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which GSTs are considered to have no role in metabolism), and the relative small 
sample sizes inspired us to conduct the study presented in Chapter 3. As already 
outlined in part I of this chapter, we showed that patients on AZA with a GSTM1-
null genotype had twofold lower steady state 6-MMPR levels. The mechanism 
probably results from a reduced proportion of AZA converted to MP leading to 
a lower quantity of MP available for further metabolism.(45) It is suggested that 
GSTA1 and GSTA2 have the largest contribution in the conversion of AZA to 
MP, however, we found no differences in metabolite levels caused by genetic 
variants in the corresponding genes.(17) GSTA1 and GSTA2 share a high degree 
of similarity. The liaison between both subclasses is illustrated by a compensatory 
increase in GSTA2 expression in case of a reduced GSTA1 expression.(46) These 
compensatory effects in combination with the presence of haplotypes, which 
ensure a certain level of GSTA1/GSTA2 activity, probably annulled individual effects 
of genetic variants in GSTA1 and GSTA2 on AZA metabolism.(47)
In conclusion, many studies have been conducted to explore the effects of genetic 
variants in GST on disease susceptibility or drug metabolism. In Chapter 3 and 
Chapter 4, we showed that a homozygous gene deletion in GSTT1 increases the 
susceptibility for UC and that a homozygous gene deletion in GSTM1 influences 
the metabolism of AZA, but not MP.
PART III
Optimizing treatment with thiopurines in IBD
Up to 40% of patients with IBD discontinue thiopurine treatment in the first 
year after treatment initiation.(48) In Chapter 6 and Chapter 7, we explored two 
factors which may be relevant in order to improve long term thiopurine use.
In Chapter 6, we focused on patients beliefs about medicine and tried to elucidate 
to which extent positive or negative beliefs are associated with premature 
treatment discontinuation and treatment adherence. Decreased treatment 
adherence results in an increased disease activity and lower quality of life.(49) In 
addition, treatment may be discontinued by the treating physician because of a 
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perceived ineffectiveness. Alternative treatment options in IBD are limited and 
often more expensive. Therefore, decreased patient adherence and premature 
treatment discontinuation may increase the burden on health-care resources.
We showed that patients with a lower perceived need for thiopurine treatment 
or high concerns towards thiopurines were more likely to discontinue treatment. 
Moreover, when a patient had both high concerns and a low necessity towards 
treatment the change for premature treatment discontinuation was even higher. 
Our findings suggest that physicians should emphasize the benefits of treatment 
and explore the patients motivation in order to increase treatment adherence. 
Detailed instructions at the start of a treatment are very important in improving 
an individual’s willingness to take these medicines and to reduce anxiety for 
side effects. In particular, this seems important with the treatment with AZA 
or MP, since within the spectrum of drugs registered for the treatment of IBD, 
patients consider thiopurines as drugs with the highest risk.(50) Especially fear 
for side effects and long-term induced drug co-morbidities (such as skin cancer 
and the risk for lymphoma) lead to significant lower adherence rates in patients 
treated with thiopurines.(51) It often takes much effort to persuade a patient for 
higher needs or lower concerns.(52-54) Trials have shown that patient education 
programmes with phone calls by the pharmacist improved adherence rates. Also 
in patients with IBD it was shown that education improved disease knowledge 
and that this resulted in higher satisfaction rates with respect to the treatment.
(54) Nurse practitioners or nurses specialized in IBD care may play an important 
role. Studies showed that physicians often lack skills or time to accentuate the 
necessity of treatment or alleviating patients concerns.(52, 55) Specialized IBD 
nurses might close this gap and provide the patient with adequate, well balanced, 
information. Especially for thiopurine treatment this is relevant since numerous, 
potentially severe, side effects may occur, while other side effects are very 
uncommon, and in the absence of proper guidance this may lead to premature 
treatment discontinuation.
In Chapter 7, we focused on thiopurine-induced leukopenia. Thiopurine-induced 
leukopenia occurs in approximately 7% of patients and often leads to dose 
reductions and treatment discontinuation.(56, 57) The pathogenesis of thiopurine-
induced leukopenia can be divided in thiopurine S-methyltransferase (TPMT) 
related or non-TPMT related. TPMT-mediated leukopenia is caused by genetic 
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variants in the TPMT gene, which leads to a reduced TPMT enzyme activity and 
subsequently to a shift in thiopurine metabolism with a preferred synthesis of 
6-TGN metabolites. Genetic variants in TPMT explain ± 25% of thiopurine-induced 
leukopenia, while the remaining 75% originates from a wide variety of known and 
unknown causes.(3, 58-60) The most severe cases of TPMT-mediated leukopenia 
are these caused by a homozygous variant in TPMT, leading to a negligible TPMT 
activity and without interference this results in a life-threatening myelosuppression 
due to excessively high 6-TGN levels.(61) Homozygous presence of genetic 
variants in TPMT occurs in 0.1 - 0.3% of the population.(62)
Given the potential life-threatening complications of TPMT-mediated leukopenia, 
much effort is put in its management. The most promising strategy to prevent 
TPMT-mediated leukopenia with thiopurine use is by genotyping patients for 
variants in TPMT prior to thiopurine initiation.(63) The benefit of TPMT testing is 
based on the identification of the small proportion of patients (0.1 - 0.3%) with 
a homozygous variant in the TPMT gene, and to a lesser extent those with a 
heterozygous variant in TPMT, who are at great risk for severe, life-threatening, 
myelotoxicity.(64) TPMT genotyping in an effort to avoid these potential serious 
events is cost-effective and results in a decreased rate of TPMT-related leukopenia.
(3, 65, 66) Current routine control of blood count is insufficient in the identification 
of these patients for several reasons. First, because patients with a genetic 
variant in TPMT may develop symptomatic leukopenia between routine blood 
count checks conducted within an interval of one week.(57) Second, despite 
immediately discontinuation of thiopurines, patients often continue to develop a 
severe pancytopenia because of the already extreme high 6-TGN levels which 
take several weeks to disappear.(57) At last, in the absence of prior to treatment 
genotyping all cases of leukopenia should be considered as TPMT-induced and 
therefore potentially life-threatening. Therefore, all patients with leukopenia during 
the first months should be handled very carefully. This includes dose reduction or 
(temporary) treatment discontinuation. Since the majority of the cases is not TPMT 
related and theoretically less dangerous, this will result in unnecessary treatment 
interference in the majority of cases.
TPMT-testing prevents (severe) cases of myelosuppression, but does not prevent 
thiopurine-induced leukopenia in general; therefore, routine white blood cell 
(WBC) monitoring remains mandatory. To date, studies exploring thiopurine-
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induced leukopenia focused on patients with a variant in TPMT, probably because 
these include the most severe and life-threatening cases. However, 90% of the 
population has no genetic variant in TPMT and overall 75% of thiopurine-induced 
leukopenia occurs in those patients without a genetic variant in TPMT. The overall 
leukopenia rate in patients without a genetic variant in TPMT is still around 6%.(3, 
67)
In Chapter 7, we explored risk factors for the occurrence of thiopurine-induced 
leukopenia in patients without a genetic variant in the TPMT gene. We showed 
that patients treated with MP have an increased risk for the development of 
thiopurine-induced leukopenia compared to patients on AZA. This probably results 
from a relative higher dosage in patients treated with MP (see Part I of this 
discussion). Furthermore, we showed that patients with a lower WBC rate at the 
start of treatment were also at risk for the development of thiopurine-induced 
leukopenia.
Patients with thiopurine-induced leukopenia are often subjected to dose reductions 
or treatment discontinuation out of fear of infectious complications.(57) This may 
result in a reduced treatment efficacy. In Chapter 7, we also showed that patients 
with a non-TPMT mediated thiopurine-induced leukopenia have no increased 
infection risk compared to patients without a leukopenia. This finding is in line 
with recent studies in hepatitis C treatment which revealed that patients with an 
interferon-induced neutropenia were not at increased risk for infections.(68) In the 
TOPIC trial, WBC was routinely assessed without cell differentiation. Studies have 
shown that neutrophil count is the most relevant factor in determining infection 
risk, with an increased infection risk when neutrophils drop beneath 1,000/µl 
and this risk further increases when neutrophils fall below <500/µl.(69) These 
levels are rarely met by patients without a genetic variant in TPMT. Thiopurine-
induced leukopenia affects all types of WBC.(70) Considering that 50-80% of 
WBCs are neutrophils, it seems safe to maintain a threshold of 2.0 x109/L for WBC 
before thiopurine dose should be reduced. In that case neutrophils will normally 
be >1,000/µl and therefore the patient is not at an increased risk for infections. 
The benefit of this strategy is that a lower number of patients is subjected to 
dose reductions or treatment discontinuation. In the TOPIC-trial, physicians were 
instructed to discontinue treatment or apply a dose reduction in case of leukopenia. 
Indeed, 66% of the patients with leukopenia were subjected to a dose reduction 
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or treatment was discontinued. However, in 33% of the patients with leukopenia 
this resolved without thiopurine dose adjustment or treatment interruption. For 
this reason, more detailed studies with close monitoring of patients with mild 
or moderate leukopenia are necessary to optimize management of thiopurine-
induced leukopenia in patients without a genetic variant in TPMT.
Figure 3 shows a proposed strategy for the management of non-TPMT mediated 
thiopurine-induced leukopenia. In brief, if a patient develops leukopenia in the 
absence of genetic variants in TPMT assessment of 6-TGN and 6-MMPR 
metabolite levels is crucial. Extreme 6-TGN levels may suggest a new or less 
common genetic variant in TPMT or concomitant use of allopurinol without 
adjustment of thiopurine dose.
Leukopenia: WBC <2.0 x 109/L
Leukopenia: WBC >2.0 x 109/L
- Temporarily withdrawal of thiopurine
- Check for concomittant allopurinol use 
- 6-TGN and 6-MMPR testing, if 6-TGN seriously 
elevated exclude a rare variant in TPMT
- Repeat WBC with differentiation to exclude 
severe pancytopenia
6-TGN levels >700 pmol/8x108 RBCs:
- check for concommittant allopurinol use
- exclude other variants in TPMT
- discontinue thiopurine treatment
- repeat WBC differentiation to exclude 
severe myelosuppression
6-TGN levels between 500 and 700 pmol/
8x108 RBCs:
- Thiopurine dose reduction in 
combination with repetitive check of 
WBC level including the differentiation
6-TGN / 6-MMPR levels normal range: 
- no dose reduction or treatment 
discontinuation
- weekly WBC control with differentiation
6-TGN and 6-MMPR 
metabolite testing
Figure 3. Proposed management of patients with inflammatory bowel diseases treated 
with azathioprine or mercaptopurine who present with a thiopurine-induced leukopenia in 
the absence of a common variant in TPMT, with no other explanation of the leukopenia. 
6-MMPR, 6‐methylmercaptopurine ribonucleotides; 6-TGN, 6‐thioguaninenucleotides; 
CD, Crohn’s disease; TPMT, thiopurine S‐methyltransferase; UC, ulcerative colitis; WBC, 
white blood cell count
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The possibility to incorporate these results in daily practice depends on the 
implementation of TPMT testing prior to start of thiopurine treatment. Currently, 
most guidelines for the use of thiopurines recommend genotyping prior to the 
start of treatment.(4, 71-73) Despite these recommendations, clinical practice 
adherence rates range from 30% to 90%.(74, 75) When TPMT testing is not 
applied, all patients with thiopurine-induced leukopenia should be considered 
as possibly bearing a hetero- or homozygous variant in TPMT. This potentially 
results in high rates of treatment discontinuation, while our results suggest that 
most of these patients (the 75% of leukopenia cases without a genetic variant in 
TPMT ) probably have no increased infection risk. Our results suggest that with 
knowledge of the TPMT status most patients may safely continue their thiopurine 
in the presence of a moderate leukopenia, with the knowledge that leukopenia 
often restores spontaneously. For this reason, TPMT genotyping prior to start of 
thiopurines should be obliged for all patients in whom AZA or MP are prescribed.
Future perspectives
Research results in the formation of new research questions. Topics for further 
research that follow from this thesis include:
 - Based on our work and the literature referred to in this thesis, no explicit 
preference can be provided for either AZA or MP as first choice thiopurine in 
the treatment of IBD. For the reasons outlined in this chapter, we suggest to 
start with AZA; and in case of discontinuation due to side effects a trial with 
MP in a starting dose between 0.90 and 1.20 mg/kg may be considered. It 
would be very interesting for future studies to explore if the lower starting 
dose of MP results in similar 6-MMPR, 6-TGN metabolite levels and equal 
rates of side effects compared to patients on AZA.
 - We showed that moderate leukopenia probably not results in an increased 
risk for the occurrence of infectious complications. This suggests that patients 
with mild or moderate leukopenia (patients with a leukocyte count ≥ 2.0x109/L) 
during thiopurine therapy (without a genetic variant in TPMT ) should not be 
subjected to dose reductions because this might reduce treatment efficacy. 
We proposed a treatment strategy for the management of leukopenia in 
patients without a genetic variant in TPMT. Future studies are needed to test 
this proposed strategy, this will provide important knowledge on the follow 
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up of patients with leukopenia not being subjected to dose reductions or 
treatment discontinuation.
 - We provided evidence for involvement of GSTs in pathophysiology of IBD 
and metabolism of AZA. The clinical relevance of the GSTM1-null genotype 
in AZA metabolism should be further clarified before definite conclusion can 
be drawn. Furthermore, case-control studies exploring effects of GSTM1- and 
GSTT1-null genotype IBD susceptibility have led to varying results. To provide 
definite evidence, international IBD-databases can be used to explore effects 
of the GSTM1- and GSTT1-null genotype on UC and CD disease susceptibility.
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ENGLISH SUMMARY
Thiopurines have an important role in the treatment of patients with inflammatory 
bowel disease (IBD). Of the three registered thiopurines; azathioprine (AZA) 
and mercaptopurine (MP) are considered as the conventional thiopurines. 
Unfortunately, thiopurines are discontinued in up to 40% of patients in the first 
year of treatment. Side effects and lack of effectiveness are important predictors 
for treatment discontinuation. Alternative treatment options in IBD are limited and 
often more expensive. For this reason, it is important to optimize the treatment 
with conventional thiopurines.  
In Chapter 1, the introduction, we have provided background information to 
provide the reader with knowledge about the history of thiopurine development, 
thiopurine metabolism, its mechanism of action and its use in clinical practice, 
including details about the most important side effects. Based on current data, 
we formulated research questions, which are further outlined in this thesis.
Chapter 2 describes the results of a post-hoc analysis with data derived 
from a large multicentre trial conducted in The Netherlands (the TOPIC trial). 
We compared AZA and MP for safety and efficacy. AZA is a pro-drug of MP, 
and after the conversion of AZA to MP its metabolism is identical. Therefore, 
interchangeability of both agents is assumed in the absence of trials in which both 
drugs are compared head to head.
We compared clinical data of 494 patients with IBD on AZA with data of 273 patients 
treated with MP and showed that patients on MP had a higher rate of dose-dependent 
side effects. The higher rates of leukopenia and hepatotoxicity did not result in more 
treatment discontinuations. However, patients on MP were more often subjected to 
dose reductions. The most likely explanation for our findings is that patients on MP 
were relatively higher dosed than patients on AZA. Current guidelines recommend to 
start MP at a dose of 1.0-1.5 mg/kg bodyweight and AZA 2.0-2.5 mg/kg bodyweight. 
A conversion rate of 2.08 is used to calculate the AZA dose from the MP dose. In 
the TOPIC trial patients treated with MP had a median dose of 1.21 mg/kg at start 
of treatment and patients treated with AZA 1.05 mg/kg (after conversion by 2.08). 
This study is unique, because of the large number of patients taking either AZA or 
MP. No differences were found in baseline patient characteristics, which excludes 
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selection bias. Based on our findings, we would recommend to reduce the start 
dose of MP to a maximum of 1.20 mg/kg, instead of 1.50 mg/kg. Furthermore, 
production of 25 mg tablets MP would allow a more personalized dose.
In Chapter 3, we explored differences in metabolism between AZA and MP. AZA 
is a MP molecule with a nitro-imidazolegroup attached to it. After absorption, 
MP is released from AZA, by cleavage of the nitro-imidazolegroup. This reaction 
is mediated by glutathione transferases (GST) classes mu 1 (GSTM1), alpha 1 
(GSTA1) and alpha 2 (GSTA2). We explored effects of genetic variations in GSTM1, 
GSTA1 and GSTA2 on thiopurine metabolite levels. We compared 6-methyl 
mercaptopurine ribonucleotides (6-MMPR) and 6-thioguanine nucleotides (6-
TGN) levels in patients on AZA with and without a genetic variant in the above 
mentioned enzymes. The same analyses were performed in patients on MP. 
Because GSTs are only involved in the conversion of AZA to MP and not in further 
downstream metabolism, genetic variations in GSTM1, GSTA1 and GSTA2 should 
not be relevant in MP metabolism.
We showed that patients on AZA, with a homozygous gene deletion in GSTM1, 
had twofold lower 6-MMPR levels compared to patients with one of two copies 
of the GSTM1 gene. In patients treated with MP no differences were observed. 
Carriers of the GSTM1 gene metabolize AZA more effectively, which results in 
more MP being available for further metabolism. Genetic variants in GSTA1 and 
GSTA2 did not have an effect on metabolite levels. A possible explanation lies in 
the presence of haplotypes with GSTA1 and GSTA2. This means that there is a 
preference for specific genetic variants to occur simultaneously. In general the 
presence of haplotypes annules large effects of individual genetic variants. 
Apart from its influence on drug metabolism, genetic variants in GST also may 
affect disease susceptibility. GSTs comprise a large family of enzymes involved 
in the conjugation and detoxification of toxic or carcinogenic compounds, such 
as reactive oxygen species. In Chapter 4, we report the findings of a large case-
control study, in which we explored the effects of a homozygous gene deletion 
in GSTM1 and GST Theta1 (GSTT1) on the susceptibility for Crohn’s disease (CD) 
and ulcerative colitis (UC). Subsequently, we performed a meta-analysis of the 
available literature and found evidence for an increased susceptibility for UC with 
a homozygous gene deletion in GSTT1.
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In Chapter 5, we explored the effects of 5-aminosalicylic acid (5-ASA) and 
allopurinol on thiopurine-induced cytotoxicity of hepatoma cells in an in vitro setting. 
Both drugs interfere in thiopurine metabolism by influencing enzyme activity. 
Concomitant administration of a non-toxic dose of allopurinol resulted in an increase 
of cytotoxicity, while 5-ASA barely affected cytotoxicity. The higher toxicity rate with 
concomitant allopurinol administration is probably caused by an increased 6-TGN 
metabolite formation resulting in an irreversible damage to the DNA.
In Chapter 6, we investigated the effect of positive and negative perceptions of 
patients with IBD on thiopurine use. In the TOPIC trial, patients were asked to 
complete the Beliefs about Medicine Questionnaire four weeks after treatment 
initiation. This questionnaire enables a quantification of personal needs and 
concerns regarding a treatment. We showed that patients with lower perceived 
needs or higher concerns towards IBD treatment were at increased risk for 
premature treatment discontinuation. Increased attention to an individual’s 
motivation or fears prior to treatment initiation might result in a higher rate of 
patients continuing thiopurine treatment. 
In Chapter 7, we explored risk factors for leukopenia during thiopurine treatment. 
Severe, life-threatening leukopenia is frequently caused by genetic variants 
in thiopurine S-methyltransferase (TPMT). For this reason, most guidelines 
recommend to screen for genetic variants in TPMT prior to the initiation of 
thiopurine treatment. However, genetic variants in TPMT only explain 25% of 
leukopenia cases. With data from the TOPIC trial, we explored risk factors for 
leukopenia in patients without a variant in TPMT, and found that treatment with MP 
compared to AZA (probably due to a relatively higher dose), and a lower leukocyte 
level at baseline increased the risk for leukopenia during thiopurine treatment. 
In the second part of this study, we investigated whether these patients had an 
increased risk for infectious complications. We analyzed data of patients with an 
infection and patients without an infection during thiopurine treatment. Risk factors 
for infectious complications were older age and concomitant use of biologics, 
while leukopenia appeared not to be associated with infections. 
In conclusion, this thesis includes several studies reporting on the use of  the 
conventional thiopurines; AZA and MP. With our findings, we aim to reduce the 
high rate of patients whom discontinue thiopurine treatment in an early stage.
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NEDERLANDSE SAMENVATTING
De ziekte van Crohn en colitis ulcerosa worden vaak samen weergegeven met 
de term ‘inflammatory bowel diseases’ (IBD). Het zijn beiden ziektes die zich 
kenmerken door periodes van ontstekingen in (delen) van het maag darm kanaal 
en worden veroorzaakt door een verstoorde balans van het immuunsysteem. 
De behandeling van deze ziektes richt zich dan ook op het onderdrukken van het 
immuunsysteem, met bijvoorbeeld thiopurines.
Thiopurines zijn in de jaren 50-60 van de vorige eeuw ontwikkeld. Initieel werden 
ze ingezet voor de behandeling van acute leukemie, maar later bleek het medicijn 
in lagere doseringen ook effectief in het remmen van het immuunsysteem. Om 
deze reden kunnen ze ook worden gebruikt voor de behandeling van andere 
ziektes, zoals IBD, psoriasis en reumatoïde artritis. Daarnaast worden thiopurines 
ook gebruikt bij patiënten met een orgaantransplantatie om zo afstoting van het 
orgaan te voorkomen. 
De groep thiopurines bestaat uit drie verschillende medicamenten; azathioprine 
(AZA), mercaptopurine (MP) en thioguanine (TG). Van deze drie zijn AZA en MP 
als eerste op de markt gekomen en worden daarom de ‘conventionele thiopurines’ 
genoemd. Dit proefschrift richt zich met name op het gebruik van de zogeheten 
conventionele thiopurines.  Na inname van AZA en MP vindt er een uitgebreide 
en complexe metabolisering in het lichaam plaats alvorens de daadwerkelijke 
farmacologisch actieve metabolieten, de 6-thioguanine nucleotiden (6-TGNs), 
gevormd worden. Naast 6-TGN worden er nog andere metabolieten gevormd, 
waarvan 6-methylmercaptopurine ribonucleotiden (6-MMPR) de belangrijkste en 
klinisch het meest relevant zijn.
Ondanks dat thiopurines effectief zijn om de ziekte van Crohn en colitis 
ulcerosa onder controle te houden, geven de medicamenten in de praktijk vaak 
bijwerkingen. Dit leidt ertoe dat binnen één jaar na het starten van AZA of MP bijna 
40% van de patiënten alweer gestopt is. Omdat de medicamenteuze opties voor 
de behandeling van IBD beperkt zijn en de overige voorhanden zijnde middelen 
vaak vele malen duurder zijn, is er veel aan gelegen om het gebruik van thiopurines 
te optimaliseren.
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In hoofdstuk 2 vergelijken we de medicijnen AZA en MP met elkaar. We 
onderzochten of er een verschil in de mate van bijwerkingen tussen beide middelen 
was.  Daarnaast keken we ook naar het aantal mensen wat binnen een bepaalde 
termijn stopte met hun voorgeschreven medicatie en naar de effectiviteit van 
beide middelen. Tot op heden zijn er nauwelijks wetenschappelijke onderzoeken 
die de medicijnen AZA en MP met elkaar hebben vergeleken. AZA wordt in het 
lichaam omgezet in MP, en is dus eigenlijk een zogeheten prodrug van MP. Om 
die reden wordt verondersteld dat beide middelen gelijkwaardig en uitwisselbaar 
zijn met elkaar. In de huidige tijd zouden bij de registratie van verschillende, doch 
op elkaar gelijkende, medicijnen strenge vergelijkingsonderzoeken moeten worden 
uitgevoerd om de veiligheid en gelijkwaardigheid te garanderen. Echter, dit is voor 
AZA en MP tot op heden nog niet gedaan.
Voor het onderzoek zijn gegevens van de TOPIC studie gebruikt. De TOPIC 
studie is een groot onderzoek geweest waar veel ziekenhuizen in Nederland aan 
hebben geparticipeerd. Het doel van dit onderzoek was om te beoordelen of het 
vooraf bepalen van bepaalde genetische variaties in een enzym effect heeft op de 
frequentie van een tekort aan witte bloedcellen (leukopenie), wat een gevreesde 
bijwerking van thiopurines is. De resultaten hiervan zijn al in een eerder artikel 
beschreven. In de TOPIC trial waren de artsen vrij in de keuze of ze een patiënt 
AZA of MP voor wilden schrijven. Van de 796 patiënten die in dit onderzoek van 
start gingen zijn er uiteindelijk 767 met een thiopurine gestart. Hiervan kregen 
494 patiënten AZA voorgeschreven en 273 patiënten het medicijn MP. Naast 
het hoge aantal patiënten wat heeft deelgenomen aan de TOPIC studie is een 
ander belangrijk gegeven dat er geen verschillen in de patiëntkarakteristieken 
zaten tussen de patiënten die MP voorgeschreven kregen of de patiënten die 
AZA slikten. Er was dus geen voorkeur voor AZA of MP bij bepaalde groepen 
patiënten. Dit maakt dat de voorwaarden voor het vergelijken van beide middelen 
legitiem zijn. 
De resultaten beschreven in hoofdstuk 2 omvatten een analyse die achteraf 
is gedaan met de gegevens van de TOPIC studie. We zagen dat patiënten die 
MP namen relatief een hogere dosering kregen dan patiënten die AZA slikten. 
Dit heeft zich waarschijnlijk vertaald in een hoger aantal dosis afhankelijke 
bijwerkingen (gestoorde leverproefafwijkingen in het bloed en leukopenie) bij 
patiënten die MP slikten. De frequentie van niet dosis afhankelijke bijwerkingen 
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(zoals misselijkheid) was gelijk. Het aantal mensen wat aan het einde van het 
onderzoek nog het medicijn gebruikte verschilde niet tussen de mensen met AZA 
en MP. Waarschijnlijk komt dit omdat bij mensen met MP de dosis vaker werd 
verlaagd, zodat het doseringsverschil bij aanvang grotendeels teniet werd gedaan. 
In een analyse waarin gecorrigeerd werd voor de hogere metabolietwaardes (als 
gevolg van de hogere dosering) was er geen verschil meer in dosis afhankelijke 
bijwerkingen tussen AZA en MP. Daarnaast werden er geen verschillen in 
effectiviteit gezien tussen AZA en MP. Om die reden kan op basis van deze 
resultaten gezegd worden dat AZA even effectief is als MP, maar minder dosis 
afhankelijke bijwerkingen heeft in de dagelijkse praktijk.
In hoofdstuk  3 gaan we dieper in op verschillen tussen AZA en MP. Na opname 
in de darmen wordt AZA in de lever omgezet in MP, daarom is AZA een prodrug 
van MP zoals eerder besproken. Het vervolg van het metabolisme is identiek met 
MP. Initieel was de gedachte dat de omzetting van AZA naar MP in de lever een 
spontane reactie was, echter recent onderzoek heeft aangetoond dat het enzym 
Glutathione Transferase (GST) hierbij betrokken is. GSTs zijn een familie enzymen 
die een belangrijke rol hebben in onder andere de afbraak van schadelijke stoffen. 
Er zijn een groot aantal klassen GSTs waarvan GST Alpha, GST Mu, GST Pi en 
GST Theta de belangrijkste zijn. Binnen de klassen zijn er weer subklassen, zoals 
GST Alpha 1 en GST Alpha 2. De verschillen tussen de (sub)klassen berusten op 
een verschil in affiniteit voor substraten. Van de verschillende GST subklassen 
zijn alleen GST Alpha 1, GST Alpha 2 en GST Mu 1 betrokken in de omzetting 
van AZA naar MP. Genetische variaties in deze enzymen kunnen een kwalitatief 
(veranderde affiniteit voor het substraat) of kwantitatief effect (meer of minder 
enzym aanmaken) hebben en daarmee kunnen ze een effect hebben op de 
mate van AZA dat wordt omgezet naar MP. De hypothese voor het onderzoek 
beschreven in hoofdstuk 3 luidt dat genetische variaties in GSTs relevant zijn 
voor patiënten die AZA gebruiken, maar niet voor patiënten die MP gebruiken. 
De achterliggende gedachte hierbij is dat er minder AZA naar MP wordt omgezet, 
met als gevolg lagere metabolietspiegels.
In hoofdstuk 3 hebben we bij 767 patiënten uit de TOPIC trial gekeken naar 
genetische variaties in GST Alpha 1, GST Alpha 2 en GST Mu1. Van al deze 
patiënten is bekend of ze ook last van bijwerkingen hebben gehad. Ook is er 
van een groot deel de metabolietspiegels bekend. De resultaten laten zien 
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dat patiënten met een gendeletie in GSTMu1, die AZA slikten, minder hoge 
metabolietwaardes hadden ten opzichte van patiënten zonder een gendeletie. In 
lijn met onze hypothese was er bij de patiënten die MP slikten geen verschil in 
metabolietwaardes te zien. Een sterk punt van dit onderzoek, in vergelijking met 
eerdere onderzoeken, is dat er zowel gekeken is bij patiënten die AZA slikten als 
patiënten die MP gebruikten. Er is dus sprake van een controle groep, wat het 
niveau van het onderzoek sterker maakt.
In hoofdstuk 4 kijken we naar de gevolgen van genetische variaties in GST 
enzymen op het risico om de ziekte van Crohn of colitis ulcerosa te krijgen. Zoals 
reeds genoemd zijn GSTs betrokken bij de omzetting van voornamelijk schadelijke 
stoffen, zodat deze makkelijker door het lichaam kunnen worden uitgescheiden. 
Wanneer door de aanwezigheid van genetische variaties deze stoffen minder goed 
kunnen worden afgebroken kan dit leiden tot een continue staat van oxidatieve 
stress. Er zijn hypotheses dat dit kan bijdragen aan de ontwikkeling van de ziekte 
van Crohn of colitis ulcerosa. Studies die tot nu toe hiernaar hebben gekeken 
laten wisselende resultaten zien. Wij hebben bij een groot aantal patiënten uit het 
RadboudUMC met de ziekte van Crohn of colitis ulcerosa gekeken naar genetische 
variaties in de GST enzymen. De uitkomsten hebben we vergeleken met het 
voorkomen van de genetische variaties in GSTs bij een gezonde groep mensen. 
Vervolgens hebben we onze uikomsten samengevoegd met de resultaten van 
alle eerdere onderzoeken, een zogeheten meta-analyse, om zo met een grotere 
nauwkeurigheid het werkelijke effect te bepalen. De resultaten laten zien dat 
mensen met een deletie in het GST Theta gen een licht verhoogd risico hebben 
voor het ontwikkelen van colitis ulcerosa.
Hoofdstuk 5 richt zich op het voorkomen van afwijkingen in leverenzymen bij 
het gebruik van thiopurines. Dit hebben wij verder onderzocht door gekweekte 
levercellen in het laboratorium bloot te stellen aan de verschillende thiopurines 
concentraties. Hierbij hebben we specifiek gekeken naar schade die ontstaat aan 
levercellen bij blootstelling aan thiopurines in combinatie met andere medicijnen, 
namelijk 5-aminosalicylzuur en allopurinol. 
We zagen dat met het toevoegen van een niet toxische concentratie allopurinol 
de celtoxiciteit drie keer zo hoog werd. Eerdere studies schreven juist een 
beschermend effect toe aan allopurinol, waarschijnlijk als gevolg van de 
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antioxidatieve effecten. Waarschijnlijk kan dit verschil worden toegeschreven 
aan het feit dat onze experimenten plaats vonden bij delende cellen terwijl 
andere studies geprepareerde levercellen uit ratten hadden gebruikt, welke niet 
meer delen. De verhoogde toxiciteit komt waarschijnlijk doordat allopurinol het 
thiopurine metabolisme beïnvloedt door het enzym TPMT te remmen. Hierdoor 
wordt er minder 6-MMPR geproduceerd en meer 6-TGN. 6-TGNs worden als 
‘valse’ basenparen ingebouwd, met als gevolg dat er steeds meer fouten in het 
DNA ontstaan, waardoor er schade ontstaat. 
In hoofdstuk 6 hebben we gekeken naar de invloed van zowel positieve als 
negatieve gedachtes van patiënten met betrekking tot de medicatie die ze slikken. 
Om de perceptie van patiënten ten opzichte van thiopurines te meten hebben we 
gebruik gemaakt van de Believes about Medicine Questionnaire (BMQ). Deze 
vragenlijst meet zowel positieve als negatieve gedachtes ten opzichte van het 
gebruik van medicatie. De scores die hieruit komen hebben we gekoppeld aan 
het voortijdig stoppen van de thiopurine, maar ook aan de bloedspiegels van 
metabolieten en het klinisch effect. 
De BMQ vragenlijst is afgenomen bij de patiënten in de TOPIC trial die net waren 
gestart met een thiopurine. Op basis van de vragenlijst kan worden gesteld dat 
het grootste deel van de patiënten (70%) een hoge noodzaak tot het slikken 
van de medicatie ziet, echter bijna 50% heeft ook zorgen omtrent het gebruik 
van thiopurines. Eerder onderzoek heeft laten zien dat binnen het scala van 
medicamenten beschikbaar voor de behandeling van IBD, patiënten zich het 
meest zorgen maken over de veiligheid van thiopurines. Mogelijk komt dit door 
het relatieve hoge gehalte aan (potentieel ernstige) bijwerkingen op korte en 
lange termijn, zoals pancreatitis, leukopenie, levertestafwijkingen, misselijkheid 
en een verhoogd risico op huidkanker. Uit ons onderzoek komt naar voren dat 
mensen die een hoge noodzaak zien tot het nemen van thiopurines en daarnaast 
weinig zorgen hebben omtrent de veiligheid het minst vaak in een vroeg stadium 
stopten met het medicijn. Patiënten die een hoge noodzaak tot het slikken 
van een thiopurine zien, gecombineerd met hoge zorgen omtrent de veiligheid 
(ambivalente instelling), maar ook patiënten met een laag gevoel voor noodzaak 
tot het slikken van een thiopurine, gecombineerd met weinig zorgen (indifferente 
instelling) stopten significant vaker voortijdig met de thiopurine. De grootste groep 
patiënten die voortijdig staakten met het gebruik van een thiopurine zaten in 
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de groep met een sceptische instelling (lage noodzaak tot het slikken van een 
thiopurine, gecombineerd met veel zorgen omtrent het gebruik ervan). 
De gedachtes van patiënten over het medicijn zijn dus een belangrijke voorspeller 
voor het voortijdig staken van het medicament. Deze kennis kan dus gebruikt 
worden om juist bij patiënten die hoge zorgen hebben omtrent het gebruik van 
thiopurines extra voorlichting te geven om deze zorgen zoveel mogelijk weg te 
nemen. 
In hoofdstuk 7 gaan we dieper in op een gevreesde bijwerking van het gebruik van 
thiopurines, namelijk het ontstaan van een te laag gehalte aan witte bloedcellen 
(leukopenie). In patiënten met een genetische variatie in het TPMT gen, een enzym 
betrokken in het metabolisme van AZA en MP, is dit risico nog veel hoger en is 
ook de mate van leukopenie veel ernstiger, zelfs levensbedreigend. Om die reden 
adviseert een groot aantal richtlijnen om vooraf aan het starten van AZA of MP 
te onderzoeken of de patiënt een dergelijke genetische variatie heeft. In zo’n 
geval kan door het geven van een lagere dosis heel eenvoudig het risico op een 
leukopenie worden gereduceerd zonder dat de effectiviteit verminderd. 
Wanneer gekeken wordt naar alle patiënten die een leukopenie ontwikkelen tijdens 
het gebruik van AZA of MP blijkt dat slechts 25% hiervan wordt veroorzaakt 
door genetische variaties in het TPMT gen. Er is maar weinig bekend over andere 
factoren die het risico op leukopenie verhogen. In hoofdstuk 7 hebben we dit 
daarom verder uitgezocht door verschillende variabelen van patiënten die een 
leukopenie ontwikkelden tijdens het gebruik van AZA en MP te vergelijken met 
de patiënten die geen leukopenie ontwikkelden. Hiervoor hebben we gebruik 
gemaakt van de klinische gegevens van patiënten die hebben deelgenomen aan 
de TOPIC trial. Van al deze mensen is bekend of zij een genetische variatie in TPMT 
hebben. Voor de analyses in hoofdstuk 7 zijn alleen de patiënten geïncludeerd 
die geen genetische variatie hebben in het TPMT gen. De analyses toonden twee 
risicofactoren voor het krijgen van leukopenie. De eerste risicofactor was de 
uitgangswaarde van witte bloedcellen: hoe lager het totaal aantal witte bloedcellen 
bij start van de behandeling hoe groter de kans was op het ontwikkelen van 
leukopenie. Daarnaast zagen we dat patiënten die MP gebruikten vaker een 
leukopenie ontwikkelden. Dit komt waarschijnlijk door de relatieve hogere dosering 
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in vergelijking met patiënten die AZA slikten, zoals reeds in hoofdstuk 2 naar 
voren kwam. 
Witte bloedcellen spelen een prominente rol in het voorkomen en bestrijden van 
infecties. Een ernstige leukopenie kan het risico op het krijgen van een infectie 
daarom verhogen. Patiënten met een genetische variant in TPMT kunnen snel 
een ernstige leukopenie ontwikkelen, echter de meeste patiënten zonder een 
genetische variant in TPMT hebben maar een milde leukopenie. In het tweede 
deel van hoofdstuk 7 laten we zien dat de mensen met een milde leukopenie 
geen verhoogd risico hebben op het ontwikkelen van een infectie. Andere risico 
factoren voor het ontwikkelen van een infectie zijn een hogere leeftijd en het 
gelijktijdig gebruik van biologicals. 
Concluderend worden in dit proefschrift verschillende onderzoeken besproken 
die er op gericht zijn om het gebruik van de conventionele thiopurines (AZA en 
MP) te optimaliseren. Het doel is om hiermee het aantal patiënten, die vroegtijdig 
de behandeling met thiopurines moeten staken in verband met bijwerkingen, te 
reduceren. 
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DANKWOORD
Het dankwoord vormt het slotstuk van dit proefschrift. Terwijl ik dit dankwoord 
schrijf is er het besef dat het alleen zover heeft kunnen komen door de 
samenwerking, hulp en steun van vele geweldige mensen om mij heen. Tijdens 
mijn vele hardloopkilometers heb ik al vaak gedacht, mocht het zover komen dat 
ik een dankwoord mag gaan schrijven, dat ik deze en diegene zeker niet moet 
vergeten. Nu het zover is wil ik dan ook op dit moment alvast iedereen bedanken 
die in welke vorm dan ook zijn steentje heeft bijgedragen in de afgelopen jaren.
Allereerst wil ik alle patiënten bedanken die in de vele studies hebben 
geparticipeerd, waarbij ik direct of indirect betrokken ben geweest. Of het nou 
de TOPIC trial, Taurosept trial, visolie studie of een van de andere studies was. 
Zonder jullie bijdrage kan er weinig vooruitgang worden geboekt in de medische 
wetenschap. 
Prof. Dr. J.P.H. Drenth, beste Joost, dank voor de mogelijkheid om, na een jaar 
als ANIOS te hebben gewerkt, te kunnen starten als junior onderzoeker. Ik heb 
bewondering voor hoe je het leiden van de kliniek combineert met de wetenschap. 
Geen tijdstip en moment is je te gek om een manuscript van commentaar te 
voorzien. Dank voor je bijdrages achter de schermen.
Dr. G.J. Wanten, beste Geert, het begon met een gewaagd idee op een half 
A4-tje. Visolie als behandelstrategie bij de ziekte van Crohn. Daarnaast waren 
er nog een aantal projecten met thiopurines. Na een lang traject met de nodige 
tegenslagen, maar ook successen, bleek dat de pilot met visolie niet het gewenste 
resultaat liet zien. Dit heeft geresulteerd in de keuze om de focus volledig op de 
thiopurines te leggen. Ik waardeer jouw enorme drive, nuchterheid en positieve 
insteek, zonder die eigenschappen was het nimmer tot dit mooie eindresultaat 
gekomen. Ook toen we hadden besloten om het proefschrift volledig te wijden 
aan de thiopurines bleef je vol enthousiasme meedenken tijdens de wekelijkse 
werkbesprekingen. Er zijn maar weinig artsen die kliniek en wetenschap zo goed 
weten te combineren. Succes in je verdere carrière!
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Dr. D.J.  de Jong, beste Dirk, zoals gezegd begon het met een plannetje op een A4-
tje, waarbij jij als IBD-expert aan boord zat. Je bent voor mij een voorbeelddokter, 
die uitgebreid de tijd neemt en een luisterend oor biedt aan zijn patiënten. Ondanks 
de drukte kon ik altijd binnen lopen voor een ogenschijnlijk kleine vraag, meestal 
resulterend in een uitgebreide bespreking. Een nadeel van je overvolle agenda 
is dat de tijd om manuscripten na te lezen schaars was. Echter ook daar is een 
promotietraject voor bedoeld: de juiste strategie ontwikkelen om zo snel mogelijk 
ieders feedback op een manuscript te krijgen.
Leden van de manuscriptcommissie, beste Prof. Dr. David M. Burger, Prof dr. 
Gerd Bouma en Prof. Dr. Frans G.M. Russel, bedankt voor het beoordelen van 
het proefschrift en zitting te nemen in de corona. 
Beste Hennie, zonder jou zou het gedeelte van dit proefschrift wat zich in 
het laboratorium heeft afgespeeld niet zijn gelukt. Dank je wel voor het leren 
van de diverse laboratoriumtechnieken. Jouw kennis van alle technieken is 
van ongelofelijke waarde voor de afdeling MDL. Van de celkweken, waarvoor 
regelmatig in het weekend nog wat gedaan moest worden, tot alle PCRs, ELISA’s 
en HPLC runs, niets was jou te gek. De stapels artikelen en mapjes op en om je 
bureau ogen chaotisch, maar jij weet precies waar alles ligt. Voorwaarden zijn er 
wel voor een goede samenwerking met jou, netjes de spullen schoonmaken en 
op juiste plek terugleggen, anders kan je rekenen op een (terechte) donderpreek. 
Leuk dat jij mijn paranimf wil zijn.
Beste Jody en Rene, dank voor jullie hulp met PCRs en andere analyses. De rik 
avonturen in de pauzes waren niet aan mij besteed, maar toch was het altijd een 
genoegen om naar het fanatisme van jullie kaartspel te kijken.
Beste Dr. W. Peeters, beste Wilbert, lange tijd de drijvende kracht van het MDL 
lab. Dank voor het meedenken en vormgeven van de eerste studies. In 2014 ben 
je van je welverdiende pensioen gaan genieten. Onverwacht kwam dan ook het 
bericht van je overlijden op 17 december 2017.
Beste Dr. M.J.H. Coenen, beste Marieke. Een drijvende kracht achter de TOPIC 
studie en alles wat er inmiddels uit is voortgekomen. Dank voor de prettige 
samenwerking.
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Dr. D. Wong, beste Dennis, de nieuwe thiopurine farmacoloog van het zuiden. 
Jij bent bij veel onderzoeken uit dit proefschrift betrokken geweest, van het 
meten van de thiopurine metabolieten in de celkweek preparaten tot de studies 
voortkomend uit de TOPIC trial. Altijd vol goede ideeën voor verder onderzoek. 
Een kort telefoongesprek met jou is niet mogelijk. Ik heb bewondering voor 
hoe jij werk, privé en onderzoek allemaal combineert. Veel succes in je verdere 
(wetenschappelijke) carrière en in de zoektocht naar een mooi huis. 
Beste leden van de TOPIC werkgroep, in willekeurige volgorde, prof. Dr. A.L.M. 
Verbeek, Dr. P. Hooymans, Prof. Dr. O.H. Klungel, Prof. Dr. B. Franke, Prof. Dr. 
S. Vermeulen, dr. L.J.J. Derijks, Dr. H. Scheffer, prof. Dr. H.J. Guchelaar, dr. C.J. 
van Marrewijk. Wat hebben jullie een geweldig project opgezet met de TOPIC 
trial, een voorbeeld van een mooie en succesvolle landelijke samenwerking, waar 
inmiddels vele mooie vruchten van zijn geplukt. 
Beste Arts-onderzoekers van de MDL, oud-collega’s. Wat was het geweldig 
om deze mooie tijd samen met jullie door te brengen. Kopjes ‘echte’ koffie bij 
Vermaat, de groepswhatsapp die vrijdagmiddag om 12:00 al schreeuwde om de 
VrMiBo. Wat een geweldige drive en creativiteit zit er in de onderzoeksgroep. Van 
een klein clubje op de buitenhoek is de onderzoeksgroep inmiddels uitgegroeid 
tot een volwaardige afdeling. Het ontwikkelplan wat is opgezet, maar ook de 
onderzoekretraites met natuurlijk de bijbehorende wijnproeverij. Met de hele club 
naar de zomerfeesten, wintersport, maar ook er voor elkaar zijn bij tegenslagen. 
Een aantal van jullie wil ik specifiek noemen. Jos, lange tijd kamergenoot op onze 
vaste ‘flex’plekken. Dankzij jou is mijn kennis van hoofdsteden en landsvlaggen 
enorm verbeterd. De lekkere cappuccino’s bij Vermaat waren altijd een goed 
excuus voor een verdiende pauze. Titus, jammer dat je naar Nijmegen bent 
verhuisd, anders hadden we nog vaker kunnen rennen, talent heb je zeker. 
Polat, kamergenoot van het eerste uur op de buitenhoek, jouw verzameling 
pindakaaspotten was legendarisch. Mieke, dank voor de leuke samenwerking bij 
alle Hepatitis C artikelen en trials. Alle andere arts-onderzoekers, Floor, Marten, 
Lauranne, Mark L, Tom, Karina, Yasmijn, Wybrich, Edgar, Simon, Evelyn, Yannick, 
Dorian, Melissa, Loes, Govert, Xavier, Isabelle, Angelique, Myrte, Hedwig, René, 
Robin, dank voor de gezellige tijd. 
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Het Trial bureau van de MDL, beste Sonja en Chantal het is mooi om te zien hoe 
jullie in een paar jaar tijd van niets naar een volwaardige trial-unit zijn gegroeid. 
Dank voor jullie hulp bij de onderzoeksprojecten zoals de visolie studie en de 
taurosept trial. Karin van Hoven-Loo, jij hoort hier natuurlijk ook bij, als studie 
verpleegkundige van het eerste uur, dank voor je hulp bij de fase 2/3 studies en 
natuurlijk bij de pilot studie met visolie.
Beste MDL-artsen, AIOS, TPV-team, verpleegkundigen, endoscopie-
medewerkers, secretaressen, diëtisten en iedereen die niet onder een van deze 
noemers valt. Bedankt voor de fijne samenwerking met jullie. Tanya, jou wil ik 
specifiek bedanken, via jou ben ik in het Radboud terecht gekomen. Ondanks de 
drukke poli’s en eigen onderzoeksprogramma was je altijd geïnteresseerd in hoe 
het ging met mijn onderzoeksprojecten en mijn hardloopwedstrijden. Dr. Wietske 
Kieviet, de methodologie en statistiek beschermheilige van de afdeling MDL, wat 
zouden wij zonder jou moeten… Het moet vast niet makkelijk geweest zijn om 
de statistische / methodologische vraagstukken aan een eigenwijs persoon zoals 
ik uit te leggen. Toch is het je gelukt. Dank voor je bijdrage. 
Beste Martin, onze paden kwamen samen in werkgroep 1 van de studie 
geneeskunde  in Utrecht. In Zeist zijn de paden nu weer samen gekomen. Dank 
voor het kritisch bekijken van de manuscripten. Hopelijk lukt het nu vaker om wat 
af te spreken.
Mark V, Bob, Walid, Pim, Firdaus, waarde collega’s, de puzzelstukjes vallen bij 
mij nu ook op zijn plek. Promotie afgerond en gestart met de opleiding Specialist 
Ouderengeneeskunde. Leuk om te zien hoe iedereen verspreid over het land 
terecht is gekomen in een scala van specialismen, met als verbindende factor de 
etentjes met z’n allen. Dat er nog vele etentjes en weekendjes weg mogen volgen. 
Mark V dank voor de organisatie van het ‘vrijgezellen’weekend naar Schotland en 
het sparren bij sollicitaties. Firdaus, jou wil ik specifiek bedanken voor het kritisch 
nakijken van mijn manuscripten. 
Beste atleten van a.v. Phoenix, teveel namen om allemaal op te noemen, 
maar wat was (en is) het heerlijk om na een dag werken met jullie te trainen 
op de atletiekbaan of in het panbos. Het harde trainen voor de prestaties heeft 
gelijkenissen met een promotietraject, vele opofferingen en af en toe een succesje 
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in de vorm van een geaccepteerd manuscript. Dat er nog maar vele kilometers 
mogen volgen.
Collega artsen en arts-assistenten uit het Diakonessenhuis in Utrecht en Zeist. 
Het was me een waar genoegen om met jullie samen te werken. Ik heb er een 
leuke tijd gehad en veel geleerd.
Collega’s van Charim, Marco, Bas, Wolf, Filip, Ine, Wilma, Annerieke en Marjolein. 
Wat een goed en prettig team zijn jullie om mee te mogen werken. Ik kijk er naar 
uit om de opleiding Specialist Ouderengeneeskunde in dit team te mogen volgen. 
Roeiers van Triton Licht 2005. Het mogen promoveren op de datum van de Triton 
lustrumwedstijden is een voorrecht (dank Anne). Peter, Thijs, roeiers van het eerste 
uur, ondanks nieuwe fases in het leven met kinderen lukt het nog om zo nu en dan 
af te spreken. Laten we dit erin houden! Dank Peter voor de enthousiasmerende 
verhalen over het vak Specialist Ouderengeneeskunde. 
Familie Carpaij, lieve schoonfamilie, dank voor alle gezellige momenten, interesse 
en steun die ik van jullie heb gekregen.
Lieve Papa en Mama, het bleef voor jullie altijd een hele uitdaging om andere 
mensen uit te leggen wat ik nou precies deed in het Radboud. Maar ondanks 
dat zijn jullie altijd geïnteresseerd in de stand van zaken. De herberg is altijd open 
om even in de watten te worden gelegd, als je maar wel van tevoren reserveert. 
Het is heerlijk om zo nu en dan uit te waaien op het platteland in Wijchen en om 
natuurlijk de heerlijke aardbeien te eten. Wat kan er gedurende een promotietraject 
veel veranderen. Van geen, naar 5 kleinkinderen (met de 6e op komst). Het is mooi 
om te zien hoe jullie van alle kleinkinderen genieten. Marieke, Carlijn en Emiel, 
wat mag ik me gelukkig prijzen met jullie als broer en zussen. Leuk dat onze band 
steeds hechter wordt! Emiel, nooit de beroerdste om met je technische handen je 
broer of zussen bij te staan, als de kids er maar zijn om nog even mee te spelen. 
Leuk dat jij mijn paranimf wil zijn. En natuurlijk niet te vergeten, Kjell, Maarten en 
Darlene, de koude kant, maar wat een gezelligheid nemen jullie altijd mee.
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Lieve Suze en Veerle, nu heeft papa ook een boek geschreven, net als mama. 
Er staan niet zo heel veel plaatjes in, maar het heeft wel een happy end. Nu het 
boekje klaar is kunnen we nog vaker leuke dingen met z’n allen doen. 
Mocht ik nog mensen vergeten te zijn te noemen in dit dankwoord, dank voor 
jullie bijdrage in welke vorm dan ook.
Lieve dr. Neeltje, lieve Neel, toen jij jouw dankwoord schreef eind 2011 stond 
onze relatie in de kinderschoenen. Nu zijn het de kinderschoenen die naast ons 
staan. Jij vroeg je nog af of je mij in jouw dankwoord moest vermelden. Nu, ruim 
6 jaar later, is er geen twijfel mogelijk over die vraag. Jij verdient deze afsluitende 
plek in het dankwoord. Jij hebt gedurende het hele promotietraject aan mijn zijde 
gestaan. De leuke momenten, zoals het openen van een flesje bubbels bij een 
geaccepteerd artikel, maar je was er ook voor mij bij tegenslagen. Met jouw steun 
is er een mooi proefschrift uitgekomen waar we oprecht trots op kunnen zijn. Ik 
hoop samen met jou, Suze en Veerle nog vele mooie avonturen te mogen beleven.
Mark
Zeist, mei 2018
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CURRICULUM VITAE
Mark Marinus Theodorus Johannes Broekman werd 
geboren op 7 september 1987 te Wijchen. In 2003 
behaalde hij zijn atheneum diploma aan het Dominicus 
College te Nijmegen. In datzelfde jaar startte hij met 
de studie Geneeskunde aan de Universiteit Utrecht.
In 2010 rondde hij deze studie succesvol af en startte 
hij als basisarts Interne Geneeskunde in het Meander 
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